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Background Acute myocardial infarction is caused by thrombotic occlusion of a
coronary artery compromised by atheromatous plaque. The interplay between acute
plaque rupture or erosion and the local haemostatic and fibrinolytic activities are critical
determinants in the initiation and resolution of the thrombotic complications of
coronary atheroma. This is exemplified by the high rate of spontaneous reperfusion in
the infarct related artery after acute myocardial infarction.
Objectives The aims of the thesis were: first, to establish a selective, specific and
reproducible model for assessing endothelial function and acute endogenous
fibrinolytic capacity in vivo in the peripheral circulation of man; second, to characterise
the underlying mechanisms of the fibrinolytic response in this model; third, to compare
the acute endogenous fibrinolytic capacity in health and disease; fourth, to examine the
influence of therapeutic intervention on the fibrinolytic response; and finally, fifth, to
apply this model to the coronary circulation in order to determine the acute coronary
fibrinolytic response and assess its relationship with the extent of coronary atheroma.
Methods Peripheral circulation. Blood flow and plasma fibrinolytic parameters
were determined in both forearms using venous occlusion plethysmography and blood
samples withdrawn from the antecubital fossae. The brachial artery of the non-
dominant forearm was cannulated and intra-artenal drugs administered. Plasma
fibrinolytic parameters were determined using enzyme linked immunosorbant and
photometric methods. The mechanisms of substance P action were explored using
neurokinin type 1 receptor antagonism, nitric oxide synthase inhibition and the nitric
oxide donor, sodium nitroprusside. The acute fibrinolytic response was examined in
habitual cigarette smokers and patients with hypercholesterolaemia: the latter were also
assessed following 6 weeks of lipid lowering therapy. Coronary circulation.
Following diagnostic coronary angiography, the proximal coronary artery plaque
volume was determined using computerised three dimensional reconstruction of
intravascular ultrasound images. Blood flow and fibrinolytic responses to selective left
anterior descending coronary artery infusion were assessed using intracoronary
ultrasound and Doppler, and coronary sinus and arterial blood sampling.
Results Intrabrachial substance P infusion was well tolerated and produced
reproducible increases in forearm blood flow and tissue plasminogen activator release
without affecting plasminogen activator inhibitor type 1 and von Willebrand factor
concentrations. In contrast, endothelin-1 and L-monomethyl arginine infusion did not
cause acute tissue plasminogen activator release. The response to substance P infusion
appears to be dependent on the endothelial cell neurokinin type 1 receptor, and is, in
part, mediated by the L-arginine:nitric oxide pathway. Whilst endothelium-dependent
vasomotion was impaired in both cigarette smokers and patients with
hypercholesterolaemia, tissue plasminogen activator release was diminished only in
cigarette smokers and was unaffected by hypercholesterolaemia or lipid lowering
therapy. Coronary fibrinolytic activity, but not endothelium-dependent coronary
vasodilatation, inversely correlated with the volume of coronary artery atheroma.
Conclusions A model to assess the acute endogenous fibrinolytic capacity has been
developed and characterised which was well tolerated and reproducible. Cigarette
smoking, but not hypercholesterolaemia, is associated with an impairment of the acute
tissue plasminogen activator release which may, in part, explain the increased
propensity of smokers to sustain an acute myocardial infarction as well as to respond
more favourably to thrombolytic therapy. The apparently normal fibrinolytic response
in patients with hypercholesterolaemia indicates that endothelial dysfunction can be
manifest in separate distinct pathways depending upon the nature of the insult. Finally,
the demonstration of an association between the extent of coronary atheroma and the
local endogenous fibrinolytic response provides a potentially important mechanism
through which endothelial dysfunction can directly contribute to the thrombotic
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ENDOGENOUS FIBRINOLYSIS AND ENDOTHELIAL FUNCTION
1.1 THE ENDOGENOUS FIBRINOLYTIC SYSTEM
The fibrinolytic pathway describes a complex process involving the hydrolytic
cleavage of fibrin, by plasmin, to cause clot dissolution and generate fibrin
degradation products (see Figure 1.1), Plasmin, a serine protease, is generated by the
action of an array of enzymes and inhibitors which have a co-ordinated action on the
zymogen, plasminogen. The principal role of this enzymatic system is to protect the
circulation from intravascular fibrin formation and thrombosis that would otherwise
result in vessel occlusion and tissue ischaemia. However, it should also be
acknowledged that in addition to its role in the degradation of intravascular
thrombus, the fibrinolytic system is involved in many disparate physiological and
pathophysiological processes including macrophage migration [Saksela & Rifkin
1988], ovulation [Strickland & Beers 1976], embryogenesis [Saksela & Holthofer
1987] and tumour invasion [Dano et al 1985],
1.1.1 Initiation Of Fibrinolysis
1.1.1.1 Plasminogen And Plasnun
Plasminogen is principally produced by the liver [Raum et al 1980] as a single chain
glycoprotein containing 791 amino acids and has a plasma concentration of ~2
pmol/L in man. The gene for human plasminogen is encoded on chromosome 6q26-
q27, encompasses 19 exons over 54 kb, and has some sequence homology with the
nearby apolipoprotein (a) gene. The protein structure of plasminogen includes a
preactivation peptide sequence, five kringle domains and a catalytic protease domain
2
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[Petersen et al 1990], Kringle domains 1 and 5 are responsible for the binding of
plasminogen to fibrin [Petersen & Suenson 1990, Wu etal 1990],
The conformational structure of plasminogen undergoes dramatic change when the
preactivation peptide is removed by plasmin. Conversion of plasminogen to plasmin
is achieved through the cleavage of the Arg561-Val562 peptide bond by plasminogen
activators, generating two polypeptide chains (60 and 25 amino acids) held together
by a single disulphide bridge. The mature plasmin molecule is then able to degrade
fibrin to generate various fibrin degradation products, such as D-dimers and fragment
E [Gaffney et al 1976],
1.1.1.2 Plasminogen Activators
The initiation of fibrinolysis is dependent on the actions of plasminogen activators of
which there are two endogenous forms: tissue plasminogen activator (t-PA) and
urinary-type plasminogen activator (u-PA). The main physiological plasminogen
activator involved in the removal of intravascular fibrin is t-PA [Astedt 1979; Kok
1979], In contrast, u-PA appears to have a role in facilitating cellular migration and,
unlike t-PA, two chain u-PA lacks fibrin-specificity and will indiscriminately
activate plasminogen.
1.1.2 Inhibition Of Fibrinolysis
Serine protease inhibitors, or serpins, represent a family of related regulatory
peptides that have a major role in the control of coagulation, fibrinolysis and
inflammation. The regulation of fibrinolysis by serpins principally occurs at two
levels: inhibition of plasmin and inhibition of plasminogen activators.
1.1.2.1 Plasmin Inhibitors
Plasmin action is principally inhibited by a2-antiplasmin although other factors, such
as histidine-rich glycoproteins and thrombospondin, may play a minor role. a2-
Antiplasmin is a 452 amino acid glycoprotein [Holmes et al 1987] that acts as a high
affinity, rapidly acting inhibitor of plasmin. Plasma concentrations of a2-antiplasmin
are ~1 pmol/L in man and consequently, even with extensive plasminogen activation,
there is a sufficent reserve to inactivate liberated plasmin. Unbound free plasmin is
rapidly complexed and inactivated by a2-antiplasmin such that the indiscriminate
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consumption of haemostatic factors, through fibrinogenolysis, is avoided [Wiman &
Collen 1978], However, fibrin bound plasmin is resistant to inactivation by a2-
antiplasmin since the binding site for cc2-antiplasmin is occupied by fibrin itself. This
creates a mechanism whereby plasmin is only locally active at the site of thrombus
formation.
1.1.2.2 Plasminogen Activator Inhibitors
There are several inhibitors of plasminogen activators but the main inhibitor of t-PA
in man is plasminogen activator inhibitor type 1 (PAI-1). Other plasminogen
activator inhibitors exist including PAI-2, PAI-3, a2-macroglobulin and CI esterase
inhibitor. Originally isolated from placental tissue, PAI-2 appears to have a
preferential inhibitory effect on u-PA suggesting that its primary role may be in
regulating extracellular u-PA, such as during placental development.
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1.2 TISSUE PLASMINOGEN ACTIVATOR
1.2.1 Protein Structure And Function
Human t-PA is principally produced by the endothelium as a glycoprotein containing
52.7 or 530 amino acids and has a plasma concentration of -70 pmol/L. The gene for
human t-PA is encoded on chromosome 8pl2-ql 1.2 and comprises of 33 kb
[Verheijen et al 1986], Cleavage at Arg275 divides the t-PA molecule into two chains,
A and B, which are held together by a single disulphide bridge. The protein structure
of t-PA includes 5 main functional domains: finger, epidermal growth factor, kringle
1, kringle 2 and protease domains (see Figure 1.2). The finger and second kringle
domains of chain A are responsible for fibrin binding whereas the protease domain of
chain B contains the catalytic site which causes plasminogen activation through
cleavage of the Arg561-Val562 bond.
In the absence of fibrin, t-PA has very weak activity as a plasminogen activator.
However, once bound to fibrin, the catalytic activity of t-PA rises a 1000-fold due to
conformational changes resulting from the binding of the finger and second kringle
domains [van Zonneveld et al 1986], and the formation of a ternary complex
between plasminogen, fibrin and t-PA [Ranby 1982],
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1.2.2 Synthesis And Release
Although t-PA synthesis can be detected in mesothelial cells [van Hinsbergh et al
1990] and naematopoetic cells [Hart et al 1989], the endothelium is the principal site
of its generation where it is released via both constitutive and regulated pathways.
Endothelial cells synthesise, store and release t-PA in most of the blood vessels of
man, and especially in the pre-capillary arterioles and post-capillary venules [Levin
& del Zoppo 1994], Regional differences in t-PA release do exist such that the upper
limbs release four times the amount of the lower limbs [Keber 1988], and the liver
and kidney do not acutely release t-PA when challenged with desmopressin
[Brommer et al 1988],
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The release of t-PA may be rapidly increased through the translocation of a dynamic
intracellular storage pool [van den Eijnden-Schrauwen et al 1995] in response to
stimulation by blood coagulation and humoral factors [Emeis 1992], This acute
release does not require de novo protein synthesis since pretreatment with
cycloheximide does not prevent t-PA release in the isolated rat hindlimb perfusion
model [Tranquille & Emeis 1989], Many physiological and pharmacological stimuli
have been shown to release t-PA, some ofwhich are listed in Table 1.1.
Table 1.1






Circadian Rhythm Endothelin Exercise
Histamine Hyperoxia Diet
Hypoxia Insulin Garlic
Interleukin-1 02 Radicals Mental Stress
PAF Prostaglandins Onions
Substance P Thrombin Temperature
TNF-oc Vasopressin Sex
VIP Venous Occlusion Smoking
There is a pronounced circadian variation in fibrinolytic activity with very low t-PA
activity in the early morning [Andreotti & Kluft 1991], Paradoxically, t-PA antigen
concentrations peak early in the morning and the markedly reduced t-PA activity is a
consequence of the four-fold rise in PAI-1 concentrations: see Figure 1.3.
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Figure 1.3
Orcadian rhythm [Andreotti & Kluft 1991]
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1.2.3 Clearance Of T-PA And The t-PA/PAI-1 Complex
The clearance of t-PA predominantly occurs through the removal of both active t-PA
and t-PA/PAI-1 complexes (see Figures 1.4 and 1.5) from the circulation by the liver
[Chandler et al 1997], This clearance process is rapid, with plasma half lives for
active t-PA and t-PA/PAI-1 complexes of 2.4 and 5.0 minutes respectively. In the
presence of high PAI-1 activity, more t-PA is complexed and the total clearance is
slowed due to the longer half life of the t-PA/PAI-1 complex. The
pharmacodynamics of t-PA clearance suggest a two compartment model [Chandler et
al 1997] and it is likely that endothelial cell t-PA receptors contribute significantly to




Clearance of plasma t-PA [Chandler et al 1997]
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1.3 PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1
1.3.1 Protein Structure And Function
Human PAI-1 is produced by several tissues [Sprengers et al 1986; Simpson et al
1991] including the endothelium, liver, platelets and vascular smooth muscle. It is a
glycoprotein containing 379 amino acids and has a plasma concentration of -500
pmol/L. The gene for human PAI-1 is located on chromosome 7q21.3-q22 and
comprises of 12 kb encompassing 9 exons [Loskutoff etal 1987],
There are two conformational forms of PAI-1: an active and inactive form [Levin
1986], The active form is unstable and conformational changes within the molecule
cause PAI-1 to become inactive, the so-called "latent" form. Loss of activity occurs
with a half life of 0.5-3 hours, although stability of the active PAI-1 form is enhanced
by binding with vitronectin [Declerck et al 1988a], PAI-1 has an Arg-Met reactive
centre in keeping with other serpins, and binds to the kringle 2 domain of t-PA
[Kaneko et al 1991], This has the effect of preventing t-PA binding to fibrin and
inhibiting its mode of action in a manner analogous to a2-antiplasmin and plasmin.
1.3.2 Synthesis And Release
The origin of plasma PAI-1 remains unclear but does not appear to arise from
platelets since plasma concentrations are normal in patients with thrombocytopenia
and grey platelet syndrome [Booth et al 1988], It would seem that the majority of
PAI-1 synthesis and release occurs in vascular tissue, namely endothelium and
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vascular smooth muscle [Simpson et al 1991], although the liver may provide a
significant further contribution.
There are high concentrations of PAI-1 in the a-granules of platelets and this may be
an important source of plasminogen activator inhibition during thrombus formation
with platelet activation leading to high local concentrations of PAI-1. The activity of
platelet-derived PAI-1 is only a fraction (5%) of plasma PAI-1, possibly due to the
lack of the stabilising influence of vitronectin. However, because of the
proportionately larger overall mass, platelet PAI-1 may account for some 50% of the
overall total inhibitory activity of PAI-1 [Booth etal 1988],
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1.4 ENDOTHELIUM
The endothelium plays a central role in the maintenance of normal vascular function
and homeostasis including the control of blood flow, coagulation, fibrinolysis and
inflammation. Consequently, the maintenance and regulation of tissue perfusion
critically depends upon the integrity of endothelial function and the release of
various endothelium-derived factors. Some of the major endothelial cell products are
listed in Table 1.2.
Table 1.2
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Leucocyte adhesion molecules: ICAM-1, VCAM-1, ELAM-1
Cytokines: IL-1, IL-6, IL-8
Major HLA antigens (class I and II)
Growth factors
Basic fibroblast growth factor







Since the seminal work of Furchgott and Zawadski [Furchgott & Zawadski 1980], it
has been widely recognised that an array of mediators can influence vascular tone
through endothelium-dependent actions [Furchgott 1984], Endothelial stimulation
results in the immediate release of a number of vasodilator mediators including
prostacyclin, nitric oxide and endothelium-derived hyperpolarising factor (EDHF).
Moreover, the endothelium is also able to generate and release vasoconstrictor
mediators, such as angiotensin II and endothelin-1, and hence provide a counter-
regulatory tonic action on the adjacent vascular smooth muscle. Indeed, there appears
to be an inextricable interplay between these endothelium-derived vasodilator and
vasoconstrictor mediators [Verhaare/a/ 1998],
Both nitric oxide and endothelin-1 are released continuously by the endothelium to
regulate basal vascular tone [Vallance et al 1989; Haynes & Webb 1994] and blood
pressure [Haynes et al 1993; Haynes et al 1996], Thus, the endothelium has a central
role in the local paracrine regulation of vascular tone, blood flow and blood pressure.
Disruption of normal endothelial function can, therefore, have a marked influence on
the local and systemic haemodynamic balance, and ultimately tissue perfusion.
1.4.2 Endothelium-Derived Haemostatic Factors
The endothelium has an intrinsic anticoagulant action due to the presence of
glycosaminoglycans, which are rich in heparan sulphates, in the cellular plasma
membrane. These glycosaminoglycans bind antithrombin III and provide a surface
that rapidly inactivates thrombin [Busch & Owen 1982], In addition,
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thrombomodulin, a cell surface glycoprotein, adds to the anticoagulant action of the
endothelium by binding of thrombin and activating protein C [Esmon 1987],
Von Willebrand factor (vWf) is only produced by the endothelium and platelets, and
is a cofactor which stabilises factor VIII:C and facilitates platelet adhesion to the
subendothelial matrix. Approximately 90% of plasma vWf originates from the
endothelium [Bowie et al 1986] where it is both constitutively secreted as well as
stored within the Weibel Palade bodies [Mayadas & Wagner 1991], However, there
is controversy as to whether the majority of stored t-PA co-localises with vWf in the
Weibe! Palade bodies [Datta et al 1999; Rosnoblet et al 1999] or is contained within
separate distinct granules [Emeis etal 1997],
1,4.3 Endothelium-Derived Fibrinolytic Factors
Endothelial cells constitutively secrete both t-PA and PAI-1 and the rate of release
can be differentially affected by cytokines, coagulant factors and endotoxin. The
synthesis and release of t-PA and PAI-1 has been reviewed above.
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1.5 ENDOTHELIAL FUNCTION, ENDOGENOUS FIBRINOLYSIS AND
ATHEROTHROMBOSIS
1.5.1 Endothelial Dysfunction And Atherosclerosis
The endothelium-dependent regulation of peripheral vascular tone is impaired by
many of the risk factors associated with atherosclerosis, such as
hypercholesterolaemia [Chowienczyk et al 1992; Stroes et al 1995; Heitzer et al
1996a], diabetes mellitus [Calver et al 1992], familial history of atherosclerosis
[Celermajer et al 1992] and smoking [Celermajer et al 1996; Heitzer et al 1996a+b;
Newby et al 1999a], This dysfunction appears to be generalised with demonstrable
impairment of endothelial function in the coronary circulation of patients with
coronary artery disease [Ludmer et al 1986] and its risk factors [Vita et al 1990]
including smoking [Zeiher et al 1995],
The formation of atherosclerosis is a complex inflammatory process that involves a
series of interactions with many cell types including the endothelium [Ross 1999]
To date, the clinical dynamic assessment of endothelial dysfunction has
predominantly relied upon the measurement of endothelium-dependent vasomotion.
This has been undertaken by determining resistance vessel responses to endothelial
cell stimulants [Ludmer et al 1986; Chowienczyk et al 1992; Stroes et al 1995] and
nitric oxide synthase inhibition [Calver et al 1992], and conduit vessel responses to
reactive hyperaemia [Celermajer et al 1996] - so called flow associated dilatation.
However, whilst providing an important indicator of endothelial function,
endothelium-dependent vasomotion can be viewed as an indirect surrogate measure
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of the main pathophysiological role of the endothelium in atherothrombosis. In
contrast, t-PA is a potentially important endothelium-derived mediator that is
intimately linked to the risk of thrombosis.
1.5.2 Ischaemic Heart Disease And Endogenous Fibrinolysis
In epidemiological studies of patients with ischaemic heart disease [Hamsten et al
1985; Thompson et al 1995], and in prospective studies in healthy populations
[Ridker et al 1993a; Thogersen et al 1998], higher total plasma t-PA (antigen)
concentrations positively and independently predict future coronary events. It would
be anticipated, however, that high t-PA concentrations would protect against
subsequent coronary events rather than the reverse. This paradoxical association is,
in part, explained by the concomitant elevation of PAI-1 which complexes with t-PA
and, therefore, causes an overall reduction in free t-PA 'activity' [Jansson et al 1993;
De Bono 1994], It is this free and unbound t-PA which is physiologically active and
central to endogenous fibrinolysis. Moreover, the time course of endogenous t-PA
release is important, with thrombus dissolution being much more effective if t-PA is
incorporated during, rather than after, thrombus formation [Brommer 1984; Fox et al
1984], Flowever, the capacity of endothelial cells to release t-PA from intracellular
storage pools, and the rapidity with which this can be mobilised, may not be reflected
in the basal circulating plasma concentrations of t-PA antigen or activity [Jern et al
1999],
17
1.5.3 Dynamic Assessment OfAcute Tissue Plasminogen Activator Release
The dynamic assessment of endogenous fibrinolysis has previously relied on the
acute release of t-PA in response to venous occlusion, systemic desmopressin
infusion or exercise [Allen et al 1985; Gris JC et al 1991; Held et al 1997; Jahun-
Vague et al 1996], However, the venous occlusion response is variable and has poor
intra-individual reproducibility [Sultan et al 1988] and gives only a relatively crude
measure of fibrinolytic capacity. In contrast, systemic desmopressin infusion appears
to provide a more predictable fibrinolytic response in healthy volunteers [Prowse et
al 1984] and patients with coronary artery disease [Duprez et al 1991] However,
desmopressin also causes marked vasodilatation and, when administered
systemically, leads to facial flushing, an increase in heart rate and a fall in blood
pressure. It has been hypothesised that the consequent systemic neurohumoral
response to desmopressin induced vasodilatation may contribute to, or even mediate,
the haemostatic and fibrinolytic response to desmopressin infusion [Grant et al
1988], Moreover, in vitro endothelial cell culture studies have suggested that
desmopressin at very high concentrations induces endothelial vWf release by a
mechanism which is dependent on the presence of peripheral blood monocytes
[Hashemi et al 1990], possibly mediated by the production of a second messenger
molecule [Hashemi et al 1993], Finally, we have recently shown that, in healthy
male volunteers, desmopressin releases t-PA, vWf and Factor VIII:C predominantly
via systemic mechanisms, possibly mediated by cytokine release [Newby et al
2000a]. There is, therefore, a need for a specific, reproducible and direct
endothelium-dependent method of assessing the capacity to release t-PA acutely in
vivo in man.
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1.5.4 Tissue Plasminogen Activator Release In The Coronary Circulation
Acute rupture or erosion of a coronary atheromatous plaque and subsequent coronary
artery thrombosis causes the majority of sudden cardiac deaths and myocardial
infarctions [Burke et al 1997], Small areas of denudation and thrombus deposition
are a common finding on the surface of atheromatous plaques and are usually sub¬
clinical [Davies et al 1988], However, in the presence of an imbalance in the
fibrinolytic system, such microthrombi may propagate, ultimately leading to arterial
occlusion [Rosenberg & Aird 1999], The importance of local fibrinolysis and acute
endogenous t-PA release is exemplified by the high rate of spontaneous reperfusion
in the infarct related artery after acute myocardial infarction; occurring in around one
third of patients within the first 12 hours [DeWood et al 1980; Armstrong et al 1989;
Rentrop et al 1989],
In the Northwick Park Heart Study [Meade et al 1993], low basal plasma fibrinolytic
activity was a leading determinant of the risk of sustaining a myocardial infarction or
sudden cardiac death in younger men. Moreover, a reduction in exercise induced
release of t-PA is associated with an increased incidence of major adverse cardiac
events in patients with stable angina pectoris [Held et al 1997], Recently, Rosenberg
and Aird [Rosenberg & Aird 1999] have postulated that vascular-bed-specific defects
in haemostasis exist, and that coronary thrombosis critically depends on the local
fibrinolytic balance. However, there have been no clinical studies to date which have
directly assessed the dynamic local fibrinolytic capacity of the coronary vascular bed
in patients with coronary artery disease.
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1.6 HYPOTHESES
Intra-brachial substance P has been previously shown to induce local fibrinolysis in
the human forearm [Fanciullacci et al 1993] although the mechanism of this effect
has not been determined. It is likely, however, that this effect is mediated through
acute t-PA release but this suggestion awaits confirmation. Given that t-PA and vWf
may co-localise within the endothelium [Datta et al 1999; Rosnoblet et al 1999] and
that previous agents co-release both t-PA and vWf [Mannucci et al 1975; Ludlam et
al 1980; Mannucci 1997], substance P may also cause acute release of vWf. This
provides the basis for a potential model to assess not only endothelium-dependent
vasomotion but also endothelium-dependent regulation of fibrinolysis and
coagulation.
After initial development and characterisation of a model to assess endothelium-
dependent vasomotion and endogenous t-PA release, the following hypotheses will
be addressed:
1. The vascular actions of substance P are dependent on the neurokinin type 1
receptor and are, in part, mediated by the L-arginine:nitric oxide pathway.
2. Endothelium-independent vasodilators do not cause acute release of t-PA, PAI-1
and vWf in the forearm ofman.
3. The acute release of endogenous t-PA is impaired in endothelial dysfunctional
states, such as cigarette smoking and hyperlipidaemia.
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4. Intra-coronary substance P causes the acute release of t-PA and PAI-1 in the
coronary vascular bed.




The aims of the thesis were:
In healthy male volunteers (Chapter 3):
• to establish the pharmacodynamics, tolerability and reproducibility of intra¬
arterial substance P, an endothelium- dependent vasodilator, in the forearm.
In healthy male volunteers (Chapter 4):
• to determine the ability of L-754,030, a neurokinin type 1 receptor antagonist, to
inhibit substance P induced vasodilatation during and 24 hours after intravenous
administration of its prodrug, L-758,298
• to confirm that substance P induced vasodilatation is mediated via the endothelial
cell NKi receptor in man.
• to determine whether endogenous substance P regulates peripheral vascular tone
or blood pressure in man.
• to evaluate the safety and tolerability of single intravenous doses of L-758,298 in
healthy male volunteers.
In healthy male volunteers (Chapter 5):
• to establish a method of determining the acute fibrinolytic capacity of the
endothelium.
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• to assess the acute release of coagulation and fibrinolytic factors within the
forearm vascular bed in response to intra-arterial substance P using an ascending
dose design to define the dose at which systemic effects intervene.
• to assess the potential release of coagulation and fibrinolytic factors in response to
locally active doses of substance P and a control endothelium-independent nitric
oxide donor, sodium nitroprusside.
In healthy male volunteers (Chapter 6):
• to determine whether endothelin-1, of exogenous or endogenous origin, acts via
the endothelial ETg receptor to regulate the release of t-PA, PAI-1 or vWf in vivo
in man using synthetic endothelin-1 peptide and the selective ETb receptor
antagonist, BQ-788.
In healthy male volunteers (Chapter 7):
• to determine if prolonged substance P infusion can cause sustained t-PA release in
the forearm.
• to ascertain whether prolonged substance P infusion can cause vWf or PAI-1
release.
• to determine whether nitric oxide synthase inhibition using L-Isp-
monomethylarginine (L-NMMA) affects basal or substance P induced t-PA
release.
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In otherwise healthy volunteers (Chapter 8):
• to compare substance P induced t-PA release from the forearm vascular bed of
smokers and age- and sex-matched non-smokers.
In patients with hypercholesterolaemia (Chapter 9):
• to determine whether there is an impairment of acute t-PA release .
• to ascertain if pre-treatment with pravastatin, a lipid lowering agent, could
enhance t-PA release in these patients.
• to determine if substance P induced t-PA release has acceptable within subject
reproducibility.
In patients with coronary artery disease (Chapter 10):
• to establish a model of assessing the dynamic local fibrinolytic capacity of the
coronary vascular bed.
• to determine the relationship between the extent of coronary atheroma, as assessed





MEASUREMENT OF FOREARM AND CORONARY BLOOD FLOW,
CORONARY PLAQUE VOLUME
AND
PLASMA FIBRINOLYTIC AND HAEMOSTATIC PARAMETERS
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2.1 INTRODUCTION
When examining in vivo vascular responses in man, systemic drug administration
causes concomitant effects on organs, such as the brain, kidney and heart, and
influences neurohumoral reflexes through changes in systemic haemodynamics.
Because of these confounding influences, vascular responses cannot be wholly
attributed to a direct effect of the drug [Webb 1995], Regional forearm and coronary
infusions combined with bilateral venous occlusion plethysmography and
intracoronary ultrasound provide methods of directly assessing peripheral and
coronary vascular responses without invoking these systemic influences.
2.1.1 Forearm Resistance Vessels
Bilateral forearm blood flow measurements using venous occlusion
plethysmography, with unilateral brachial artery infusion of vasoactive drugs at
subsystemic, locally active doses, provides a powerful and reproducible method of
directly assessing vascular responses in vivo [Benjamin et cil 1995, Webb 1995], This
technique has been utilised very successfully to demonstrate the major contribution
of nitric oxide and endothelin-1 to the maintenance of basal peripheral vascular tone
in healthy man [Vallance et al 1989; Haynes et al 1994] and to predict that systemic
inhibition of these systems would increase [Haynes et al 1993] and decrease [Haynes
etal 1996] blood pressure respectively.
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2.1.2 Coronary Circulation
The explosion in catheter based technology has put many innovative techniques at
the disposal of the clinical investigator. Some of these techniques, such as the
measurement of coronary and fractional flow reserves, have also found a role in
clinical practice [White 1993] as a means of assessing the functional severity of
intermediate coronary artery stenoses and thereby guide coronary intervention [Segal
1993], Moreover, the advent of intravascular ultrasound, in particular, has facilitated
the more detailed functional and morphological assessment of the coronary
circulation.
Regional intracoronary infusions have the advantage of assessing the heart and
coronary circulation in relative isolation without invoking systemic effects. This is
particularly important for the assessment of cardiac and coronary function which is
heavdy dependent on changes in the systemic vasculature and haemodynamics. In
addition, relatively high doses can be administered locally which may be important
for the desired physiological or therapeutic effect and may be further facilitated by
the use of local drug delivery systems. Finally, combining intracoronary drug
administration with coronary sinus catheterisation and sampling can further extend





All studies were undertaken in accordance with the Declaration of Helsinki of the
World Medical Association and with the approval of the Lothian Research Ethics
Committee The written informed consent of each subject or patient was obtained
before entry into the study.
2.2.2 Subject Preparation
None of the normal healthy volunteers and controls received vasoactive or non¬
steroidal anti-inflammatory drugs in the week before each phase of the study. All
subjects and patients abstained from alcohol for 24 hours and from food, tobacco and
caffeine-containing drinks for at least five hours before each study. Studies were
performed in a quiet, temperature controlled room maintained at 23.5 - 24.5°C.
2.2.3 Blood Pressure Measurement
During forearm venous occlusion plethysmography, blood pressure was monitored in
the non-infused arm at intervals throughout each study using a semi-automated non¬
invasive oscillometric sphygmomanometer (Takeda UA 751, Takeda Medical Inc,
Tokyo, Japan) [Wiinberg etal 1988],
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2.3 FOREARM VENOUS OCCLUSION PLETHYSMOGRAPHY
2.3.1 Brachial Artery Cannulation
The brachial artery of the non-dominant arm was cannulated with a 27-G steel needle
(Cooper's Needle Works Ltd, Birmingham, UK) under 1% lignocaine (Xylocaine;
Astra Pharmaceuticals Ltd, Kings Langley, UK) local anaesthesia. The cannula was
attached to a 16-gauge epidural catheter (Portex Ltd, Hythe, UK) and patency
maintained by infusion of saline (0.9%: Baxter Healthcare Ltd, Thetford, UK) via an
IVAC PI000 syringe pump (IVAC Ltd, Basingstoke, UK). The total rate of intra¬
arterial infusions was maintained constant throughout all studies at 1 mL/min.
2.3.2 Blood Flow Measurement
Blood flow was measured in the infused and non-infused forearms by venous
occlusion plethysmography using mercury-in-silastic strain gauges that were applied
to the widest part of the forearm [Webb 1995], During measurement periods, the
hands were excluded from the circulation by rapid inflation of the wrist cuffs to a
pressure of 220 mmHg using E20 Rapid Cuff Inflators (D.E. Hokanson Inc,
Washington, USA). Upper arm cuffs were inflated intermittently to 40 mmHg
pressure for 10 s in every 15 s to achieve venous occlusion and obtain
















Substance P 4 pmol/min
Figure 2.3
Forearm venous occlusion plethysmography: typical recording.
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plethysmograph (D.E. Hokanson) was processed by a MacLab® analogue-to-digital
converter and Chart™ v3.3.8 software (AD Instruments Ltd, Castle Hill, Australia)
and recorded onto a Macintosh Classic II computer (Apple Computers Inc,
Cupertino, USA). Calibration was achieved using the internal standard of the
plethysmograph.
2.3.3 Data Analysis
Plethysmographic data were extracted from the Chart™ data files and forearm blood
flows were calculated for individual venous occlusion cuff inflations by use of a
template spreadsheet (Excel v5.0; Microsoft). Recordings from the first 60 seconds
after wrist cuff inflation were not used because of the variability in blood flow that
this incurs [Kerslake 1949, Webb 1995], Usually, the last five flow recordings in
each three minute measurement period were calculated and averaged for each arm
To reduce the variability of blood flow data, the ratio of flows in the two arms was
calculated for each time point: in effect using the non-infused arm as a
contemporaneous control for the infused arm [Benjamin et al 1995; Webb 1995],
Percentage changes in the infused forearm blood flow were calculated [Benjamin et
al 1995; Webb 1995] as follows:
% Change in blood flow = 100 x (It/NIt - h/NIb} / VNIb
where lb and Nib are the infused and non-infused forearm blood flows at baseline
(time 0) respectively, and It and NIt are the infused and non-infused forearm blood
flows at a given time point respectively.
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2.4 INTRACORONARY ULTRASOUND
2.4.1 Left Coronary Artery Cannulation
Following diagnostic coronary angiography, patients with left main stem disease or a
minimal luminal diameter of <2 mm in the left anterior descending artery were
excluded because of the potential of the imaging catheter to impede anterograde
coronary blood flow. All patients received 5,000 IU of intravenous heparin and,
through an 8 F haemostatic sheath (Cordis®, Cordis Europa N.V., Roden, The
Netherlands), the left coronary artery was cannulated with a 7 F guide catheter
(Cordis®).
2.4.2 Morphometric Assessment: Intravascular Ultrasound (IVUS)
Following insertion of the 0.014 inch Doppler guide wire, 3.2 F Ultracross™ IVUS
imaging catheter (SCIMED®, Boston Scientific Corporation, MN, USA) was
advanced into left anterior descending coronary artery over the guide wire. The
imaging probe was retracted within the imaging catheter sheath at 0.5 mm/s using a
motorised pullback device (Boston Scientific Corp). Ultrasound images were
recorded onto S-VHS tape using the Clearview™ ultrasonogram (Boston Scientific
Corp).
Computerised three-dimensional reconstructions of the proximal left anterior
descending coronary artery were performed off-line by a single blinded operator
using the TomTec computer system (Echoscan, TomTec Imaging Systems,
Unterschleissheim, Germany). The proximal atheromatous plaque volume was
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calculated using a well validated edge detection algorithm [von Birgelen et al 1996a;
von Birgelen et al 1997], The planar contours were checked by the operator and, if
necessary, edited. The plaque area was defined as the region between the luminal
border and the echogenic interface of the external elastic lamina as previously
described [Di Mario etal 1998; von Birgelen etal 1996b],
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Figure 2.4
Intravascular ultrasound: cross-sectional views and three dimensional reconstruction









Doppler wire measurement of coronary flow velocity.
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2.4.3 Intracoronary Drug Infusion
Selective left anterior descending coronary artery drug infusion was attained by
infusion through the flush port of the IVUS catheter [Schwarzacher et al 2000], All
drugs were dissolved in saline (0.9%: Baxter Healthcare Ltd, Thetford, UK) and
infused via an IVAC PI000 syringe pump (IVAC Ltd, Basingstoke, UK). The total
rate of intracoronary infusions was maintained constant throughout all studies at 1
mL/min.
2.4.4 Coronary Blood Flow Measurement
Following recording of the IVUS pullback examination, the IVUS imaging catheter
was repositioned at the ostium of the left anterior descending artery just distal to the
bifurcation of the left main stem The Doppler guide wire (0.014 inch Flowire™,
Cardiometrics, Endosonics, Rancho Cordova, CA) was retracted to the tip of the
imaging sheath. The average peak velocity of the Doppler signal was recorded onto
S-VHS tape using the Flomap™ (Cardiometrics, Endosonics, Rancho Cordova, CA)
Doppler velocimeter.
The left anterior descending artery cross-sectional area was measured using
computerised planimetry (Clearview™, Boston Scientific Inc) of the IVUS vessel
luminal area. The images were gated to the electrocardiogram and measurements
were made at the onset of the QRS complex. Blood flow velocity was determined
using average peak velocity of the Doppler signal (Flopmap™ (Cardiometrics,
Endosonics). Blood flow in the left anterior descending coronary artery was defined
as [Doucette et al 1992]:
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Coronary blood flow (mL/min) = CSA . APY. 60
2 100
where CSA = cross-sectional area (mm2) and APV = average peak velocity (cm/s).
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2.5 FIBRINOLYTIC AND HAEMOSTATIC PARAMETERS
2.5.1 Forearm Venous Sampling
Venous cannulae (17G) were inserted into large subcutaneous veins of the
antecubital fossa in both arms as described previously [Plumpton et al 1995],
TenmL of blood was withdrawn simultaneously from each arm and collected into
acidified buffered citrate (Biopool® Stabilyte™, Umea, Sweden) and citrate
(Monovette®, Sarstedt, Niimbrecht, Germany) tubes, and kept on ice before being
centrifuged at 2,000 g for 30 minutes at 4°C. Platelet free plasma was decanted and
stored at -80°C before assay [Kluft & Verheijen 1990],
2.5.2 Arterial And Coronary Sinus Blood Sampling
Arterial samples were obtained through an 8 F haemostatic sheath placed in the right
femoral artery. Cannulation of the coronary sinus from the femoral vein was
performed using a preformed specific 6F catheter (modified Simmons Torcon NB
catheter, HNB6.0-NT-100-PW-2S-112393-BH) [Katritsis & Webb-Peploe 1997], To
avoid .atrial blood mixing, the catheter was advanced, sometimes with the assistance
of a guide wire, deep into the ostium and beyond the posterior interventricular vein.
Adequate positioning of the catheter was ensured by determining coronary sinus
blood oxygen saturations using an automated oximeter (Oxicam™ 300, Watco
Services, Basingstoke, UK).
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2.5.3 Plasma Fibrinolytic Parameter Assays
Plasma PAI-1 and t-PA antigen concentrations were determined using an enzyme-
linked immunosorbent assay; Coaliza® PAI-1 [Declerck et al 1988b] and Coaliza® t-
PA [Booth et al 1987] (Chromogenix AB, Molndal, Sweden) respectively. Plasma
PAI-1 and t-PA activities were determined by a photometric method, Coatest® PAI-1
[Wiman et al 1988] and Coaset® t-PA [Gram et al 1987] (Chromogenix AB). Intra-
assay coefficients of variation were 7.0% and 5.5% for t-PA and PAI-1 antigen, and
4.0% and 2.4% for activity, respectively. Inter-assay coefficients of variability were
4.0%, 7.3%, 4.0% and 7.6% respectively. The sensitivities of the assays were 0.5
ng/mL, 2.5 ng/mL, 0.10 IU/mL and 5 AU /mL respectively.
2.5.4 Plasma Haemostatic Factor Assays
Von Willebrand factor (vWf) antigen was determined [Cejka 1982] using an
enzyme-linked immunosorbent assay (Dako A/S, Glostrup, Denmark) with a
sensitivity of 0.05 IU/mL. The intra-assay and inter-assay coefficients of variability
were 5.2% and 7.3% respectively. Factor VIITC procoagulant activity was
determined using a standard one stage assay on an ACL-3000+ coagulometer
(Instrumentation Laboratory, Warrington, UK).
2.5.5 Haematocrit Measurement
Haematocrit was determined by capillary tube centrifugation of blood anticoagulated
by ethylene diamine tetraacetic acid.
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2.5.6 Data Analysis And Statistics
For the forearm studies, estimated net release of t-PA activity and antigen was
defined as the product of the infused forearm plasma flow (based on the haematocrit,
Hct and the infused forearm blood flow, FBF) and the concentration difference
between the infused ([t-PAJinf) and non-infused arms ([t-PA]Non-inf)-
Estimated net forearm t-PA release = FBF x {1 -Hct} x {[t-PAJinf. [t-PA]Non-inf}
Because the coronary sinus drains some regions of the heart outwith the left anterior
descending coronary artery territory, the net release of t-PA will tend to be under
estimated. Flowever, an index of cardiac t-PA release was defined as the product of
the left anterior descending artery plasma flow (based on the haematocrit, Hct and
the left anterior descending coronary blood flow, CBF) and the plasma arterial ([t-
PAjArt) and coronary sinus ([t-PA]ven) concentration differences.
Estimated net cardiac t-PA release = CBF x {1-Hct} x {[t-PA]ven - [t-PA] Art)
Data were examined by analysis of variance (ANOVA) with repeated measures, two
tailed paired Student's t-test and regression analysis using Excel v5.0 (Microsoft). All
results are expressed as mean ± standard error of the mean. Statistical significance
was taken at the 5% level.
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CHAPTER 3
INTRA ARTERIAL SUBSTANCE P MEDIATED VASODILATATION
IN THE HUMAN FOREARM: PHARMACOLOGY,
REPRODUCIBILITY AND TOLERABILITY
Newby DE, Sciberras DG, Mendel CM, Gertz BJ, Boon NA, Webb DJ.
Intra-arterial substance P mediated vasodilatation in the human forearm,
pharmacology, reproducibility and tolerability.
Br JClin Pharmacol 1997;43:493-499.
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3.1 SUMMARY
The current studies were designed to characterise the pharmacology, reproducibility
and tolerability of the vasodilator response to intra-arterial substance P infusion in
the forearm of healthy man. On different occasions, eight healthy male volunteers
received brachial artery infusions of substance P at doubling doses ranging from 0.5
to 128 pmol/'min. Blood flow was measured in both arms using venous occlusion
plethysmography. Substance P induced dose-dependent vasodilatation in the human
forearm which had a log-linear relationship to dose. At doses of 1 to 8 pmol/min,
mean responses were highly reproducible both within and between days. There were
no differences between responses to discontinuous doses and continuous doses of
substance P. Substance P was generally well tolerated at doses of >64 pmol/min with
no significant alteration in arterial blood pressure or heart rate. Skin oedema in the
infused forearm and systemic vasodilatation, manifested by facial flushing and non-
infused forearm vasodilatation, occurred at doses of >16 pmol/min. Forearm
vasodilatation to substance P represents a reproducible and useful model in the
assessment of peripheral endothelial cell NKi receptor function.
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3.2 INTRODUCTION
Substance P is a widely distributed endecapeptide which is found principally in the
neural tissue of the central, peripheral and enteric nervous systems [Hokflet et al
1977; Lundberg et al 1979; Pernow 1983; Aronin et al 1986], The physiological
functions of substance P include neurotransmission in primary sensory neurones,
with particular involvement in nociception and emesis. In addition to functioning as a
neurotransmitter, it also acts as an inflammatory mediator [Barnes et al 1990;
Cappugi et al 1992; Smith et al 1993] and neurohumoral regulator [Aronin et al
1986; Coiro et al 1992a+b], Substance P is a member of the tachykinin family of
peptides and acts through stimulation of the neurokinin receptors, having a
particularly high affinity for the type 1 (NKi) receptor [Stjarne et al 1994],
When given intra-arterially, substance P is a potent vasodilator [Lofstrom et al 1965;
Eklund et al 1977; McEwan et al 1988] through an endothelium-dependent
mechanism [Gross et al 1994] which is predominantly mediated by nitric oxide
release [Cockcroft et al 1994], This response is induced via stimulation of the
endothelial cell NKi receptor [Stjarne et al 1994] and, increasingly, substance P is
being used to assess endothelial cell function in health and disease in man [Crossman
et al 1989; Okumura et al 1992; Holdright et al 1994; Panza et al 1994; Casino et al
1995], Indeed, substance P has been infused into the coronary artery of man at doses
up to 90 pmol/min [Crossman et al 1989; Okumura et al 1992; Holdright et al 1994],
However, the reproducibility and tolerability of intra-arterial substance P in the
human forearm has not been fully characterised and validated. Previous studies
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describing such infusions in the forearm have either used less precise methodology,
including unilateral plethysmography and inclusion of the hand circulation [Eklund
etal 1977], or have only incompletely described the nature of the response [McEwan
etal 1988],
Therefore, the aim of the present study was to characterise the pharmacodynamics,
reproducibility and tolerability of the vasodilator responses to arterial administration




Eight healthy male subjects aged between 20 and 34 years participated in a series of
four studies.
3.3.2 Drugs
Synthetic pharmaceutical-grade substance P (Clinalfa AG, Laufelfingen,
Switzerland) of >95% purity, was administered following dissolution in
physiological saline (0.9% sodium chloride: Baxter Healthcare Ltd, Thetford, UK).
3.3.3 Study Design (Figure 3.1)
Subjects rested recumbent throughout each study. Strain gauges and cuffs were
applied, and the brachial artery of the non-dominant arm cannulated. Saline was
infused for the first 30 minutes to allow for equilibration. Forearm blood flow was
measured for 3 minutes beginning at 25, 15 and 6 minutes before commencing
substance P infusions. Throughout all studies, substance P was infused for 6 minutes
at each dose. Forearm blood flow measurements were made for the last 3 minutes of
each infusion period.
The tolerability of substance P was assessed in seven subjects who were given
incremental doubling doses of substance P from 0.5 pmol/min to a maximum of
128 pmol/min [Eklund et al 1977], followed by a 30 minute infusion of saline
(protocol a). To determine within and between day reproducibility, each subject
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Figure 3.1
Study design: protocols a, b, c and d with saline (g|) and substance P (□) infusions.
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re-attended 7 to 14 days later and received 1, 2, 4 and 8 pmol/min of substance P
followed by saline for 30 minutes before receiving further incremental doses of 1, 2,
4 and 8 pmol/min of substance P (protocol b).
In order to examine whether responses to substance P undergo tachyphylaxis, seven
subjects were given substance P infusions at sequential doses of 1, 2, 4, 8, 4, 2 and
1 pmol/min, followed by saline for 30 minutes before receiving substance P at
sequential doses of 8, 4, 2, 1, 2, 4 and 8 pmol/min (protocol c). Seven to 14 days
later, each subject re-attended and received an infusion of substance P at doses of
0.5, 1, 2, 4 and 8 pmol/min with each dose separated by a 24 minute period of saline
infusion (protocol d). One subject withdrew for personal reasons after completing
protocols a and b, and was replaced for protocols c and d.
3.3.4 Data Analysis And Statistics
Data were examined by two way analysis of variance (ANOVA) with repeated
measures, regression analysis and two tailed Student's /-test using Excel v5.0
(Microsoft). All results are expressed as means ± standard errors of the mean
Statistical significance was taken at the 5% level. Within and between day
reproducibility was assessed using the method of Bland & Altman [1986] and




3.4.1 Tolerability Of Intra-Arterial Substance P Infusion
Transient and patchy flushing of the infused arm occurred at all doses, whereas facial
flushing was only observed at doses of >32 pmol/min. Five subjects received
64 pmol/min and two subjects received 128 pmol/min as the maximal dose: further
infusion of substance P was discontinued because of extensive forearm skin oedema
and facial flushing. There were no significant increases in heart rate or decreases in
blood pressure up to 64 pmol/min (Table 3.1). No subject reported discomfort or
local fullness with substance P infusion, but two subjects described transient light¬
headedness at doses of 16 and 64 pmol/min. In the infused forearm, patchy skin
oedema developed in some subjects at 16 pmol/min and consistently, in all by
32 pmol/min. The oedema had an urticarial appearance, taking the form of a raised
wheal with a yellow hue. However, there was no associated pruritis and the lesions
were non-tender. The extent of oedema varied between subjects, beginning at the
level of the elbow and extending distally with increasing dose. The affected areas
ranged from 1 to 10 cm in diameter, but all resolved completely within 1 to 2 hours
of stopping the infusion.
3.4.2 Blood Flow Responses
3.4.2.1 Dose Range Of Vasodilator Responses
Substance P increased blood flow in the infused forearm (p<0.001) in a dose-
dependent manner which reached a maximum of 21 ± 3.1 mL/lOOmL/min (466 ±
192%) by 16 pmol/min (Table 3.2 and Figure 3.2). There was a significant increase
50
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in the blood flow of the contralateral, non-infused arm (p = 0.001, ANOVA) which
was apparent from 16 pmol/min (p = 0.05, /-test) Relative percentage increase in
blood flow of the infused to non-infused arm was dose-dependent and peaked at
32 pmol/min before declining at 64 pmol/min. The increases in blood flow had a
linear relationship to the logarithm of substance P dose (Figure 3.2\y = 174 + 242x;
r = 0.997, p<0.001) at doses <32 pmol/min.
3.4.2.2 Reproducibility Of Vasodilator Responses
There were no significant differences between the mean vasodilator responses to
substance P either between days or within a single day (Figure 3.3A). The
reproducibility of individual within day and between day responses are shown in
Table 3.3. The 95% confidence intervals indicated by the coefficients of
repeatability, are ~2 to 4-fold smaller for within day responses compared to those
between day. These data, for a sample population of eight subjects, give 95% power
to detect a mean shift in the dose response of >4-fold and >8-fold when comparing
within day and between day responses respectively.
There.was a trend for the magnitude ofmean vasodilator responses to substance P to
undergo attenuation with continuous infusions, but this did not achieve statistical
significance (Figure 3.3B). Likewise, there were no significant differences between
the vasodilatation to isolated discontinuous doses and incremental continuous doses
of substance P (Figure 3,3C). Absolute forearm blood flows in both arms in all four
protocols are shown in Table 3.2.
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Table3.3. WithinAndBetweenDayR producibilityF rIndividualP rcentageIncr asesFo rmBloodl wAt1,248pmol/min SubstanceP Dose(pmol/min)WithinDayResponses
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Panel A - within and between day mean increases in forearm blood flow to 1, 2, 4 and 8
pmol/min: protocol a dose response (o); protocol b, first dose response and protocol b,
second dose response Q. Panel B - development of tachyphylaxis with protocol c: first dose
response (O); second and third dose responses (f|; both were superimposable and the second
response only is shown for the sake of clarity); and fourth dose response Q. Panel C -
comparison of isolated discontinuous and incremental continuous infusions: protocol c. first
dose response and protocol d, first dose response (O).
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3.5 DISCUSSION
Intra-arferial substance P infusion at doses up to and including 64 pmol/min were
generally well tolerated with no significant changes in supine blood pressure and
heart rate. Previous studies [Eklund et al 1977; Schaffalitzky et al 1986; Fuller et al
1987] using intravenous dosing have induced flushing, tachycardia and decreased
blood pressure at higher doses (>150 pmol/min). However, skin oedema associated
with arterial infusion has not been reported before, despite intra-brachial infusions of
up to 48 pmol/min [Eklund et al 1977], This disparity may reflect the previously
shorter infusion times of 4 minutes per dose [Eklund et al 1977] or the relative
purities of substance P administered. Nevertheless, our observations are consistent
with the action of substance P as an inflammatory mediator inducing protein
extravasation and leucocyte migration [Cappugi et al 1992], These effects may affect
baseline forearm circumference but not the rate of forearm expansion with
plethysmography measurements unless the rate of oedema formation were to
approach that of forearm blood flow, or oedema formation were to raise tissue
extracellular fluid pressure above 40 mmHg. This would be associated with
substantial tissue swelling and would exceed the observed limited oedematous
response.
Substance P has been used as an endothelium-dependent vasodilator in the human
coronary circulation [Crossman et al 1989; Okumura et al 1992; Holdright et al
1994], Total coronary blood flow is -300 mL/min (60 to 90 mL/100 mL of
tissue/min) which compares with -50 mL/min (3 to 5 mL/100 mL of tissue/min) in
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the forearm. Although left coronary artery blood flow is, therefore, ~3 to 4 times
higher than that in the brachial artery, substance P does increase left coronary blood
flow and at concentrations similar to those achieved in the forearm [Holdright et al
1994],. Therefore, given that substance P can cause oedema in the forearm and the
consequences of unrecognised myocardial oedema may be serious, we would caution
against the intra-coronary administration of high doses of substance P in man.
Intra-arterial substance P caused consistent and dose-dependent local increases in
forearm blood flow without systemic effects at doses up to and including
8 pmol/min. In agreement with previous studies [Eklund et al 1977; McEwan et al
1988; Hirooka et al 1992; Cockcroft et al 1994; Panza et al 1994; Casino et al 1995],
the vasodilator response was linearly related to the logarithm of the substance P dose.
However, at doses of greater than or equal to 16 pmol/min, substance P induced
systemic vasodilatation as indicated by facial flushing and an increase in forearm
blood flow of the contralateral non-infused arm, although no significant decrease in
blood pressure, or increase in heart rate, was observed. The use of comparative
increases in forearm blood flow of the infused forearm with respect to the non-
infused arm, becomes invalid at systemic doses and accounts for the breakdown of
the log-linearity of responses at doses ofmore than 32 pmol/min.
McEwan and colleagues [McEwan et al 1988] have shown that substance P at
1 pmol/min undergoes tachyphylaxis when infused continuously for 10 minutes or
more. However, we did not find a statistically significant attenuation of the responses
when administering decremental doses of substance P. Moreover, we found no
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greater response with incremental discontinuous infusions than with incremental
continuous doses of substance P. Mean increases in forearm blood flow to substance
P at doses of 1 to 8 pmol/min were of equivalent magnitude both within day and
between days. Eklund and colleagues [Eklund et al 1977] have reported variable
measurements with substance P, but their results are confounded by utilising cruder
methodology with unilateral forearm plethysmography and inclusion of the hand
circulation. In contrast to the muscular forearm, the hand is predominantly skin and
has a heterogeneous circulation which is regulated in a complex and non-linear
manner [Webb 1995], We have demonstrated good reproducibility when comparing
individual within day responses. Based on a sample size of eight, the confidence
intervals would indicate that we would have 95% power to detect >4-fold shift in the
dose-response relationship when comparing within day responses at each dose.
In surnmary, we have found using within day comparisons, that at doses up to
8 pmol/min, vasodilatation to substance P is generally well tolerated and highly
reproducible. Such methodology should provide a practical and sensitive method of




SUBSTANCE P INDUCED VASODILATATION IS MEDIATED BY THE
NEUROKININ TYPE 1 RECEPTOR BUT DOES NOT CONTRIBUTE TO
BASAL VASCULAR TONE IN MAN
Newby DE, Sciberras DG, Ferro CJ, Gertz BJ, Sommerville D,
Majmadar A, Lowry RC, Webb DJ.
Substance P induced vasodilatation is mediated by the neurokinin type 1 receptor but
does not contribute to basal vascular tone in man.
Br J Clin Pharmacol 1999;48:336-344.
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4.1 SUMMARY
Following intravenous administration of its prodrug, L-758,298, we assessed the
pharmacodynamics of L-754,030, a novel and highly selective NK] receptor
antagonist, by examining systemic haemodynamics and the blood flow responses to
intra-arterial substance P infusion. Sixteen healthy male volunteers participated in a
double blind, randomised, placebo controlled crossover trial of L-758,298. Forearm
blood flow was measured using venous occlusion plethysmography during intra-
brachial substance P infusion (0.125-128 pmol/min). In Part 1, eight subjects
received substance P infusions before and during placebo, 0.25 mg, 1 mg or 5 mg of
L-758,298. In Part 2, eight subjects received substance P infusions 24 hours after
placebo or 1.43 mg of L-758,298 L-758,298 caused dose-dependent inhibition of
substance P induced vasodilatation during administration (p<0.001). Placebo
adjusted differences (95% CI) in baseline forearm blood flow, mean arterial pressure
and heart rate showed no relevant changes with 5 mg of L-758,298 (>1400-fold shift
in substance P response): 0.00 (-0.49 to +0.49) mL/100 mL/min, 1.0 (-3.2 to +5.2)
mmHg and 1.9 (-5.9 to +9.7) /min respectively. Twenty-four hours after 1.43 mg of
L-758,298, there was ~34-fold shift in response to substance P induced
vasodilatation (p<0.008) at plasma L-754,030 concentrations of 2 to 3 ng/mL.
L-758,298 was generally well tolerated without serious adverse events. Substance P
induced forearm vasodilatation is mediated by the endothelial cell NKi receptor in
man but endogenous substance P does not appear to contribute to the maintenance of
peripheral vascular tone or systemic blood pressure.
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4.2 INTRODUCTION
Substance P is a widely distributed endecapeptide which is found principally in the
neural tissue of the central, peripheral and enteric nervous systems [Hokfelt et al
1977; Lundberg et al 1979; Pernow 1983; Aronin et al 1986], The physiological
functions of substance P include neurotransmission in primary sensory neurones with
particular involvement in nociception and emesis. In addition to functioning as a
neurotransmitter, it also acts as an inflammatory mediator [Barnes et al 1990;
Cappugi et al 1992; Smith et al 1993] and neurohumoral regulator [Hokfelt et al
1977; Coiro et al 1992a+b],
Substance P is a member of the tachykinin family of peptides and acts through
stimulation of the neurokinin receptors, having a particularly high affinity for the
type 1 (NKi) receptor [Stjarne et al 1994], When given intra-arterially, substance P
is a potent vasodilator [Lofstrom et al 1965; Eklund et al 1977; McEwan et al 1988]
through an endothelium-dependent mechanism [Gross et al 1994] which is partly
mediated by nitric oxide release [Cockcroft et al 1994], In animal studies, this
response is induced via stimulation of the endothelial cell NKi receptor [Stjarne et al
1994] although, to date, this has not been confirmed in vivo in man. Substance P is
found in perivascular neural tissue [Weihe et al 1981] and has been postulated to
play a role in the regulation of vascular tone [Crossman et al 1989; Quyyumi et al
1997],
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Antagonism of the NKi receptor has potentially diverse therapeutic indications such
as in the treatment of pain, inflammation and emesis [Navari et al 1999], L-754,030
(2-(R)-(l-(R) -3,5-bis (trifluoromethyl) phenylethoxy)-3-(S)-(4-fluoro) phenyl-4-(3-
(5-oxo-4H-l,2,4-triazolo)methyl morpholine; also known as MK-869) is a long
acting, highly selective, competitive NKi receptor antagonist with poor solubility in
aqueous solution. L-754,030 is more selective for the NKi than the NK3
(3,000-fold) or the NK2 and other G-protein linked receptors and ion channels
(>50,000-fold) [Kramer et al 1998], N-phosphorylation of L-754,030 produces
L-758,298, a prodrug which is readily soluble in aqueous solutions. L-758,298
undergoes rapid in vivo conversion to L-754,030 and thereby provides a prodrug
which can be administered intravenously.
The primary aims of the present study were: first, to determine the ability of
L-754,030 to inhibit substance P induced vasodilatation during and 24 hours after
intravenous administration of L-758,298; second, to confirm that substance P
induced vasodilatation is mediated via the endothelial cell NKi receptor in man; and
third, to determine whether endogenous substance P regulates peripheral vascular
tone or blood pressure in man. An additional important aim of the study was to





Healthy non-smoking men aged between 18 and 45 years participated in a series of
studies which were undertaken with the approval of the Lothian Research Ethics
Committee and the written informed consent of each subject.
4.3.2 Drug Administration
Synthetic pharmaceutical-grade substance P (Clinalfa AG, Laufelfingen,
Switzerland) of >95% purity, was administered following dissolution in saline.
Matched placebo and L-758,298 (Merck Research Laboratories, West Point, USA)
were reconstituted with 0.9% saline in glass vials containing 50 mg of mannitol
alone or 6 mg of L-758,298 and 50 mg of mannitol respectively. The 5 mg initial
dose of L-758,298 was chosen to exceed the ID90 of 50 pg/kg in the guinea pig
sensorotoxin-induced systemic vascular leak model (Merck Research Laboratories,
Terlings Park, UK). Cannulae were inserted into the veins of the antecubital fossae of
both arms. L-758,298 was administered into the dominant arm via a 19-G cannula
(Wallace Y-Can; Wallace Ltd, Colchester, UK) and venous samples were withdrawn
from the non-dominant arm via a 17-G cannula (Venflon; BOC Ohmeda AB,
Helsingborg, Sweden).
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4.3.3 Pharmacokinetics, Safety and Tolerability
Ten mL of blood was withdrawn from the non-dominant arm before and after the
incremental infusion of substance P and admixed with 1 mL of 1% disodium EDTA.
Blood samples were placed on ice before being centrifuged at 2,000 g for
30 minutes. Plasma was frozen and stored at -80°C prior to assay. Plasma L-754,030
concentrations were determined using high performance liquid chromatography and
mass spectrometry using an internal standard (L-752,611). The assay was validated
over a concentration range of 1 to 500 ng/mL with a limit of detection at 1 ng/mL
and a coefficient of variation of <9%.
Safety and tolerability assessments were made before, during and following
completion of the study and included: clinical examination, repeated questioning for
symptoms, clinical chemistry screen (liver enzymes, bilirubin, electrolytes, urea,
creatinine, protein and albumin), haematology screen (full blood and differential
count), urinalysis and 12-lead electrocardiogram.
4.3.4 Study Design (Figure 4.1)
Subjects attended at 9.00 am, rested recumbent throughout each study and
intravenous cannulae were inserted into each arm. Strain gauges and cuffs were
applied, and the brachial artery of the non-dominant arm cannulated. Saline was
infused into the arterial cannula for the first 30 minutes to allow for equilibration.
Forearm blood flow was measured for 3 minutes beginning at 23, 13 and 3 minutes
before commencing substance P infusions. Throughout all studies, substance P was
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infused for 10 minutes at each dose. Forearm blood flow measurements were made
from 3 to 6 minutes of each infusion period.
4.3.4.1 Screening
Before inclusion in the main study, subjects received intra-arterial infusions of
substance P at 0.125, 0.5, 2, 8 and 32 pmol/min [Newby et al 1997a], To reduce
overall variability in the responses, subjects were recruited to the main study if
2 pmol/min of substance P increased forearm blood flow by :> 100% and =s500%.
4.3.4.2 Part 1 -Maintenance L-758,298 Infusion
On each occasion, eight subjects received incremental intra-arterial infusions of
substance P at 0.125, 0.5, 2 and 8 pmol/min followed by 60 minutes of saline. A
second infusion of substance P was then administered at 0.125, 0.5, 2, 8, 32 and
128 pmol/min [Newby et al 1997a],
At the beginning of the intervening 60 minute saline infusion, subjects received a
double blind, randomised intravenous infusion of either L-758,298 or placebo:
Table 4.1. An intravenous bolus (two-thirds of the total dose over 20 minutes) was
given followed by a continuous maintenance infusion (one-third of the total dose
over the subsequent 100 minutes) throughout the second challenge of intra-arterial
substance P administration. From earlier phase I pharmacokinetic studies in man
(Merck; data on file), this dosage regimen was predicted to produce a stable plasma
concentration of L-754,030 during the second incremental infusion of intra-arterial




























Figure4.1 Schematicofprotocol. DosesfsubstancePgiveninpmol/min.Arrowindic tbl dsamplingti ep i tsf rhe imatiofpl maL-754,030concentratio s.P t2i fusion werecommenced24hou safter1. 3gfintravenousL-758,298administration.
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Table 4.1.
Schematic of drug allocation

































Di =5mg of L-758,298
*If the PDioo increases by >40-fold then D2 - 1 mg of L-758,298; if <40-fold, D2 = 20 mg
|If the PD100 continues to be >40-fold then d3 = 0.25 mg of L-758,298 or <40-fold,
d3 = 80 mg: otherwise the study is completed after 3 weeks i.e. d3 = placebo
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120 minutes after the start of the intravenous infusion of L-758,298 or placebo. In the
first week, subjects received a total dose of 5 mg of L-758,298 or placebo. The next
dose administered in the second week would be increased to 20 mg if the PDioo
(defined below) was increased by <40-fold by 5 mg of L-758,298 or reduced to 1 mg
if >40-fold (based on data from six subjects). The same criteria were applied to
determine' whether the final dose (80 mg or 0.25 mg) of L-758,298 was to be
administered, or the study completed after two doses of L-758,298 and placebo
(based on data from four subjects; see Table 4.1). If the third dose was not to be
given then this would be replaced by placebo and the study terminated after 3 weeks.
To maintain double blind randomisation, all data analysis and dosage decisions were
made at the central co-ordinating centre (Merck Research Laboratories, Terlings
Park, UK) independent of the investigators.
4.3.4.3 Part 2 — 24 Hours Post L-758,298 Infusion
Eight further subjects attended on two occasions, one week apart, and received an
intravenous infusion of either L-758,298 or placebo over 30 minutes in a double
blind randomised manner. Subjects returned 24 hours later to receive infusions of
intra-arterial substance P at 0.125, 0.5, 2, 8, 32 and 128 pmol/min [Newby et al
1997a], Plasma samples to measure L-754,030 concentrations were taken 24 and
25 hours after the start of the intravenous infusion of L-758,298 or placebo. The dose
of L-758,298 was derived from the pharmacodynamic and pharmacokinetic data of
part 1 and was chosen to produce an approximately 40-fold increase in the PDjoo
24 hours after L-758,298 administration. L-754,030 has a plasma half life of
15 ± 4 hours in man.
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4.3.5 Data Analysis And Statistics
Percentage change in forearm blood flow from baseline was calculated using the
ratios of flows in the two arms for each of the substance P infusions. Natural
logarithm transformations of the substance P doses were used to estimate individual
PDioo values using linear regression techniques. The PDioo was defined as the
interpolated or extrapolated dose of substance P which provokes a 100% increase in
forearm blood flow. To determine whether there was a within day difference in
PDioo following placebo, an analysis of variance (ANOVA) with the terms 'subjects'
and 'time' (predose and postdose) was used to analyse the natural logarithm
transformed PDioo data from the placebo treatment group in Part 1.
The influence of each dose of L-758,298 in Parts 1 and 2 on the forearm blood flow
response to substance P were evaluated relative to placebo. In these analyses, the
PDioo after administration of a placebo dose was used as the control for assessment
of the fold shifts in PDioo due to the administration of the various doses of
L-758,298. An ANOVA with the terms 'subject' and 'treatment' was used to analyse
the natural logarithm transformed PDioo data from the treatments in Part 1. An
ANOVA appropriate for a two period crossover study was used to analyse the natural
logarithm transformed PDioo data from the treatments in Part 2. These ANOVA
analyses were used to estimate the geometric means, their ratios and 95% confidence
interval's for the geometric mean ratio for PDioo-
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Mean arterial pressure, heart rate and blood flow data were examined, where
appropriate, by multifactorial ANOVA with repeated measures and paired Student's
t-test. All results are expressed as mean ± standard error of the mean. Statistical
significance was taken at the 5% level.
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4.4 RESULTS
Twenty-two healthy male volunteers were required to identify 16 subjects who met
the entry criteria: forearm blood flow increased by >500% in two subjects and
<100% in four subjects. The sixteen volunteers subsequently recruited were aged
30 ± 2 years (range 20 to 40 years) and weighed 76 ± 3 kg (range 61 to 95 kg).
There were no significant baseline differences in forearm blood flow, blood pressure
or heart rate between any parts of the study.
4.4.1 Part 1
Substance P caused dose-dependent vasodilatation in the non-dominant arm
(p<0.001; ANOVA) during the first incremental infusion of substance P which was
not significantly different between screening or the four separate study days.
L-758,298 was administered in three descending doses: 5, 1 and 0.25 mg. During
placebo and L-758,298 infusion, there were no significant changes in blood pressure,
heart rate, or blood flow in the dominant forearm (Table 4.2). Placebo adjusted
differences (95% CI) in dominant forearm blood flow, mean arterial pressure and
heart rate with 5 mg of L-758,298 were 0.00 (-0.49 to 0.49) mL/100 mL/min,
1.0 (-3.2 to 5.2) mmHg and 1.9 (-5.9 to 9.7) /min respectively. Plasma concentrations
of L-754,030 were not significantly different immediately before and after the
second incremental infusion of substance P (Table 4.2).
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*p<0.001(vsbaseline;M t)t . 5bas li ;t-test). {n=8for0.25mg,n=71i43and25fL-758,29 . §MaximumsubstancePdose:8pmol/minf rt1,pre-inf sion;28pmol/miadur ginfu io ;p ol/ irt2
73
In comparison to the response to the first incremental infusion, the response to the
second infusion of substance P was significantly different following placebo
(p<0.006) and all doses of L-758,298 in a dose-dependent manner (Table 4.2;
Figure 4.2). The geometric mean PDioo (95% CI) increased by 1.85-fold
(1.27 to 2.86) during placebo infusion. The influence of each dose of L-758,298 on
the forearm blood flow response to substance P was examined relative to placebo.
The geometric mean PDioo (95% CI) increased by 30-fold (9-99) with 0.25 mg,
319-fold (98 to 1044) with 1 mg and >1400-fold with 5 mg of L-758,298 (p<0.001
for all).
Forearm blood flow in the dominant arm increased at doses s>32 pmol/min of
substance P only during placebo (p=0.02 vs baseline; paired t-test). Fleart rate and
blood pressure did not change significantly (Table 4.2).
4.4.2 Part 2
Following placebo infusion, substance P again caused dose-dependent vasodilatation
in the non-dominant arm (p<0.001; ANOVA: Figure 4.3). However, 24 hours
following intravenous administration of 1.43 mg of L-758,298, substance P induced
vasodilatation was significantly inhibited (Table 4.2; Figure 4.3). The geometric
mean PDioo (95% CI) was increased by 34-fold (4 to 299; p<0.008). The PDioo and
plasma L-754,030 concentrations (Table 4.2) were similar to those obtained with
0.25 mg of L-758,298 in Part 1.
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0 0 0 0.125 0.5 2 8 32 128
Substance P Infusion (pmol/min)
Figure 4.3
Part 2: Forearm blood flow responses to intra-brachial substance P infusion. Mean ± SEM.
° Placebo; ■ 1.43 mg ofL-758,298
* pCO.OOl; L-758,298 vs placebo, ANOVA.
Forearm blood flow in the dominant arm increased at doses >32 pmol/min following
placebo (p<0.02 vs baseline; paired t-test) and at 128 pmol/min following 1.43 mg of
L-758,298 (p=0.03 us baseline; paired Atest). Heart rate and blood pressure did not
change significantly (Table 4.2).
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4.4.3 Concentration-Response Relationship
Plasma L-754,030 concentrations significantly correlated with the logarithm of the
PD10o of the rate of substance P infusion (r=0.62, p=0.003; Figure 4.4).
4.4.4 Safety And Tolerability
L-758,298 was generally well tolerated by all the subjects, with no excess of adverse
events (mild headaches and back pain) in comparison to placebo. There were no
serious adverse events during the study and no clinically significant abnormalities












Figure4.4 Concentration-responserelation hipbetweethplasmaconcentrationfL-754,030a dthPD100v lufothr fsubstainfusio . Individualvaluesshownwithmean±SEM.Thr epo n swithindeter natPD100values>1454anotsho . °Placebo;"0.25mg,A1and*24hoursfter1.43fL-758,298 r=0.62,p 0.003
4.5 DISCUSSION
For the first time, we have shown that substance P induced forearm vasodilatation is
inhibited by a selective NKi receptor antagonist in vivo in man. During L-758,298
infusion, substance P induced forearm vasodilatation was inhibited in a dose-
dependent manner. At the highest dose of L-758,298, the vasodilator response to
substance P was abolished at doses up to 8 pmol/min, suggesting that substance P
mediated vasodilatation is entirely dependent on the endothelial NKi receptor.
Moreover, persistent inhibition of substance P induced vasodilatation was present
24 hours after L-758,298 infusion.
Despite previous proposals [Crossman et al 1989, Quyyumi et al 1997], it would
appear that substance P, acting via the NKj receptor, does not play a role in the
regulation of peripheral vascular tone or blood pressure. We observed no alterations
in baseline forearm blood flow or systemic haemodynamics following L-758,298
infusion despite a greater than 1454-fold shift in the PDioo for substance P induced
forearm vasodilatation. The 95% confidence intervals indicate that if substance P
provides any contribution to basal peripheral vascular tone or systemic
haemodynamics then it is rather small.
We have previously shown that repeated responses to substance P are reproducible
and well tolerated [Newby et al 1997a], In the current study, we have again seen
good reproducibility of both within-day and between-day responses to intra-arterial
substance P infusions. Systemic effects, such as increases in contralateral forearm
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blood flow, were also observed at substance P doses of >32 pmol/min without
significant changes in heart rate or blood pressure. Moreover, these increases in
contralateral forearm blood flow were also inhibited by L-758,298 infusion. Finally,
L-758,298 infusion was generally well tolerated without any significant adverse
events.
4.5.1 Study Limitations
Because L-758,298 was administered systemically, there remains the possibility that
compensatory mechanisms may have obscured a potential haemodynamic effect.
Direct intra-arterial administration of an NKi receptor antagonist would provide a
more precise method of assessing the role of substance P in the regulation of vascular
tone. However, L-758,298 is a prodrug which requires conversion by systemic
hepatic phosphatases to the active form L-754,030 and its intra-arterial
administration would, therefore, not result in local NKi receptor antagonism.
In the present study, we did not assess the selectivity of L-754,030 for the NKi
receptor by comparing substance P induced vasodilatation with an alternative non-
NKq receptor mediated, endothelium-dependent vasodilator, such as bradykinin or
acetylcholine, and this requires confirmation in future studies. However, L-754,030
has been shown to be highly selective for theNKi receptor [Kramer etal 1998],
We conclude that substance P induced forearm vasodilatation is mediated by the
endothelial cell NKi receptor in man. Endogenous substance P does not appear to
contribute to the maintenance of peripheral vascular tone or systemic blood pressure.
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In this study, intravenous L-758,298 was generally well tolerated with L-754,030
causing long lasting and potentNKi receptor antagonism in man.
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CHAPTER 5
AN IN VIVO MODEL FOR THE ASSESSMENT OF ACUTE FIBRINOLYTIC
CAPACITY OF THE ENDOTHELIUM
Newby DE, Wright RA, Ludlam CA, Fox KAA, Boon NA, Webb DJ.
An in vivo model for the assessment of




The effects on blood flow and plasma fibrinolytic and coagulation parameters of
intra-arterial substance P, an endothelium-dependent vasodilator, and sodium
nitroprusside, a control endothelium-independent vasodilator, were studied in the
human forearm circulation. At subsystemic locally active doses, both substance P
(2 to 8 pmol/min) and sodium nitroprusside (2 to 8 pg/min) caused dose-dependent
vasodilatation (p<0.001 for both) without affecting plasma concentrations of PAI-1,
von Willebrand factor antigen or factor VIII:C activity. Substance P caused local
increases in t-PA antigen and activity (p<0.001) in the infused arm while sodium
nitroprusside did not. At higher doses, substance P increased blood flow and t-PA
concentrations in the non-infused arm. We conclude that brief, locally active and
subsystemic infusions of intra-arterial substance P cause a rapid and substantial local
release of t-PA which appear to act via a flow and nitric oxide independent
mechanism. This model should provide a useful and selective method of assessing
the in vivo capacity of the forearm endothelium to release t-PA acutely.
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5.2 INTRODUCTION
Endothelial cells of the pre-capillary arterioles and post-capillary venules [Levin etal
1994] synthesise and constitutively secrete tissue-type plasminogen activator (t-PA)
and its inhibitor, plasminogen activator inhibitor type 1 (PAI-1). The release of t-PA
may be rapidly increased through the translocation of a dynamic intracellular storage
pool [van den Eijnden-Schrauwen et al 1995] in response to stimulation by blood
coagulation and humoral factors [Emeis 1992], Acute t-PA release plays a pivotal
role in endogenous fibrinolysis and this is exemplified by a plasminogen activator
deficient gene knockout mouse model that exhibits an increased incidence of
endotoxin-induced thrombosis [Carmeliet et al 1994], The time course of t-PA
release is important, with thrombus dissolution being much more effective if t-PA is
incorporated during, rather than after, thrombus formation [Brommer 1984; Fox et al
1984], Thus, the speed with which, and extent to which, t-PA can be released from
endothelial cells may have a substantial impact on the efficacy of endogenous
fibrinolysis.
When studying in vivo vascular responses in man, systemic drug administration can
cause concomitant effects on other organ systems, such as the liver, brain, kidney
and heart, as well as influence neurohumoral reflexes through changes in systemic
haemodynamics. Therefore, because of these confounding influences, vascular and
humoral responses cannot be wholly attributed to a direct effect of the drug on the
blood vessels. Endogenous fibrinolysis in man has been assessed using systemic
infusion of agents such as desmopressin [Ludlam et al 1980; Duprez et al 1991] and
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angiotensin II [Ridker et al 1993b], These agents are vasoactive, producing changes
in blood pressure and regional blood flow, as well as having widespread effects on
many tissues. Thus, changes in systemic fibrinolytic parameters might be attributable
to a number of factors including changes in hepatic release and clearance of t-PA and
PAI-1, and the concomitant release of other stimulatory, vasoactive and humoral
mediators. In contrast, the use of bilateral forearm blood flow measurements coupled
with unilateral brachial artery infusion of vasoactive drugs at subsystemic, locally
active doses, provides a powerful and reproducible method of directly assessing
vascular responses in vivo [Benjamin et al 1995; Webb 1995], Combined with
bilateral forearm venous sampling, this technique permits the assessment of local
release of tissue and endothelium-derived factors [Plumpton etal 1995],
The initial aim of the present study was to assess the acute release of coagulation and
fibrinolytic factors within the forearm vascular bed in response to intra-arterial
substance P using an ascending dose design to define the dose at which systemic
effects intervene. Thereafter, endothelial cell release of these factors was assessed in
response to locally active doses of substance P and a control endothelium-





Sixteen healthy non-smoking men aged between 20 and 34 years participated in two
studies which were undertaken with the approval of the local Research Ethics
Committee and in accordance with the Declaration of Helsinki.
5.3.2 Drugs
Pharmaceutical-grade substance P (Clinalfa AG, Laufelfingen, Switzerland) and
sodium nitroprusside (Nipride; Roche, Welwyn Garden City, UK) were administered
following dissolution in saline (0.9%: Baxter Healthcare Ltd, Thetford, UK).
5.3.3 Study Design
Subjects rested recumbent throughout each study. Strain gauges and cuffs were
applied and the brachial artery of the non-dominant arm cannulated. Measurements
of forearm blood flow were made between 3 and 6 minutes of each infusion period
unless otherwise stated. Before participating in one of the following protocols, saline
was infused for the first 30 minutes to allow time for equilibration, with forearm
blood flow measured every 10 minutes and the final measurement taken as basal
blood flow.
5.3.3.1 Dose Ranging Study
In seven men, intra-brachial substance P was administered in incremental doubling
doses from 0.5 to a maximum of 128 pmol/min for 6 minutes at each dose and was
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followed by a 30 minute saline infusion. Venous samples were taken at baseline,
following 2 pmol/min, 16 pmol/min and the maximal dose of substance P, and after
the final 30 minute saline infusion.
5.3,3.2 Local Forearm Study
Twelve men were given intra-arterial doubling doses of substance P at 2, 4 and 8
pmol/min for 10 minutes at each dose, and sodium nitroprusside at 2, 4 and 8 pg/min
for 10 minutes at each dose, separated by a 30 minute saline infusion. Substance P
and sodium nitroprusside were given single blind, in randomised order. Venous
samples were obtained at the end of each period of saline infusion and with each
dose of substance P and sodium nitroprusside.
5.3.4 Data Analysis And Statistics
Data were examined, where appropriate, by two way analysis of variance (ANOVA)
with repeated measures and two tailed paired Student's t-test using Excel v4.0
(Microsoft). All results are expressed as means ± standard errors of the mean.
Statistical significance was taken at the 5% level.
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5.4 RESULTS
All subjects were normotensive (Tables 5.1 and 5.2) and had a normal fasting lipid
profile with a mean total cholesterol concentration of 3.90 ± 0.16 mmol/1 (150 ± 6
mg/dl), high density lipoprotein cholesterol concentration of 1.02 ± 0.05 mmol/1
(39 ± 2 mg/dl) and triglyceride concentration of 0.87 ± 0.08mmol/l (77 ± 7 mg/dl).
5.4.1 Dose ranging study
There were no significant changes in arterial pressure or heart rate throughout the
study. Substance P caused an increase in blood flow of the infused forearm (p<0.001)
from a baseline of 3.7 ± 0.7 mL/100 mL/min to a maximum of 22 ± 2.4 mL/100
mL/min at 64 pmol/min in a dose-dependent manner (Figure 5.1). Five subjects
received 64 pmol/min and two received 128 pmol/min as the maximum dose, further
infusion of substance P being discontinued because of forearm skin edema and facial
flushing. There was a significant increase in the blood flow of the contralateral, non-
infused arm (p=0.001, ANOVA) which was apparent from 16 pmol/min (p=0.05)
The relative percentage increase in blood flow of the infused compared with the non-
infused arm was dose-dependent, peaking at 32 pmol/min before declining at
64 pmol/min (Figure 5.1).
Substance P caused increases in plasma t-PA antigen and activity concentrations in
the infused (p<0.001 for both) and non-infused arm (p=0.003 for both) which were
dose-dependent (Figure 5.2). Plasma from the infused arm demonstrated significantly
greater increases in both t-PA activity and antigen concentrations than the non-
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Dose ranging study: venous plasma tissue plasminogen activator (t-PA) antigen (circles) and activity
(squares), and plasminogen activator inhibitor type 1 (PAI-1) antigen (triangles) and activity (diamonds)
concentrations in the infused (closed symbols) and non-infused (open symbols) forearms in response to
substance P infusions (n=7). Maximum substance P dose was 64 pmol/min in 5 subjects and 128
pmol/min in 2 subjects. pO.OOl for all t-PA concentrations (ANOVA)
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infused arm (p<0.001). At the maximal dose, mean t-PA activity increased by 630%
in the infused arm and 210% in the non-infused arm, whilst mean t-PA antigen
increased by 240% and 62% respectively.
There were no significant or consistent changes in plasma PAI-1 antigen or activity
concentrations in the infused arm. There was a significant decrease in the plasma
PAI-1 activity in the non-infused arm (p=0.03) although PAI-1 antigen
concentrations did not change significantly (p=0.64). There were no significant
changes in plasma vWf concentration or factor VIITC activity in either arm
(Table 5.1).
5.4.2 Local Forearm Study
There were no significant changes in blood pressure, heart rate or forearm blood flow
in the contralateral arm throughout the study (Table 5.2).
Both substance P and sodium nitroprusside caused selective increases in forearm
blood flow in the infused arm (p<0.001 for both) in a dose-dependent manner
(Table 5.2). Substance P caused a selective and dose-dependent increase in the
estimated net release (p<0.001 for both) and venous plasma concentrations (p<0.001
for both) of both t-PA activity and antigen (Table 5.2; Figure 5.3). In contrast, there
were no significant changes in plasma t-PA activity or antigen concentrations in the
non-infused arm, or in PAI-1 antigen and activity, vWf or factor VIITC



























Substance P (pmol/min)Sodium Nitroprusside (pg/min)
Figure 5.3
Local forearm study: venous plasma tissue plasminogen activator (t-PA) antigen (circles) and activity
(squares), and plasminogen activator inhibitor type 1 (PAI-1) antigen (triangles) and activity (diamonds)
concentrations in the infused (closed symbols) and non-infused (open symbols) forearms in response to
sodium nitroprusside and substance P infusions (n=12). * p<0.001 (ANOVA).
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changes in t-PA, PAI-1, vWf or factor VIII:C in either arm during sodium
nitroprusside infusion (Table 5.2; Figure 5.3).
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5.5 DISCUSSION
We have shown, for the first time, that intra-arterial substance P administration
causes acute, selective and substantial t-PA release in vivo in man. At both systemic
and locally active doses, substance P causes t-PA release from the forearm vascular
bed without significant effects on the release of PAI-1, vWf and factor VIII:C. This
model provides a selective in vivo method of assessing acute t-PA release from the
endothelium in man.
Intra-brachial substance P has been previously shown to induce local fibrinolysis in
the forearm [Fanciullacci et al 1993] although the mechanism of this effect had not
been determined. However, taken together with our findings, it is apparent that this
enhancement of fibrinolytic activity is, at least in part, mediated through t-PA
release. Previously, bradykinin was thought to be one of the most potent agents
causing t-PA release in animals [Emeis 1992; Tranquille et al 1992] and man [Emeis
1992; Brown et al 1995], However, a recent study in man [Brown et al 1999] using
systemic intravenous bradykinin administration at doses of up to 380 pmol/kg/min,
did not show a significant release of t-PA antigen except in the presence of
angiotensin converting enzyme inhibition and alterations in systemic haemodynamic
parameters. Jern and colleagues [Jern et al 1994] have shown a significant net local
release of t-PA antigen and activity in response to intra-brachial methacholine.
However, a significant increase in venous concentrations of t-PA antigen was not
detected and, although measurement of arteriovenous differences should enhance the
accuracy of assessing local tissue release, there were no significant increases in the
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arteriovenous gradients of t-PA antigen or activity. Indeed, the clearest changes were
observed in the arterial t-PA activity which should have remained constant,
suggesting that there was systemic stimulation of t-PA release in this study.
Venous plasma t-PA concentrations obtained from a given tissue bed are composed
of three components; circulating arterial t-PA, basal or constitutive endothelial cell
release of t-PA and facultative or stimulated endothelial cell release of t-PA. The net
tissue release of t-PA is equivalent to the product of the plasma flow through the
tissue and the arteriovenous difference in plasma t-PA concentrations across it. In the
absence of endothelial cell stimulation, but with an increase in blood flow across the
tissue bed, venous plasma t-PA concentrations would be expected to fall secondary
to a dilutional effect. However, this ignores the potential for clearance of t-PA across
the vascular bed [Hajjar 1991], and stimulation of its release by shear stress and flow
[Diamond et al 1990; Iba et al 1991], Without measuring the arteriovenous
concentration gradient across the forearm, net tissue release can only be derived and
estimated. However, arterial sampling requires the insertion of large bore cannulae
which do not lend themselves to multiple cannulations within the same subject.
There is also the potential to introduce artefact from the presence of a larger
thrombogenic surface given that activated factor Xa is the most potent stimulant for
t-PA release yet known [Emeis 1992], Rather than assessing arteriovenous
differences, we have compared venous plasma t-PA concentrations between infused
and non-infused arms and have used very fine gauge arterial cannulae for drug
administration only. This method may potentially underestimate the net release of
t-PA and fail to detect a modest effect due to the potential flow-dependent, dilutional
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changes in venous concentrations. However, typical resting arteriovenous differences
are only -10% of the total venous concentration [Gough et al 1992; Jern et al 1994]
and the basal constitutive release of t-PA antigen is -0.9 ng/100 mL of tissue/min in
the forearm [Jern et al 1994], Thus, in the presence of large increases in t-PA release,
the dilutional effect of increased blood flow on constitutive t-PA release will be
reduced. Indeed, using this bilateral venous sampling methodology, we have been
able to demonstrate a substantial, dose-dependent release of t-PA from the forearm
vascular bed in response to substance P infusion. Moreover, despite in vitro evidence
that t-PA release may be influenced by shear stress [Diamond et al 1990; Iba et al
1991], we have found that the endothelium-independent nitric oxide donor, sodium
nitroprusside, has no significant effect on the venous t-PA concentrations despite
comparable increases in blood flow to those with substance P. Sodium nitroprusside
is known to have no direct effect on the endothelial cell release of t-PA and PAI-1 in
vitro [Pannocchia et al 1996] and, therefore, it is likely that either shear stress and
flow-dependent stimulation of endothelial cell t-PA release is counterbalanced by the
potential dilutional effects of increased flow, or that this theoretical flow-dependence
of venous concentrations is negligible. This also indicates that increases in nitric
oxide and blood flow are not sufficient in themselves to release t-PA from the
endothelium. However, it remains a possibility that the L-arginine:nitric oxide
pathway plays a role in substance P-induced t-PA release and requires further studies
using a combined infusion of substance P and a nitric oxide synthase inhibitor such
as L-A'G-monomethyl arginine.
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Although we have produced substantial increases in both t-PA activity and antigen,
we did not detect release ofPAI-1, or the coagulation factors, vWf and factor VIII:C.
This would indicate that these agents are not stored in a rapidly translocatable pool
within the endothelial cells of the forearm vascular bed or that they are not released
in response to substance P over the time course and at the doses used here. However,
protracted endothelial cell stimulation may release these factors [Ludlam et al 1980;
Ridker et al 1993b], In this respect, it is interesting to note the time-dependent
reduction in PAI-1 concentrations seen in our studies, although these only achieved
statistical significance in the non-infused arm during the dose ranging study. The
most likely explanation for a reduction in PAI-1 is that the released and active t-PA
is complexed by circulating PAI-1 and subsequently cleared from the circulation by
the liver [Otter et al 1992], Thus, substantial local t-PA release will tend to reduce
systemic PAI-1 concentrations in the short term, as seen with the administration of
pharmacological doses of t-PA [Lucore et al 1988],
As anticipated, local substance P infusion did not affect the rate of release of
hepatically derived factor VIII:C. In contrast, it is perhaps surprising that we did not
observe a rise in plasma vWf concentrations to accompany the release of t-PA. To
date, stimulation of t-PA release using a wide range of secretagogues such as
thrombin, vasopressin, bradykinin, histamine and desmopressin, has invariably been
accompanied by concomitant vWf release [Ludlam et al 1980; Levin et al 1984;
Casonato et al 1992], However, we were unable to detect an acute local release of
vWf even in the presence of high local concentrations of substance P in the dose
ranging study. This novel selectivity suggests that the endothelium is able to mobilise
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different cytoplasmic storage pools in response to specific (NKi) receptor
stimulation. Further studies with more prolonged infusions of substance P would be
required to determine whether the endothelial cell vWf or PAI-1 release is delayed or
is truly not influenced by substance P.
In summary, brief, locally active and subsystemic infusions of intra-arterial
substance P produce a rapid and substantial increase in plasma t-PA activity and
antigen concentrations across the forearm bed which appear to act via a flow and
nitric oxide independent mechanism. This model provides a powerful method of
assessing the in vivo capacity of the endothelium to acutely release t-PA within the
forearm vascular bed and would be applicable to the assessment of diseases




ENDOTHELIN-1 DOES NOT CONTRIBUTE TO THE RELEASE OF
TISSUE PLASMINOGEN ACTIVATOR IN VIVO IN MAN
Newby DE, Strachan FE, Johnston NR., Webb DJ.
Endothelin-1 does not contribute to the release of
tissue plasminogen activator in vivo in man.
Fibrinolysis Proteol 1999; 13:185-191.
6.1 SUMMARY
Endothelin-1 is a potent endothelium-derived vasoconstrictor peptide with autocrine
and paracrine actions. Tissue plasminogen activator (t-PA) and its inhibitor,
plasminogen activator inhibitor type 1 (PAI-1), are also released from the vascular
endothelium and play a pivotal role in endogenous fibrinolysis. We, therefore,
examined the effects of exogenous and endogenous endothelin-1 on t-PA and PAI-1
release in vivo in man. Unilateral brachial artery infusions of endothelin-1 at 2.5 and
10 pmol/min, and the selective endothelin type B (ETb) receptor antagonist, BQ-788,
at 1 nmol/min were administered. Blood flow and plasma fibrinolytic factors were
measured in both forearms using venous occlusion plethysmography and venous
blood samples withdrawn from the antecubital fossae. Endothelin-1 caused a slow
onset dose-dependent forearm vasoconstriction (p<0.001) with a maximal reduction
in blood flow of 40 ± 4% and 63 ± 3% at 2.5 and 10 pmol/min respectively. BQ-788
also caused a slow onset reduction in forearm blood flow (p<0.001) reaching a
maximum of 21 ± 3%. However, BQ-788 and endothelin-1 did not affect plasma
concentrations of t-PA or PAI-1 in the venous effluent of the infused forearm.
Despite sustaining significant vasoconstriction, neither endogenous nor exogenous
endothelin-1 influences the release of t-PA or PAI-1 in the forearm vascular bed of
man. This suggests that endothelin-1 does not provide a major contribution to the
regulation of endogenous fibrinolysis in man.
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6.2 INTRODUCTION
Endothelin-1 is a potent endothelium-derived vasoconstrictor peptide with autocrine
and paracrine actions. It is continuously released by the endothelium and contributes
to the maintenance of basal vascular tone [Haynes et al 1994] and blood pressure
[Haynes et al 1996], There are two main endothelin receptor subtypes, ETa and
ETg, but only the ETb receptors are present on the endothelium. Endothelin-1 causes
vasoconstriction mainly through stimulation of the smooth muscle cell ETa receptor,
although smooth muscle ETb receptors may also contribute in some vessel types.
This vasoconstrictor response is modulated by autocrine endothelial cell ETb
receptor-mediated generation of the endothelium-derived vasodilators, nitric oxide
and prostacyclin.
Following an acute myocardial infarction, plasma endothelin-1 concentrations are
elevated and provide an important prognostic marker of survival at one year [Omland
et al 1994], Furthermore, on the basis of in vitro studies, it has been suggested that
endothelin-1 may contribute to the regulation of endogenous fibrinolysis and t-PA
release [Lidbury et al 1990; Pruis et al 1990; Yamamoto et al 1992], However, the
evidence is contradictory, with endothelin-1 being found to either inhibit [Yamamoto
et al 1992] or stimulate [Lidbury et al 1990; Pruis et al 1990] endothelial cell t-PA
release. The role of endothelin-1 in the regulation of endogenous fibrinolysis in man
is currently unknown.
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We [Newby et al 1997b; Newby et al 1998] and others [Jern et al 1994a+b; Jern et al
1997a] have shown, using bilateral forearm venous occlusion plethysmography and
unilateral brachial artery infusions, that the forearm release of t-PA and PAI-1 can be
determined in vivo in man. Therefore, the aim of the current study was, using
synthetic endothelin-1 peptide and the selective ETb receptor antagonist, BQ-788, to
determine whether endothelin-1, of exogenous or endogenous origin, acts via the




Fourteen healthy men aged between 20 and 33 years participated in three studies
which were undertaken with the approval of the local Research Ethics Committee
and in accordance with the Declaration ofHelsinki.
6.3.2 Drugs
Endothelin-1 (Clinalfa AG, Laufelfingen, Switzerland) and BQ-788 (American
Peptide Company, Sunnyvale, USA) were administered following dissolution in
saline.
6.3.3 Study Design
On each study day, subjects attended fasted and rested recumbent throughout the
study. Strain gauges and cuffs were applied and the brachial artery of the non-
dominant arm cannulated. Throughout each of the studies, measurements of forearm
blood flow were made every 10 minutes. Before drug administration, saline was
infused for 30 minutes to allow time for equilibration and the final blood flow
measurement during saline infusion was taken as the basal forearm blood flow.
Eight subjects received an intra-brachial infusion of endothelin-1 at 2.5 and
10 pmol/min for 120 minutes given in random order, on two separate occasions, at
least one week apart. Eight subjects (two had also attended for endothelin-1
infusions) received an intra-brachial infusion of BQ-788 at 1 nmol/min for
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120 minutes. Venous samples were withdrawn from each arm at baseline and at 10,
20, 30, 50, 80 and 120 minutes after the start of endothelin-1 or BQ-788 infusion.
6.3.4 Data Analysis And Statistics
Data were examined by two-way analysis of variance (ANOVA) with repeated
measures and two tailed paired Student's t-test using Excel v5.0 (Microsoft) where
appropriate. All results are expressed as mean ± standard error of the mean.
Statistical significance was taken at the 5% level. Based on previous data, [Newby et
al 1997b; Newby et al 1998] the study had 90% power to detect a 20% change in
plasma t-PA concentrations between treatment periods at the 5% level.
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6.4 RESULTS
All subjects were normotensive and there were no significant changes in blood
pressure, heart rate or blood flow in the contralateral arm throughout any of the
studies (Table 6.1). Haematocrit decreased slightly in each endothelin study (Table
6.1). Between the three protocols there were no significant differences in the baseline
values of blood pressure, heart rate, forearm blood flow, haematocrit or plasma
concentrations of t-PA and PAI-1.
6.4.1 Endothelin-1 Infusions
Endothelin-1 decreased blood flow in the infused arm (p<0.001) in a dose-dependent
manner (Figure 6.1) reaching a minimum of 2.5 ± 0.3 mL/100 mL/min at 2.5
pmol/min and 1.6 ± 0.1 mL/100 mL/min at 10 pmol/min, after 120 minutes. This
corresponds to a relative reduction in forearm blood flow of 40 ± 4% and 63 ± 3%
respectively. The plasma concentrations of t-PA and PAI-1 did not change in the
infused arm (Figure 6.2) during endothelin-1 infusion at either concentration (p=NS;
one-way ANOVA). In comparison to the non-infused arm, there was a trend (p=0.06;
two-way ANOVA) for the infused forearm plasma t-PA antigen concentration to be
greater with 10 pmol/min of endothelin-1. However, there were no significant
differences in plasma concentrations of PAI-1 antigen (Table 6.2) or t-PA activity
between the forearms.
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Figure 6.1.
Absolute (mL/100 mL of tissue/min; upper panel) and percentage (% relative to the non-infused forearm,
lower panel) change ofblood flow in the infused forearm during intra-arterial infusion of BQ-788 (1
nmol/min;o) and endothelin-1 (2.5 pmol/min;© and 10 pmol/min;»).
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Figure 6.2
Plasma concentrations of tissue plasminogen activator (t-PA) antigen (ng/mL; solid lines) and activity
(IU/mL; dashed lines) in the infused (solid circles) and non-infused (open circles) forearm during intra¬
arterial infusion of BQ-788 (1 nmol/min) and endothelin-1 (2.5 and 10 pmol/min).
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6.4.2 BQ-788 Infusion
In comparison to the non-infused arm, BQ-788 decreased blood flow in the infused
forearm after 120 minutes (relative reduction of 21 ± 3%) although the absolute
blood flow was unchanged (Table 6.1 and Figure 6.1). The plasma concentrations of
t-PA and PAI-1 (Table 6.2 and Figure 6.2) did not change in the infused forearm
(p=NS; one-way ANOVA) or in comparison to the non-infused forearm (p=NS; two-
way ANOVA).
There was no significant net release of t-PA with infusions of either endothelin-1 or
BQ-788 (Table 6.3).
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6.5 DISCUSSION
We have demonstrated that, despite causing significant reductions in blood flow,
neither endogenous nor exogenous endothelin-1 influences the release of t-PA or
PAI-1 in the forearm vascular bed of man. This suggests that endothelin-1 does not
contribute to the regulation of endogenous fibrinolysis in man.
Endothelial cell culture techniques have limitations in the investigation of t-PA
release and may not be truly representative of the in vivo function of these cells. The
amount of t-PA released in culture is small and necessitates prolonged incubation
periods and sensitive assays. Moreover, the phenotype of endothelial cells in culture,
and the ability to release t-PA, changes with increasing passages. This may account
for the disparity of our findings with previous endothelial cell culture studies
[Yamamoto etal 1992],
Studies in intact whole animals have suggested that systemic endothelin-1 infusion is
associated with stimulation of t-PA release [Lidbury et al 1990], although plasma t-
PA concentrations are not increased by low sub-pressor doses of endothelin-1 in man
[Kapiotis et al 1997], Systemic endothelin-1 administration, particularly at pressor
doses, will induce changes in cardiac function and regional blood flow as well as
having widespread effects on disparate tissues. Thus, the consequent changes in
systemic fibrinolytic parameters will be a combination of many factors, potentially
including hepatic production and clearance of t-PA and PAI-1. One approach, to
avoid these confounding systemic effects, has been to use the isolated perfused rat
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hindlimb model. This ex vivo model has been reported to demonstrate that
endothelin-1 infusion stimulates modest amounts of t-PA release [Pruis et al 1990],
However, this increased 'release' may, in part, reflect the concentrating effects of a
reduction in blood flow associated with endothelin-1 infusion and the concentrations
of endothelin-1 administered. In studies conducted to date [Lidbury et al 1990; Pruis
et al 1990; Yamamoto et al 1992], endothelin-1 has been administered in nanomolar
concentrations. Although local abluminal concentrations may be high, normal human
plasma endothelin-1 concentrations are in the femtomolar range. Indeed, in the
present study, assuming a total forearm blood flow of 30 to 50 mL/min, the forearm
tissue concentration of endothelin-1 during the 10 pmol/min infusion will be 200 to
300fmol/mL. The previous ex vivo animal studies [Pruis et al 1990], therefore,
represent some 4 to 5 orders of magnitude higher concentrations and the release of t-
PA is likely to represent a pharmacological rather than physiological effect.
We have not detected a significant release of t-PA from the forearm with endothelin-
1 infusion despite a 63% reduction in blood flow at the higher dose. Basal t-PA
release is of the order of ~0.9 ng/100 mL of tissue/min in the forearm [Jern et al
1994] and the apparent trend for an increase in t-PA antigen concentrations may, in
part, reflect the reduction in blood flow associated with the marked forearm
vasoconstriction (see Figure 6.3). This is borne out by the unchanged t-PA activity,
because it would be anticipated that plasma PAI-1 and t-PA antigen concentrations
would increase proportionately with reductions in blood flow. ETg receptor
antagonism causes both inhibition of endothelium-derived vasodilators such as nitric



















Theoretical components of venous plasma t-PA concentration under basal conditions and
during increases (upper panel) and decreases (lower panel) in blood flow with and without
direct stimulation of t-PA release.
Open bars - circulating or arterial t-PA
Grey bars - basal "constitutive" t-PA released from the tissue bed
Black bars - stimulated "facultative" t-PA released from the tissue bed
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with endothelin-1, BQ-788 did not affect plasma concentrations of t-PA or PAI-1 in
the infused forearm.
Forearm release of t-PA has been demonstrated using various endothelial cell
stimulants including methacholine [Jern et al 1994a+b; Jern et al 1997],
noradrenaline [Jern et al 1997] and desmopressin [Wall et al 1998], Using the same
technique as in the present study, we have previously demonstrated in vivo t-PA
release of up to 80 ng/100 mL of tissue/min across the human forearm using intra-
brachial substance P infusion [Newby et al 1997b] and this release is sustained for at
least 2 hours [Newby et al 1998], In contrast, stimulation or antagonism of the
endothelial ETb receptor, with endothelin-1 and BQ-788 respectively, does not
appear to influence forearm t-PA release. It is, therefore, unlikely that endothelin-1
provides a major contribution to the regulation of t-PA release in man, although v/e
cannot exclude a small stimulatory effect.
6.5.1 Study Limitations
In the forearm, typical resting arteriovenous differences are only -10% of the total
venous t-PA concentration and the basal constitutive release of t-PA antigen is
-0.9 ng/100 mL of tissue/min [Jern et al 1994a], We have measured venous-venous
differences between the infused and non-infused arms which, unlike the
measurement of arteriovenous differences of the infused arm, has the disadvantage of
not being able to correct for blood flow-dependent changes in venous plasma t-PA
concentrations. Theoretically (see Figure 6.3), in the absence of an alteration in t-PA
release, a 60% reduction in blood flow would be anticipated to increase total venous
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plasma t-PA concentrations by only ~7%, whereas a 200% increase in flow would
reduce t-.PA concentrations to the same degree (-7%). In the presence of stimulated
t-PA release, these small flow-dependent changes are proportionately reduced even
further. ■
The measurement of arteriovenous differences necessitates arterial sampling and the
insertion of large bore cannulae (19-G to 20-G) which do not lend themselves to
multiple cannulations within the same subject. Moreover, there is also the potential
to introduce artefact from the presence of a larger thrombogenic surface, given that
activated factor Xa is the most potent stimulant for t-PA release yet known [Emeis
1992], To minimise arterial trauma and facilitate repeated studies in the same
subjects, we have used 27-G arterial cannulae which permit drug infusion but not
arterial blood sampling. However, we would suggest that flow-dependent changes in
venous t-PA concentrations are small, within the variability of the t-PA assays (~5 to
7%) and are not of practical importance. Interestingly, a significant fall in the
arteriovenous difference, or venous plasma concentration, of t-PA has not been
detected during blood flow increases of up to 600% with sodium nitroprusside
infusion [Jern etal 1994a; Newby etal 1997b; Stein etal 1998],
Measurement of venous-venous and arteriovenous differences both have the potential
limitation that they can only estimate the net release of t-PA from the forearm and
are unable to take account of clearance of t-PA within the forearm. However, the
majority of t-PA is removed from the circulation by the liver [Chandler et al 1997]
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and the contribution of forearm clearance of t-PA is, therefore, likely to be very
small.
During the present study, we did not see changes in heart rate or blood pressure to
suggest systemic effects of endothelin-1 [Pernow et al 1996] or BQ-788 infusion
[Strachan et al 1999], However, measuring venous concentrations bilaterally will
control for any potential systemic effects which may go unrecognised if
arteriovenous differences are measured in isolation. Once a drug has a systemic
rather than a local effect, there is always the concern that subsequent t-PA release
may be influenced or mediated by the release of other humoral factors, such as
catecholamines. Moreover, if the main mechanism of t-PA release is mediated by a
systemically released intermediate factor, then measuring arteriovenous differences
could fail to detect this since arterial concentrations may remain unchanged and
venous concentrations will rise in both forearms.
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CHAPTER 7
THE L-ARGININE:NITRIC OXIDE PATHWAY CONTRIBUTES TO THE
ACUTE RELEASE OF TISSUE PLASMINOGEN ACTIVATOR
IN VIVO IN MAN
Newby DE, Wright RA, Dawson P, Ludlam CA, Fox KAA, Boon NA, Webb DJ.
The L-arginine:nitric oxide pathway contributes to the acute release of tissue




Effective endogenous fibrinolysis requires rapid release of endothelial tissue
plasminogen activator (t-PA). Using the nitric oxide synthase inhibitor, L-A^-
monomethylarginine (L-NMMA), we examined the contribution of endogenous
nitric oxide to substance P induced t-PA release in vivo in man. Blood flow and
plasma fibrinolytic and haemostatic factors were measured in both forearms of eight
healthy male volunteers who received unilateral brachial artery infusions of
substance P (2 to 8 pmol/min) and L-NMMA (1 to 4 pg/min). Substance P caused
dose-dependent increases in blood flow (p<0.001) and plasma t-PA antigen (p=0.04)
and activity (p<0.001) concentrations confined to the infused forearm but had no
effect on plasminogen activator inhibitor type 1 (PAI-1) or von Willebrand factor
concentrations. In the presence of L-NMMA, substance P again caused significant
increases in blood flow (p<0.001) and t-PA antigen (p=0.003) and activity (p<0.001)
concentrations but these increases were significantly less than with substance P alone
(p<0.001, p=0.05 and p<0.01 respectively). L-NMMA alone significantly reduced
blood flow in the infused arm, but had no measurable effect on t-PA or PAI-1
concentrations. The L-arginine:nitric oxide pathway contributes to substance P
induced t-PA release in vivo in man. This provides an important potential mechanism
whereby endothelial dysfunction increases the risk of atherothrombosis through a
reduction in the acute fibrinolytic capacity.
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7.2 INTRODUCTION
Endothelial cell culture techniques have limitations in the investigation of t-PA
release and may not be truly representative of the in vivo function of these cells. The
amount of t-PA released in culture is small and necessitates prolonged incubation
periods and sensitive assays. Moreover, the phenotype of endothelial cells in culture,
and the ability to release t-PA, changes with increasing passages. In contrast, under
in vivo physiological conditions, the endothelium is arranged within a non-planar
three dimensional vascular bed, has a more favourable volume to surface area ratio,
and is exposed to pulsatile blood flow and pressure changes.
We have recently described an in vivo model to assess acute t-PA release in man
[Newby et al 1997b], Using intra-brachial infusions of substance P, we have shown a
dose-dependent release of t-PA from the human forearm without causing significant
release of vWf or plasminogen activator inhibitor type 1 (PAI-1). This suggests
either a selective action of substance P or the lack of a rapidly translocatable pool of
PAI-1 and vWf. However, we have previously used only brief (-10 min) substance P
infusions [Newby et al 1997b] and protracted stimulation may release these factors
[Ludlam etal 1980; Tranquille et al 1992; Ridker et al 1993b],
Substance P causes endothelium-dependent vasodilatation [Gross et al 1994] which
is mediated by the endothelial cell neurokinin type 1 receptor [Stjarne et al 1994] and
is, in part, related to the release of nitric oxide [Cockcroft et 1 1994; Newby et al
1997c; Quyyumi et al 1997], However, because t-PA release is not seen with
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infusions of the nitric oxide donor and vasodilator, sodium nitroprusside [Jern et al
1994a; Newby et al 1997b], an increase in nitric oxide and blood flow together do
not release t-PA from the endothelium. Nevertheless, it remains a possibility that the
L-arginine:nitric oxide pathway contributes to substance P induced t-PA release.
Therefore, the aims of the current study were 2-fold: first, to ascertain whether
prolonged substance P infusion can cause vWf or PAI-1 release; and second, to
determine whether nitric oxide synthase inhibition using L-A^-monomethylarginine




Eight healthy men aged between 20 and 33 years participated in three studies which
were undertaken with the approval of the local Research Ethics Committee and in
accordance with the Declaration ofHelsinki.
7.3.2 Drugs
Pharmaceutical-grade substance P (Clinalfa AG, Laufelfingen, Switzerland) and L-
M'-monomethylarginine (L-NMMA; Clinalfa AG) were administered following
dissolution in saline.
7.3.3 Study Design
On three separate occasions, at 9.00 am, subjects attended fasted and rested
recumbent throughout each study. Strain gauges and cuffs were applied and the
brachial artery of the non-dominant arm cannulated. Throughout all protocols,
measurements of forearm blood flow were made every 10 minutes. Saline was
infused for the first 30 minutes to allow time for equilibration and the final blood
flow measurement during saline infusion was taken as the basal forearm blood flow.
Thereafter, subjects underwent the following protocols, in random order, each
separated by at least one week: protocol 1, each subject received intra-arterial
substance P at 2, 4 and 8 pmol/min, for 10 minutes at each dose, followed by a
continuous infusion of 8 pmol/min for a further 90 minutes; protocol 2, L-NMMA
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was co-infused at 4 pmol/min for 10 minutes before and throughout the same
substance P infusion as protocol 1; and protocol 3, subjects received intra-arterial L-
NMMA at 1, 2 and 4 pmol/min for 10 minutes at each dose followed by a continuous
infusion of 4 pmol/min for a further 90 minutes. Venous samples were withdrawn
from each arm at baseline and at 10, 20, 30, 50, 80 and 120 minutes after the start of
substance P (for protocols 1 and 2) or L-NMMA infusion (protocol 3).
7.3.4 Data Analysis And Statistics
Data were examined, where appropriate, by two-way analysis of variance (ANOVA)
with repeated measures and two tailed paired Student's /-test using Excel v5.0
(Microsoft). Tachyphylaxis was assessed by comparing the 30 minute (peak) and
120 minute (final) values with a two tailed paired Student's /-test. Area under the
curve (AUG) was calculated for the estimated net release of t-PA across the study
period. All results are expressed as mean ± standard error of the mean. Statistical
significance was taken at the 5% level.
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7.4 RESULTS
All subjects were normotensive and there were no significant changes in blood
pressure, heart rate or blood flow in the contralateral arm throughout any of the
studies (Table 7.1). Haematocrit decreased slightly in each study (Table 7.1).
Between the three protocols there were no significant differences in the baseline
values of blood pressure, heart rate, forearm blood flow, haematocrit or plasma
concentrations of t-PA and PAI-1 antigen and activity.
7.4.1 Isolated Infusions Of Substance P And L-NMMA
Substance P increased blood flow in the infused arm (p <0.001) in a dose-dependent
manner (Table 7.2; Figure 7 1) reaching a maximum increase of
15.9 ± 1.9 mL/100 mL/min after 10 minutes at 8 pmol/min. Following prolonged
infusion, substance P induced vasodilatation demonstrated tachyphylaxis and
decreased to 12.1 ± 1.3 mL/100 mL/min after 100 minutes of substance P at
8 pmol/min (p<0.003 vs 10 minutes). In comparison to the non-infused arm,
substance P caused a dose-dependent increase in venous plasma t-PA activity
(p<0.001) and antigen (p<0.04) concentrations of the infused arm which did not
undergo significant tachyphylaxis (Figure 7.2). Concentrations of plasma PAI-1
activity were also reduced in the infused arm (p=0.04; Figure 7.2). In contrast, there
were no significant changes in plasma PAI-1 antigen, vWf or factor VIILC
concentrations in either arm (Table 7.2 and Figure 7.2).
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Table7.2. Bloodfl wanplasmav nWillebrandfactorndf tVIII:Cctivityco ce t ationsb harmdu i gis latedsubstancei fus n: protocol1 Baseline1020Time(min) 305
80
120






vonWillebrandNon-infusedArm0.84±0.136 00. 5±0.1360995±0.1880. 01 2±0.16 Factor (IU/mL)InfusedArm0.73±0920.150.73± .1186±0.200.98±0. 60 99±0.171 3±0 FactorVIII:C (IU/mL)Non-infusedArm0.50±0.0648.041±0. 50.5. 896± .1072.09 InfusedArm0.50±0.05.0.51±0. 7264±0.07. 869± .10 *p<0.001
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Infused forearm blood flow and estimated net release of t-PA antigen and activity during protocol 1
(substance P alone; o), protocol 2 (substance P and L-NMMA, •) and protocol 3 (L-NMMA alone; ■).
*p<0.001; tp=0.05; Jp=0.09 (ANOVA).
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L-NMMA decreased blood flow in the infused arm (p<0.001) in a dose-dependent
manner (Table 7.2 and Figure 7.1) reaching 2.1 ± 0.2 mL/100 mL/min after 100
minutes at 4 pmol/min. There were no significant changes in the concentrations of
plasma t-PA and PAI-1 antigen or activity in either arm during infusion of L-NMMA
(Figure 7.2).
7.4.2 Co-infusion Of L-NMMA And Substance P
In the presence of L-NMMA, substance P increased blood flow in the infused arm
(p<0.001) in a dose-dependent manner (Figure 7.1) reaching a maximum increase of
13.7 ± 1.7 mL/100 mL/min after 10 min at 8 pmol/min. This response underwent
tachyphylaxis and decreased to 9.3 ± 14 mL/100 mL/min after 100 min of substance
P at 8 pmol/min (p<0 002 vs 10 minutes). In comparison with the non-infused arm,
substance P co-infused with L-NMMA caused a dose-dependent increase in plasma
t-PA activity (p<0.001) and antigen (p<0.003) concentrations of the infused arm
which did not undergo significant tachyphylaxis (Figure 7.2). L-NMMA caused a
significant attenuation of substance P induced increases in blood flow (p<0.001) and
plasma t-PA activity concentrations (p<0.003) in the infused forearm, but not plasma
t-PA antigen.
7.4.3 Estimated Net t-PA Production
L-NMMA infused alone had no significant effects on t-PA release: 95% confidence
intervals for t-PA antigen and activity release are 0.31 to -0.68 ng/100 mL/min and
0.27 to -0.06 IU/100 mL/min respectively. Substance P caused dose-dependent
increases in the estimated net release of t-PA antigen and activity in the presence or
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absence of L-NMMA (p<0.001) which did not undergo significant tachyphylaxis.
However, the magnitude of the increase in release of both t-PA antigen (p=0.05) and
activity (p<0.01) was significantly reduced in the presence ofL-NMMA (Figure 7.1).
L-NMMA reduced the AUC for the substance P induced release of t-PA antigen and
activity by 40% and 46% respectively.
132
7.5 DISCUSSION
We have shown that intra-brachial substance P infusion increases forearm blood flow
and plasma t-PA concentrations for up to 2 hours without a demonstrable effect on
plasma PAI-1 or vWf concentrations. Although the nitric oxide synthase inhibitor, L-
NMMA, significantly reduced forearm blood flow without affecting basal t-PA
release, it inhibited the increases in blood flow, plasma t-PA concentrations and t-PA
release produced by substance P administration in the forearm. These data suggest
that the L-arginine:nitric oxide pathway contributes to substance P induced t-PA
release in vivo in man. In contrast, we [Newby et al 1997b] and others [Jern et al
1994a+b] have shown previously that t-PA release is not seen with the large local
increases in nitric oxide delivery and blood flow associated with infusions of the
nitric oxide donor, sodium nitroprusside. Taken together, these findings indicate that
increases in nitric oxide and blood flow are not sufficient per se to release t-PA but,
through the L-arginine:nitric oxide pathway, are able to enhance substance P induced
t-PA release.
The permissive role of intracellular mediators in the mechanism of t-PA release has
been described previously. In the rat perfused hindlimb model, increasing
intracellular calcium alone is insufficient to cause t-PA release whilst it is essential
for bradykinin induced t-PA release [Tranquille et al 1991], However, the regulation
of t-PA release is complex and may involve several signal transduction pathways
[Rydholm et al 1995], This is reflected by the diversity of mediators - such as
thrombin, bradykinin and desmopressin - which can release t-PA and increase t-PA
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activity [Ludlam et al 1980; Levin et al 1984; Casonato et al 1992; Tranquille et al
1992], One can, therefore, only speculate as to whether our findings extend to the
acute t-PA release seen with in situ thrombosis. However, both nitric oxide mediated
endothelial dysfunction [Panza et al 1994; Casino et al 1995; Stroes et al 1995;
Celermajer et al 1996] and abnormalities of endogenous fibrinolysis [Hamsten et al
1985; Ridker et al 1993a; Ridker et al 1994; Thompson et al 1995] have been
described in many atherosclerotic diseases and the associated risk factors. Thus, the
coupling of acute t-PA release to the L-arginine:nitric oxide pathway provides an
important potential mechanism whereby endothelial dysfunction might increase the
risk of atherothrombosis through a reduction in the acute fibrinolytic capacity. Our
initial findings would suggest that this model could be applied to the assessment of
the acute fibrinolytic capacity of patients with endothelial dysfunction such as those
with hypercholesterolaemia and a smoking habit [Stroes et al 1995; Celermajer et al
1996], and to the examination of the subsequent effect of L-arginine
supplementation.
Substance P induced vasodilatation undergoes tachyphylaxis [McEwan et al 1988]
which may relate to internalisation of the neurokinin type 1 receptor from the
endothelial cell surface membrane [Bowden et al 1994], It has been suggested from
ex vivo animal studies [Kuroiwa et al 1995; Gross et al 1994] that the residual
vasodilatation following the development of tachyphylaxis is almost completely
nitric oxide dependent. In the present study, the degree of inhibition of substance P
induced vasodilatation by L-NMMA was less than we [Newby et al 1997c] and
others [Cockcroft et al 1994] have previously described and may reflect the higher
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potency and doses used in this study. Whilst we have readily demonstrated
tachyphylaxis of substance P induced vasodilatation, the co-infusion of L-NMMA
did not affect the development of tachyphylaxis and did not abolish the residual
substance P induced vasodilatation following its development. Thus, in contrast to
animal studies, residual vasodilatation after the development of tachyphylaxis does
not appear to be predominantly nitric oxide mediated in the human forearm. In
addition, we were unable to detect significant tachyphylaxis of substance P induced
increases in plasma t-PA antigen and activity concentrations suggesting that not all
the actions of substance P undergo tachyphylaxis.
The substance P induced reductions in plasma PAI-1 activity of the infused arm
without significant alterations in PAI-1 antigen concentrations are consistent with
acute t-PA release in the absence of PAI-1 release [Chandler et a 1997], PAI-1 binds
to the newly released t-PA to form an inactive PAI-l/t-PA complex, thereby reducing
the plasma PAI-1 activity. The trend for PAI-1 antigen concentrations to fall in both
arms as the study progressed is consistent with systemic (hepatic) clearance of the
PAI-l/t-PA complex [Lucore et al 1988; Otter et al 1992; Chandler et al 1997],
However, this trend was also seen with isolated L-NMMA infusion in which there
was no significant release of t-PA consistent with a circadian fall of PAI-1 antigen
during the morning [Andreotti et al 1991],
Despite reducing forearm blood flow by half, L-NMMA did not significantly affect
the constitutive release or plasma concentrations of t-PA and PAI-1 antigen and
activity. The 95% confidence intervals indicates that if L-NMMA has an effect on
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basal t-PA or PA1-1 release then it is rather small. This suggests that the L-
arginine:nitric oxide pathway does not play a major role in the basal release of t-PA
or PAI-1 in the peripheral vasculature ofman.
7.5.1 Study limitations
Since the derivation of t-PA release is a function of plasma flow, it could be argued
that the inhibition by L-NMMA of substance P induced t-PA release reflects the
simultaneous reduction in blood flow. However, the reduction in absolute blood flow
was only modest (15 to 20%) in comparison to the reduction in t-PA release (40 to
46%) and the plasma t-PA activity concentrations in the infused forearm were also
significantly reduced by co-infusion of L-NMMA. The findings of the present study
would be strengthened by utilising a control vasoconstrictor and demonstrating a
neutral. effect on substance P induced t-PA release. However, standard receptor
coupled vasoconstrictors used in forearm studies, such as noradrenaline, vasopressin
and angiotensin II, are known to stimulate t-PA and PAI-1 release [Ludlam et al
1980; Casonato et al 1992; Ridker et al 1993; Jern et al 1997a; Wall et al 1998;
Larsson et al 1999] and would not help in interpreting the influence of L-NMMA on
substance P induced t-PA release.
We have previously been unable to detect an acute local release of either vWf or
PAI-1 during 10 minute infusions of substance P given at 8-fold higher
concentrations [Newby et al 1997b], In the present study, substance P did not cause
significant vWf or PAI-1 release despite infusion times of up to 120 minutes
suggesting that the dissociation of substance P induced t-PA release from vWf is not
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a temporal effect. However, this dissociated release does not appear to be unique to
substance P since this has also been recently described with local forearm infusions
of desmopressin [Wall et al 1998], These findings are, however, limited to the
peripheral forearm vascular bed and the endothelium in other tissue beds may
respond differently to substance P stimulation. The extension of this model to
vascular beds associated with atherosclerosis such as the coronary circulation, will be
of crucial relevance in determining the influence of atheroma and endothelial
dysfunction on the acute local release of t-PA during thrombotic occlusion and
plaque rupture.
In summary, in the forearm vascular bed in vivo, we have shown for the first time
that the L-arginine:nitric oxide pathway contributes to substance P induced t-PA
release in man. This coupling of acute t-PA release to the L-arginine:nitric oxide
pathway provides an important potential mechanism whereby endothelial




ENDOTHELIAL DYSFUNCTION, IMPAIRED ENDOGENOUS
FIBRINOLYSIS AND CIGARETTE SMOKING:
A MECHANISM FOR ARTERIAL THROMBOSIS AND
MYOCARDIAL INFARCTION
Newby DE, Wright RA, Labinjoh C, Ludlam CA, Fox KAA, Boon NA, Webb DJ.
Endothelial dysfunction, impaired endogenous fibrinolysis and cigarette smoking:




Effective endogenous fibrinolysis requires rapid release of tissue plasminogen
activator (t-PA) from the vascular endothelium. Smoking is a known risk factor for
arterial thrombosis and myocardial infarction, and causes endothelial dysfunction.
We, therefore, examined the effects of cigarette smoking on substance P induced
t-PA release in vivo in man. Blood flow and plasma fibrinolytic factors were
measured in both forearms of 12 smokers and 12 age- and sex-matched non-smokers
who received unilateral brachial artery infusions of substance P (2 to 8 pmol/min). In
both smokers and non-smokers, substance P caused dose-dependent increases in
blood flow and local release of plasma t-PA antigen and activity (p<0.001 for all) but
had no effect on the local release of plasminogen activator inhibitor type 1. In
comparison to non-smokers, increases in forearm blood flow (p=0.03), and release of
t-PA antigen (p=0.04) and activity (p<0.001) caused by substance P, were reduced in
smokers. Area under the curve for release of t-PA antigen and activity decreased by
51% and 53% respectively. Cigarette smoking causes marked inhibition of
substance P induced t-PA release in vivo in man. This provides an important
mechanism whereby endothelial dysfunction may increase the risk of
atherothrombosis through a reduction in the acute fibrinolytic capacity.
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8.2 INTRODUCTION
Acute rupture or erosion of a coronary atheromatous plaque and subsequent coronary
artery thrombosis causes the majority of sudden cardiac deaths and myocardial
infarctions [Burke et al 1997; Davies 1997], Cigarette smoking is not only strongly
associated with atherosclerosis [Chen et al 1995] and ischaemic heart disease
[Njolstad et al 1996], but is also a major risk factor for acute coronary thrombosis
[Hung et al 1995; Burke et al 1997], Indeed, three-quarters of sudden cardiac deaths
due to acute thrombosis are in cigarette smokers [Burke et al 1997], Smoking causes
endothelial dysfunction [Celermajer et al 1996] and is associated with increased
platelet thrombus formation [Hung et al 1995], Small areas of denudation and
thrombus deposition are a common finding on the surface of atheromatous plaques
[Davies et al 1988; Biirrig 1991] and are usually sub-clinical. However, in the
presence of an imbalance in the coagulation or fibrinolytic systems, such
microthrombi may propagate, ultimately leading to arterial occlusion.
Using the endothelium-dependent vasodilator, substance P, to stimulate t-PA release
we have recently described an in vivo model to assess the acute fibrinolytic capacity
of the human forearm [Newby et al 1997b], Moreover, we have been able to
demonstrate a reduction in t-PA release after inducing experimental 'endothelial
dysfunction' with nitric oxide synthase inhibition [Newby et al 1998], We, therefore,
hypothesised that cigarette smoking might impair endogenous fibrinolysis by
reducing the capacity of the endothelium to release t-PA acutely. The aim of the
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study was to compare substance P induced t-PA release from the forearm vascular




Twelve healthy smokers (5 to 20 cigarettes/day), and 12 age- and sex-matched non-
smokers, aged between 25 and 55 years participated in the study which was
undertaken with the approval of the local Research Ethics Committee and in
accordance with the Declaration of Helsinki.
All subjects were normotensive without a history of diabetes mellitus or vascular
disease. Female subjects were premenopausal and not receiving hormonal
contraceptives. They were clinically well and taking no regular medications. Control
subjects were life-long non-smokers and were not exposed to regular environmental
tobacco smoke. Smokers had a history of regular daily cigarette smoking of at least
5 years standing and maintained their normal smoking habit in the week before
attendance.
8.3.2 Drugs
Pharmaceutical-grade substance P (Clinalfa AG, Laufelfingen, Switzerland) was
administered following dissolution in saline.
8.3.3 Study Design
At 9.00 am, subjects attended fasted and then rested recumbent throughout each
study. Strain gauges and cuffs were applied and the brachial artery of the non-
dominant arm cannulated. Forearm blood flow was measured every 10 minutes.
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Saline was infused for the first 30 minutes to allow time for equilibration. The final
blood flow measurement during saline infusion was taken as the basal forearm blood
flow. Thereafter, subjects received intra-arterial substance P at 2, 4 and 8 pmol/min,
for 10 minutes at each dose.
8.3.4 Data Analysis And Statistics
The study population size, based on power calculations derived from previous
studies [Newby et cil 1997b], gives 90% power of detecting a 18% difference in t-PA
release at a significance level of 5%. Coefficients of repeatability [Bland & Altman
1986] for plasma concentrations of t-PA antigen and activity during substance P
infusion at 8 pmol/min are 1.6 ng/mL and 1.4 IU/mL respectively [Newby et al
1999b]
Data were examined, where appropriate, by two-way analysis of variance (ANOVA)
with repeated measures and two tailed Student's Etest using Excel v5.0 (Microsoft).
Area under the curve (AUC) was calculated for the estimated net release of t-PA
across the study period. All results are expressed as mean ± standard error of the
mean. Statistical significance was taken at the 5% level.
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8.4 RESULTS
There were no significant differences in baseline characteristics except smokers had
a slightly lower high density lipoprotein concentration (Table 8.1). There were no
significant changes in blood pressure, heart rate, haematocrit or blood flow in the
non-infused forearm during the study (Table 8.2). In the non-infused arm, plasma t-
PA antigen concentrations were higher in smokers than non-smokers (p=0.02; Table
8.2). There were no significant differences in plasma PAI-1 antigen and activity
between the groups.
Substance P caused dose-dependent increases in forearm blood flow in the infused
arm in both smokers and non-smokers (Table 8.2, Figure 8.1) but the increase in
blood flow was greater in non-smokers (p=0.03; two-way ANOVA: non-smokers vs
smokers). In comparison to the non-infused arm (two-way ANOVA), substance P
caused dose-dependent increases in plasma concentrations of t-PA antigen (p<0.001)
and activity (p<0.001) in the infused arm of both smokers and non-smokers
(Table 8.2). There were no significant changes in plasma PAI-1 antigen or activity in
either group. The increase in plasma t-PA activity in the infused arm was greater in
the non-smokers (p=0.001; two-way ANOVA: non-smokers vs smokers).
Substance P increased the net release of t-PA antigen (p=0.009) and activity
(p<0.001) in smokers (Figure 8.1). In non-smokers, substance P increased the net
release of t-PA antigen (p<0.001) and activity (p<0.001) significantly more than in





Age (years) 35 ± 3 34 ±2
Sex (male:female) 10 : 2 10 : 2
Body Mass Index (kg/m^) 23.9 ±0.5 24.5 ±1.1
Mean Arterial Pressure (mmHg) 92 ±2 91 ±2
Heart Rate (/min) 59 ±3 66 ±2
Fasting Plasma Glucose (mmol/L) 5.3 ±0.1 5.4 ±0.1
Total Cholesterol (mmol/L) 5.0 ±0.4 5.3 ±0.4
LDL Cholesterol (mmol/L) 3.0 ±0.3 3.4 ±0.4
HDL Cholesterol (mmol/L) 1.3 ± 0.1 1.0 ± 0.1 *
Triglycerides (mmol/L) 1.6 ± 0.2 1.9 ± 0.3
Baseline Haematocrit 0.41 ±0.01 0.43 ±0.01
*p = 0.01 (unpaired /-test, smokers vs non-smokers)
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AbsoluteForearmNon-infusedA n2.8±0.3 BloodFl w (mL/100mL/min)InfusedAr3.7±0.4 t-PAAntigen (ng/mL)Non-infusedArm InfusedArm
2.9±0.4.±0.2.8.32 8±0.29±0.3 11.2±.13.5316.2*3 6±0.39.4±0.4
2.9±0.33.0±0. 11.5±0.74 2.8*t
3.3±0.54.53.±0.7±0.54 0±0.534± .56f 3.2±0.54.1.64±0.6 2.8*4 1±0.5±0.65 2.79±0.9*
t-PAActivity (IU/mL)
Non-infusedArm0.8±0.2.9.1.0±0.2 InfusedArm0.8±0.22.1±0.5.8.




Non-infusedA n11.8±.7.12.1±1.6482.0±2.1179 2± .40 2±1.3 InfusedArm10.7±1.68.8±1.510 8±1.79 3.52±1.90 6±1.5.2±1.1
One-wayANOVA:*p<0.001 Two-wayANOVA(non-smokersvssmokers):tp<0.05;itp=0.001
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Infused forearm blood flow and the net release of t-PA antigen and activity in smokers (solid
circles) and non-smokers (open circles).
One-way ANOVA: p<0.001 for all responses.
Two wayANOVA (non-smokers vj smokers): * p<0.05; t p<0.001
smokers). In comparison to the non-smokers, the AUC for net t-PA antigen and
activity release was reduced by 51% and 53% respectively in the smokers.
Subgroup analysis following exclusion of female subjects did not alter the magnitude
or the statistical significance of the above findings. Qualitatively, the responses in




We have shown here, for the first time, that despite higher basal plasma t-PA antigen
concentrations, cigarette smokers have a markedly impaired capacity of the
endothelium to release t-PA acutely. This establishes an important mechanism
whereby cigarette smoking can lead to arterial thrombosis and myocardial infarction.
The rapid mobilisation of t-PA from the endothelium is crucial if endogenous
fibrinolysis within the arterial circulation is to be effective, with thrombus
dissolution being much more effective if t-PA is incorporated during, rather than
after, thrombus formation [Brommer 1984 Fox et al 1984], The increased risk of
spontaneous thrombosis seen in smokers may, therefore, plausibly relate to the
propagation of thrombus which would otherwise undergo lysis and remain sub¬
clinical. Although cigarette smokers have a higher overall mortality from myocardial
infarction than non-smokers [Haheim et al 1993], the in-hospital mortality is lower
[Mueller et al 1992; Barbash et al 1993; Zahger et al 1995], This apparent paradox
can be explained by the observation that the infarct related artery is more than twice
as likely to become patent in current smokers compared to non-smokers following
thrombolytic therapy for acute myocardial infarction [Gomez et al 1993; Zahger et al
1995; De Chillou et al 1996], Indeed, it has been suggested [De Chillou et al 1996;
Bowers et al 1996] that thrombolytic therapy should only be given to smokers and
alternative strategies such as primary angioplasty used in non-smokers. These
observations are consistent with the current findings since it might be anticipated that
patients with impaired endothelial cell t-PA release would benefit most from
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thrombolytic therapy whilst those with a normal endogenous fibrinolytic capacity are
more likely to have t-PA resistant thrombus which would respond less favourably.
Our findings in smokers are consistent with the previous observational data
[Hamsten et al 1985; Ridker et al 1993a; Thompson et al 1995] that increased basal
plasma concentrations of t-PA antigen are associated with future coronary events.
The assessment of endogenous fibrinolysis has previously relied on measurement of
basal plasma t-PA concentrations and the acute release of t-PA in response to venous
occlusion, systemic desmopressin infusion or exercise [Allen et al 1985; Gris et al
1991; Jahun-Vague et al 1996; Held et al 1997], However, because of confounding
systemic effects and the non-uniformity of the stimuli applied, these responses can be
variable and give only a relatively crude measure of fibrinolytic capacity. Moreover,
although it has previously been shown that systemic desmopressin infusion causes
less t-PA release in smokers [Allen et al 1985], this effect may not be directly
endothelium dependent [Mannucci 1997], In contrast, we have used locally active
doses of substance P to provide a more precise pharmacological stimulus to the
endothelium, and to cause a substantial and dose-dependent local release of t-PA
[Newby et al 1997b; Newby et al 1998], This has enabled us to demonstrate a
distinct and marked inhibition of stimulated endothelial t-PA release in smokers.
Although thrombin is more physiologically relevant to acute t-PA release than
substance P, we have used the latter because its vascular actions are endothelium-
dependent [Gross et al 1994], mediated in part through nitric oxide [Newby et al
1997c], and its administration intra-arterially is safe and well tolerated [Newby et al
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1997a], Consistent with previous workers [Celermajer et al 1996; Heitzer et al
1996a; Heitzer et al 1996b], we have also found an attenuation of the endothelium-
dependent forearm blood flow responses in smokers. This inhibition of both the
blood flow and t-PA response may, in part, relate to an impairment of the L-
arginine:nitric oxide pathway in smokers [Heitzer et al 1996a; Newby et al 1998],
Whilst differences exist [Hirooka et al 1994], the forearm model may provide a
useful surrogate for the coronary vascular bed [Sax et al 1987; Pedrinelli et al 1993]
and permits a readily accessible and reliable assessment of endothelial cell function.
However, the present findings need to be confirmed in the coronary circulation.
We have studied the sustained effect of chronic smoking in a selected healthy and
predominantly male population at a single time point. Although total and low density
lipoprotein cholesterol concentrations were similar in both smokers and non-
smokers, high density lipoprotein cholesterol concentrations were slightly lower in
smokers. This is not unexpected since cigarette smoking is known to be associated
with a selective reduction in HDL cholesterol concentrations [Shennan et al 1985;
Ferrara et al 1997], However, the application of this model to other conditions
associated with endothelial dysfunction, such as dyslipidaemia, is warranted. Finally,
since hormonal status influences fibrinolytic parameters [Koh et al 1997], the
assessment of the acute fibrinolytic capacity in pre and postmenopausal women, and
the modulating effect of hormonal therapy, will also be of particular interest.
In conclusion, we have demonstrated a major impairment of t-PA release from the
vascular endothelium of smokers. Our findings suggest that the fundamental
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mechanism whereby cigarette smoking causes arterial thrombosis and myocardial




HYPERCHOLESTEROLAEMIA AND LIPID LOWERING THERAPY
DO NOT AFFECT THE ACUTE ENDOGENOUS
FIBRINOLYTIC CAPACITY IN VIVO
Newby DE, Witherow FN, Wright RA, Bloomfield P, Ludlam CA,
Boon NA, Fox KAA, Webb DJ.
Hypercholesterolemia and lipid lowering therapy do not affect the acute endogenous




Endothelial dysfunction, demonstrated by impaired endothelium-dependent
vasodilatation, is found in patients with hypercholesterolemia. The aims of the
present study were to assess acute tissue plasminogen activator (t-PA) release in vivo
in patients with hypercholesterolemia, in the presence and absence of lipid lowering
therapy, and in matched normocholesterolaemic controls. Blood flow and plasma
fibrinolytic factors were measured in both forearms of eight patients with
hypercholesterolaemia (>7.8 mmol/L) and eight matched normocholesterolaemic
controls (<5.5 mmol/L). Subjects received unilateral brachial artery infusions of the
endothelium-dependent vasodilator, substance P (2 to 8 pmol/min), and the
endothelium-independent vasodilator, sodium nitroprusside (1 to 4 pg/min). In
patients, measurements were made on 3 occasions: at baseline and after 6 weeks of
placebo or pravastatin 40 mg daily administered in a double blind, randomised,
crossover'design. In comparison to patients, substance P caused greater dose-
dependent increases in forearm blood flow (p<0.05) in normocholesterolaemic
controls, but similar increases in plasma t-PA antigen and activity concentrations.
During pravastatin therapy in patients, total serum cholesterol fell by 22% from 8.1 ±
0.3 to 6.4-± 0.4 mmol/L (p=0.002) and substance P induced vasodilatation was no
longer significantly impaired in comparison to controls. However, despite
reproducible responses, pravastatin therapy was not associated with significant
changes in basal or substance P induced t-PA release. Hypercholesterolaemia and
lipid lowering therapy cause no demonstrable effects on acute substance P induced t-
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PA release in vivo. This suggests that the preventative benefits of lipid lowering
therapy are unlikely to be mediated by improvements in endogenous fibrinolysis.
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9.2 INTRODUCTION
Hypercholesterolaemia impairs endothelial cell function [Creager et al 1990;
Chowienczyk et al 1992; Casino et al 1995], predisposes to vessel damage and
contributes to vascular occlusion [Burke et al 1997], Previous studies have shown
that endothelium-dependent, nitric oxide mediated vasodilatation is impaired in
patients with hypercholesterolaemia [Creager et al 1990; Chowienczyk et al 1992;
Casino et al 1995], an effect which is reversed by lipid lowering therapy [Egashira et
al 1994; Stroes et al 1995; O'Driscoll et al 1997], Further measures of endothelial
cell dysfunction are lacking but the fibrinolytic factor, t-PA and its inhibitor,
plasminogen activator inhibitor type 1 (PAI-1), are potentially important markers and
are intimately linked to the risk of atherothrombosis [Hamsten et al 1985,Thompson
etal 1995],
We have recently described an in vivo model to assess the acute release of t-PA in
the forearm ofman [Newby et al 1997b], Using intra-brachial infusions of substance
P, we have shown a dose-dependent release of t-PA without causing a significant
release in PAI-1. Moreover, we have also reported [Newby et al 1998] that t-PA
release is inhibited by nitric oxide synthase inhibition with L-jV0-
monomethylarginine suggesting that endothelial dysfunction may impair the release
of t-PA. Given that substance P induced vasodilatation has been reported to be
impaired in patients with hypercholesterolemia [Casino et al 1995], the aims of the
present study were to determine whether there is also an impairment of t-PA release
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in patients with hypercholesterolaemia, and if treatment with pravastatin [Egashira et
al 1994] could enhance t-PA release in these patients.
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9.3 METHODS
9.3.1 Patients And Control Subjects
Patients with primary hypercholesterolaemia were recruited from the clinic if their
seaim cholesterol concentrations exceeded 7.8 mmol/L. Following screening with
clinical examination, repeated questioning for symptoms, clinical chemistry screen
(liver enzymes, electrolytes, urea and creatinine), haematology screen (full blood and
differential count), urinalysis and 12-lead electrocardiogram, patients were excluded
if they had diabetes mellitus, hypertension, ischaemic heart disease, peripheral
vascular disease, an abnormal resting electrocardiogram or other clinically
significant disease. Patients were matched with normocholesterolaemic (<5.5
mmol/L) healthy controls for age, sex and smoking habit. All studies were
undertaken with the approval of the local research ethics committee and in
accordance with the Declaration ofHelsinki.
9.3.2 Drugs
Pharmaceutical-grade substance P (Clinalfa AG, Laufelfingen, Switzerland) and
sodium nitroprusside (David Bull Laboratories, Warwick, U.K.) were administered
following dissolution in saline. Pravastatin (Bristol-Myers Squibb, Hounslow, U.K.)
40 mg daily or sucrose placebo capsules were administered orally.
9.3.3 Serum Lipid Assays
Serum cholesterol and triglyceride concentrations were determined by an enzymatic
colorimetric method (Boehringer Mannheim GmbH Diagnostica, Mannheim,
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Germany). LDL cholesterol was determined by the method of Friedewald and
colleagues [Freidewald etal 1972],
9.3.4 Study Design
All patients attended on each of the three separate study days: baseline and following
6 weeks treatment with placebo and 6 weeks with pravastatin 40 mg daily. Placebo
and pravastatin treatments were given in a randomised, double blind, crossover
design. Control subjects attended on one occasion only.
On each study day, subjects attended fasted at 09.00 hours and rested recumbent
throughout. Strain gauges and cuffs were applied and the brachial artery of the non-
dominant arm cannulated. Throughout all protocols, measurements of forearm blood
flow were made every 10 minutes. Before substance P and sodium nitroprusside
administration, saline was infused for 30 minutes to allow time for equilibration and
the final blood flow measurement during saline infusion was taken as the basal
forearm blood flow. Substance P was infused at 2, 4 and 8 pmol/min for 10 minutes
at each dose [Newby et al 1997b; Newby et al 1998; Newby et al 1999a] and sodium
nitroprusside was infused at 1, 2 and 4 pg/min for 10 minutes at each dose [Newby et
al 1997b], The order of substance P and sodium nitroprusside was randomised.
9.3.5 Data Analysis And Statistics
Data were examined, where appropriate, by two-way analysis of variance (ANOVA)
with repeated measures and two tailed paired Student's t-test using Excel v5.0
(Microsoft). Reproducibility of the responses to substance P infusion was assessed
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by comparing the baseline and placebo treatment study days using the method of
Bland and Altman [Bland & Altman 1986] Coefficients of reproducibility were
determined for 95% confidence intervals using the Student's t distribution. All results
are expressed as mean ± standard error of the mean. Statistical significance was
taken at the 5% level. Based on previous data [Newby et al 1997b] the study had
90% power to detect a 20% change in plasma t-PA concentrations between treatment
periods at the 5% level.
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9.4 RESULTS
Patient and control subject characteristics are shown in Table 9.1. The groups were
well matched for age, sex, body mass index, smoking habit, blood pressure, heart
rate, haematocrit and forearm blood flow. Total cholesterol and LDL cholesterol
concentrations were significantly higher in the patient group and fell during
pravastatin but not placebo treatment (Table 9.1). On each of the study days in the
patient and control groups, blood pressure, heart rate, haematocrit, and the blood
flow and t-PA concentrations of the non-infused forearm did not change.
9.4.1 Blood Flow Responses
Substance P caused dose dependent increases in blood flow of the infused forearm in
both patients and controls (p<0.001 for both; ANOVA: Figure 9.1). In comparison to
the control group, the substance P induced increases in blood flow were significantly
less than in the patient group (p<0.05; two-way ANOVA: Figure 9.1). During
pravastatin treatment, substance P appeared to cause a slightly greater increase in
blood flow but this was not statistically significant from baseline responses (p=0.30;
two-way ANOVA, baseline vs pravastatin) although it was no longer significantly
different from the control group (p=0.24; two-way ANOVA).
Sodium nitroprusside also caused dose-dependent increases in blood flow of the
infused forearm (p<0.001; ANOVA: Figure 9.1) which were similar in patient and
control groups. Neither pravastatin nor placebo therapy influenced the response to
sodium nitroprusside infusion.
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Forearm blood flow responses to substance P and sodium nitroprusside administration in controls (open circles;
upper panels) and patients at baseline (closed circles; upper panels), and in patients during placebo (open squares;
lower panels) and during pravastatin (closed squares; lower panels).
p<0.001 for each forearm blood flow response (one-way ANOVA)
*p<0.05 (2-.way ANOVA, controls vs patients)
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9.4.2 Fibrinolytic Factor Responses
Substance P caused dose-dependent increases in plasma t-PA antigen and activity
concentrations in the infused forearm of both patients and controls (p<0.001 for both;
ANOVA: Table 9.2). Substance P induced increases in plasma t-PA concentrations
were similar in both groups and, in the patient group, was unaffected by pravastatin
or placebo therapy. The concentration differences between the forearms and the
estimated net release of t-PA antigen and activity also demonstrated dose-dependent
increases (p<0.001; ANOVA: Figure 9.2) which did not differ between the patient
and control groups or during pravastatin and placebo therapy. There were no
significant differences in plasma PAI-1 antigen and activity concentrations at
baseline, although there appeared to be a trend for plasma PAI-1 antigen
concentrations to be lower in the control group (p>0.12; unpaired /-test: Table 9.3).
Plasma PAI-1 concentrations were unaffected by substance P infusion or pravastatin
treatment (Table 9.3).
9.4.3 Reproducibility Of Substance P Responses
Comparison of responses at baseline and during placebo therapy demonstrates good
reproducibility for substance P induced increases in plasma t-PA concentrations and
forearm blood flow (Table 9.4).
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Concentration difference between infused and non-infused forearms (upper panels) and estimated net release
(lower panels) of plasma t-PA antigen (solid lines; left panels) and activity (dashed lines; right panels) during
substance P administration in controls (open circles), and patients at baseline (closed circles), and during
placebo (open squares) and pravastatin (closed squares) therapy.
p<0.001 for each response (one-way ANOVA)
Concentration Difference Between
Forearms of Plasma t-PA




Despite impaired endothelium-dependent forearm vasodilatation, we have shown
that, in patients with hypercholesterolaemia, intra-brachial substance P infusions are
associated with a normal capacity to release t-PA acutely. Moreover, pravastatin
therapy, sufficient to reduce cholesterol concentrations by 22%, had no significant
effects on acute t-PA release. This suggests that, despite the presence of endothelial
dysfunction, hypercholesterolaemia does not influence the acute fibrinolytic capacity
of the endothelium, and that the preventative benefits of lipid lowering therapy are
unlikely to be mediated by improvements in endogenous fibrinolysis.
Consistent with previous findings [Casino et al 1995], we have demonstrated that, in
patients with hypercholesterolaemia, there is an impairment of endothelium-
dependent vasodilatation in response to substance P infusion. However, in contrast to
the marked impairment of t-PA release that we have recently described in cigarette
smokers [Newby et al 1999a], hypercholesterolaemia and lipid lowering therapy do
not appear to influence substance P induced t-PA release. Taken together, our
findings suggest that although smoking is associated with impaired endogenous
fibrinolysis, hypercholesterolaemia is not. This is consistent with the observations
that the patency rate of the infarct related artery following thrombolytic therapy
during myocardial infarction is enhanced in cigarette smokers [Mueller et al 1992;
Barbash et al 1993; Zahger et al 1995] but not in patients with hypercholesterolaemia
[De Chillou et al 1996], and that cigarette smoking is associated with thrombotic
occlusion whereas hypercholesterolaemia is linked to atherogenesis and plaque
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rupture [Burke et al 1997], This would also indicate that endothelial dysfunction can
be manifest in separate distinct pathways depending upon the nature of the insult.
The WOSCOPS study [Shepherd et al 1995] was the first major randomised
controlled trial to show the primary preventative benefits of lipid lowering therapy.
We, therefore, chose to examine the effects of pravastatin 40 mg daily on endothelial
and fibrinolytic function in a well defined and otherwise healthy
hypercholesterolaemic population. Although the total cholesterol was reduced by
22% and pravastatin was used at doses which have been shown to confer major
preventative benefits in several large scale clinical trials [Shepherd et al 1995; Sachs
et al 1996; The LIPID Study Group 1998], the total serum cholesterol concentration
remained significantly higher than the normocholesterolemic population. It may be
that a greater reduction in cholesterol concentrations may have facilitated a
significant improvement in endothelium-dependent vasodilatation. However, the
mean cholesterol concentrations of the patients in the WOSCOPS study were similar
to the present study and the relative risk reduction in ischaemic events is the same
across a broad range of cholesterol concentrations [The LIPID Study Group 1998],
Moreover, it would appear that statins do not just lower cholesterol and may have
many ancillary vascular actions [Vaughan et al 1996], Finally, since we did not
observe a significant difference in t-PA release between hypercholesterolaemic and
normocholesterolaemic subjects, it is unlikely that additional reductions in lipid
concentrations, using higher doses of pravastatin or more potent statins, would
influence the acute release of t-PA.
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The influence of lipid lowering therapy on endothelial dysfunction was initially
studied in patients with hypercholesterolemia following 3 to 6 months of treatment
[Egashira et al 1994; Stroes et al 1995], However, more recent studies have
demonstrated that endothelial dysfunction can be reversed by six [Koh et al 1999] or
even four weeks [O'Driscoll et al 1997] of statin therapy. Indeed, two hours
treatment with plasma LDL apheresis is associated with rapid and immediate reversal
of endothelial dysfunction [Tamai et al 1997], It is, therefore, unlikely that the
absence of an effect of pravastatin therapy is due to the length of treatment.
Moreover, in contrast to previous studies, we have used a randomised double blind
crossover study design which provides a greater sensitivity to detect potential
differences in responses. The coefficients of reproducibility are consistent with our
previous studies [Newby et al 1997a; Newby et al 1997b] and indicate a power
sufficient to detect an -20% change in blood flow and fibrinolytic responses.
In summary, whereas endothelium-dependent vasodilatation is abnormal in both
cigarette smoking and hypercholesterolaemia, acute t-PA release appears to be
impaired only by cigarette smoking [Newby et al 1999a], These observations support
the concept that endothelial dysfunction is not a homogenous condition and may be
manifested in differing ways depending on the nature of the injury. Moreover, the
benefits of lipid lowering therapy in the primary [Shepherd etal 1995] and secondary
[Sachs et al 1996; The LIPID Study Group 1998] preventation of coronary events are
unlikely to be mediated by improvements in endogenous fibrinolysis.
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CHAPTER 10
CORONARY ATHEROSCLEROSIS AND CIGARETTE SMOKING IMPAIR
CORONARY TISSUE PLASMINOGEN ACTIVATOR RELEASE:
DIRECT ASSOCIATION BETWEEN ENDOTHELIAL DYSFUNCTION AND
ATHEROTHROMBOSIS
Newby DE, McLeod AL, Uren NG, Flint L, Ludlam CA,
Webb DJ, Fox KAA, Boon NA. Impaired coronary fibrinolytic capacity is associated
with coronary atherosclerosis and cigarette smoking:




The objective of the study was to establish the relationship between the volume of
proximal coronary artery atheroma, the presence of associated risk factors and the
stimulated release of tissue plasminogen activator (t-PA) from the heart. Following
diagnostic coronary angiography in 25 patients, the left anterior descending artery
(LAD) was instrumented and the proximal LAD plaque volume was determined
using intravascular ultrasound (IVUS). Blood flow and fibrinolytic responses to
selective LAD infusion of saline, substance P (10-40 pmol/min) and sodium
nitroprusside (5-20 pg/min) were measured using intracoronary IVUS and Doppler,
combined with arterial and coronary sinus blood sampling. Mean plaque burden was
5.5 ± 0.8 mm3 per mm of vessel (range 0.6-13.7). LAD blood flow increased with
both substance P and sodium nitroprusside (p<0.001), although coronary sinus
plasma t-PA antigen and activity concentrations increased only during substance P
infusion (p<0.006 for both). There was a significant inverse correlation between the
LAD plaque burden and release of active t-PA (r=-0.61, p=0.003). Cigarette
smoking, but no other risk factor, was associated with an impairment of coronary
release of active t-PA (smokers, 42 ± 21 versus nonsmokers, 202 ± 73 IU.min"1;
p=0.01). We have found an association between both the coronary atheromatous
plaque burden and smoking habit with the acute local fibrinolytic capacity of the
heart. These important findings potentially provide a direct link between endogenous
fibrinolysis, endothelial dysfunction and atherothrombosis.
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10.2 INTRODUCTION
The endothelium plays a vital role in the control of blood flow, coagulation,
fibrinolysis and inflammation. Consequently, the maintenance and regulation of
tissue perfusion critically depends upon the integrity of endothelial function and the
release of potent endothelium-derived factors. Following the seminal work of
Furchgott and Zawadski [Furchgott & Zawadski 1980], it has been widely
recognised that an array of mediators can influence vascular tone through
endothelium-dependent actions. There is an extensive body of evidence to show that
endothelium-dependent vasomotion is abnormal in patients with atherosclerosis
[Ludmer et al 1986] and its associated risk factors [Celermajer et al 1992;
Chowienczyk et al 1992; Celermajer et al 1996], Flowever, whilst endothelium-
dependent vasomotion is an important indicator of endothelial cell function, it is an
indirect surrogate measure of the central pathophysiological role of the endothelium
in atherothrombosis.
Acute rupture or erosion of a coronary atheromatous plaque and subsequent coronary
artery thrombosis causes the majority of sudden cardiac deaths and myocardial
infarctions [Burke et al 1997; Davies 2000], Small areas of denudation and thrombus
deposition are a common finding on the surface of atheromatous plaques and are
usually sub-clinical [Davies 2000], However, in the presence of an imbalance in the
fibrinolytic system, such microthrombi may propagate, ultimately leading to arterial
occlusion [Rosenberg & Aird 1999], Indeed, genetic murine models indicate that t-
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PA deficiency is associated with myocardial necrosis and the development of
regional wall motion abnormalities [Christie etal 1999],
In the Northwick Park Heart Study [Meade et al 1993], low basal plasma fibrinolytic
activity was a leading determinant of the risk of sustaining a myocardial infarction or
suddeh cardiac death in younger men. Moreover, a reduction in exercise induced
release of t-PA is associated with an increased incidence of major adverse cardiac
events in patients with stable angina pectoris [Held et al 1997], Recently, Rosenberg
and Aird [Rosenberg & Aird 1999] have postulated that vascular-bed-specific defects
in haemostasis exist, and that coronary thrombosis critically depends on the local
fibrinolytic balance. However, there have been no clinical studies to date which have
directly assessed the acute local fibrinolytic capacity of the coronary vascular bed in
patients with coronary artery disease.
Using forearm venous occlusion plethysmography and the endothelium-dependent
agonist, substance P, we have recently developed and characterised a novel model of
assessing the acute release of endogenous t-PA in vivo in man [Newby et al 1997b],
This has enabled us to demonstrate that cigarette smoking is associated with an
impairment of acute t-PA release [Newby et al 1999a] although this has yet to be
confirmed in the coronary circulation. The aims of the present study were: first, to
apply this approach to the coronary circulation and thereby establish a method of
assessing acute coronary t-PA release; second, to determine the relationship between
the extent of coronary artery atheroma, quantified by intravascular ultrasound
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(IVUS), and the acute fibrinolytic capacity of the coronary vascular bed; and third, to




Patients undergoing elective coronary angiography were recruited unless they had
significant aortic stenosis, severe left ventricular dysfunction or recent (<3 months)
myocardial infarction. Following angiography, patients were excluded if they had
significant left main stem disease or a minimal luminal diameter of less than 2 mm in
the proximal left anterior descending coronary artery. All patients had their risk
factor profile determined by standard clinical criteria: smoking habit (current/ex-
smoker or non-smoker), family history of premature (male: <50 years, female: <55
years) coronary artery disease, and a history of hypertension (systolic blood pressure
>160 mmHg or diastolic blood pressure >90 mmHg on 3 or more occasions),
diabetes mellitus (fasting blood glucose concentration >7.8 mmol/L or >11.1 mmol/L
2 hours after 75 g glucose load) or hypercholesterolaemia (total serum cholesterol
concentration >5.0 mmol/L). Since many patients discontinued a regular smoking
habit just prior to angiography, current and ex-smokers were considered as a single
group. The study was undertaken with the approval of the local research ethics
committee and in accordance with the Declaration of Helsinki. The written informed
consent of each subject was obtained before entry into the study.
10.3.2 Study Protocol
All patients discontinued their medication on the study day, attended fasted and
underwent diagnostic coronary angiography at 08.00 h. Following angiography,
patients fulfilling the entry criteria were entered into the study and received 5,000 IU
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of intravenous heparin. Cannulation of the coronary sinus was established from the
femoral vein using a preformed specific 6 F catheter (modified Simmons Torcon NB
catheter, HNB6.0-NT-100-PW-2S-112393-BH) [Katritsis & Webb-Peploe 1997], To
avoid atrial blood mixing, the catheter was advanced, sometimes with the assistance
of a guide wire, deep into the ostium and beyond the posterior interventricular vein.
Stable and selective cannulation of the coronary sinus was achieved in all but three
subjects. Arterial samples were obtained through an 8 F haemostatic sheath placed in
the right femoral artery.
The left coronary artery was cannulated with a 7 F guiding catheter and a 0.014 inch
12.5 MHz Doppler wire (Flowire™, Cardiometrics, Endosonics, Rancho Cordova,
CA, USA) was passed into the left anterior descending coronary artery. A 3.2 F
Ultracross™ 20 MHz IVUS imaging catheter (SCIMED®, Boston Scientific
Corporation, MN, USA) was advanced into the left anterior descending coronary
artery over the guide wire. The IVUS examination of the proximal artery was
performed at 0.5 mm/s using a motorised pullback device (Boston Scientific Corp)
whilst recording the ultrasound images onto S-VHS tape using the Clearview™
ultrasonogram (Boston Scientific Corp). Following the pullback examination, the
IVUS imaging catheter was repositioned just distal to the ostium of the left anterior
descending artery. The Doppler guide wire was retracted to the tip of the imaging
catheter and maintained in a stable position by the short monorail segment of the
IVUS catheter [Schwarzacher et al 2000], The average peak velocity of the Doppler




Pharmaceutical-grade substance P (Clinalfa AG, Laufelfingen, Switzerland), an
endothelium and neurokinin type 1 receptor dependent vasodilator [Newby et al
1999c], and sodium nitroprusside (David Bull Laboratories, Warwick, U.K.), an
endothelium independent vasodilator, were administered following dissolution in
saline (0.9%: Baxter Healthcare Ltd, Thetford, UK). Five minute infusions were
administered using an IVAC PI000 syringe pump (IVAC Ltd, Basingstoke, UK) at 1
mL/min via the IVUS catheter flush port [Schwarzacher et al 2000], The agents were
given in the following order: saline, substance P 10 pmol/mL, substance P 20
pmol/mL, substance P 40 pmol/mL, sodium nitroprusside 5 pg/mL and sodium
nitroprusside 20 pg/mL. Due to limitations in procedural time, the sodium
nitroprusside responses were determined in 14 patients only.
10.3.4 Measurement Of Plaque Volume And Coronary Blood Flow
Computerised three dimensional reconstructions of the proximal left anterior
descending coronary artery were performed off-line by a single blinded operator
using the TomTec computer system (Echoscan, TomTec Imaging Systems,
Unterschleissheim, Germany). The proximal atheromatous plaque volume was
calculated using a well validated edge detection algorithm [von Birgelen et al 1996a;
von Birgelen et al 1997], The planar contours were checked by the operator and, if
necessary, edited. The plaque area was defined as the region between the luminal
border and the echogenic interface of the external elastic lamina as previously
described [Di Mario etal 1998; von Birgelen etal 1996b],
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The left anterior descending coronary artery cross-sectional area was measured using
computerised planimetry (Clearview™, Boston Scientific Inc) of the vessel lumen.
The IVUS images were gated to the electrocardiogram and measurements were made
at the onset of the QRS complex. Blood flow velocity was determined using average
peak velocity of the Doppler signal (Flopmap™, Cardiometrics). Blood flow in the
left anterior descending coronary artery was determined from the mean of five
measurements made in the final minute of each infusion period and was defined as
[Doucette etal 1992]:
Coronary blood flow (mL/min) = CSA . APY . 60
2 100
where CSA = cross-sectional area (mm2) and APV = average peak velocity (cm/s).
10.3.5 Blood Sampling And Plasma Assays
Ten mL.of arterial and coronary sinus blood were obtained simultaneously at the end
of each infusion period, collected into acidified buffered citrate (Biopool®
Stabilyte™, Umea, Sweden) and citrate (Monovette®, Sarstedt, Numbrecht,
Germany) tubes, and kept on ice before being centrifuged at 2,000 g for 30 minutes
at 4°C. Platelet free plasma was decanted and stored at -80°C before assay. Coronary
sinus oxygen saturations were determined at the end of each infusion period using an
automated oximeter (Oxicam™ 300, Watco Services, Basingstoke, UK).
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10.3.6 Data Analysis And Statistics
Coronary t-PA release was defined as the product of the left anterior descending
artery plasma flow (based on the haematocrit, Hct and the left anterior descending
coronary blood flow, CBF) and the plasma arterial ([t-PA] Art) and coronary sinus ([t-
PAJvcn) concentration differences.
Estimated net coronary t-PA release = CBF x {1-Hct} x {[t-PA]ven - [t-PA]Art}
In order to compare vasomotor and fibrinolytic responses with proximal
atheromatous plaque volume, the area under the curve (AUC) was calculated for
each response: coronary blood flow, plasma arterial and coronary sinus t-PA
concentration differences, and estimated net t-PA release.
Data were examined by analysis of variance (ANOYA) with repeated measures, two
tailed paired and unpaired Student's /-test, and univariate and multivariate regression
analysis using StatView v5.0.1 (SAS Institute Inc., Cary, North Carolina, USA). All
results are expressed as mean ± standard error of the mean. Statistical significance
was taken at the 5% level.
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10.4 RESULTS
Baseline patient characteristics are shown in Table 1. In keeping with the anticipated
profile of patients undergoing coronary angiography, the study population was
predominantly middle-aged, male and had a combination of risk factors. Throughout
the study there were no significant changes in heart rate, mean arterial pressure or
haematocrit (0.40 ± 0.01).
10.4.1 Plaque Volume And Blood Flow Responses
The proximal 29 ± 1 mm of the left anterior descending coronary artery were
reconstructed and found to contain 160 ± 24 mm3 of atheromatous plaque: a plaque
burden of 5.5 ± 0.8 mm3 per mm of vessel (range, 0.6 to 13.7). There was a
significant linear correlation between the plaque burden and the serum total
cholesterol: HDL-cholesterol ratio (r=0.55, p=0.004).
Left anterior descending coronary artery blood flow increased with both substance P
and sodium nitroprusside infusion (p<0.001, ANOVA; see Table 2). There was a
significant linear correlation between the percentage increase in coronary sinus
oxygen saturations and left anterior descending coronary artery flow (r=0.46,
p<0.001). However, there was no correlation between the plaque burden and the
AUC for the coronary blood flow responses to substance P or sodium nitroprusside
infusion. In contrast, there was an association between the number of risk factors for






Age 56 ± 2 years
Sex 17 male
Body Mass Index 28 ± 1 kg/m2





Serum Lipid Profile Total Cholesterol 5.8 ± 0.3 (mmol/L)
LDL Cholesterol 3.2 ±0.2 (mmol/L)
HDL Cholesterol 1.3 ±0.1 (mmol/L)
Total/HDL Cholesterol Ratio 4.9 ± 0.5
Triglycerides 2.3 ±0.1 (mmol/L)




Lipid Lowering Therapy 16
ACE Inhibition 3
Diuretics 3
Previous Myocardial Infarction 6
Non-Invasive Testing Low Risk 9
High Risk 12
Not Performed 4
Angiographic Data Good Left Ventricular Function 24
Normal/Mild Disease 8
Single Vessel Disease 9
Two Vessel Disease 6
Three Vessel Disease 2
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IntravascularUltr o ndndDopp er LuminalCross-sectionalAr AverageP kV locity AbsoluteCoronaryBl odFl w ChangeioronaryBloodFl w
(mm2) (cm/s) (mL/min) (%)
15.7±.0 21.4±1.6 103±2 0
16.4±1.0® 27.3±.2* 138±8® 36±6*
16.5±.0* 27.5±.4* 140±9* 37±7*
16.9±.0* 28.0±2.3* 143±8* 46±10*
14.9±1.1 22.7±2.2 109±8 0
15.4±1.1* 27.0±2.2* 131±20* 29±9*
16.1±1.3* 47.1±4.6* 242±42* 140±2 *
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Endothelium-Dependent Increases









Prevalence of risk factors and influence on coronary blood flow responses to substance P
infusion.
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10.4.2 Plasma Fibrinolytic Parameters
There was a significant rise in plasma t-PA antigen and activity concentrations from
the coronary sinus during substance P infusion (Figure 2: ANOVA, p<0.001 and
p<0.006 respectively) but not during sodium nitroprusside infusion. There was a
significant inverse correlation between the plaque burden and the AUC for active t-
PA release (Figure 3: r=-0.61, p=0.003), and a trend for the AUC for t-PA antigen
release (r=-0.34, p=0.15). There was also an inverse linear correlation between the
basal coronary sinus plasma t-PA antigen concentration and the AUC for active t-PA
release (r=-0.58, p<0.005).
Ex- and current cigarette smokers had a higher basal plasma t-PA antigen
concentration and an impaired active t-PA response to substance P infusion in
comparison to non-smokers despite similar plasma PAI-1 concentrations and
coronary arterial plaque burden (Table 3). Subgroup analysis demonstrated that
current smokers (n=4) had similar release of active t-PA compared to ex-smokers
(n=13). 49 ± 32 and 40 ± 28 IU/min respectively. Hypercholesterolaemia,
hypertension, diabetes mellitus and a family history of premature coronary artery
disease had no influence on t-PA release.
There were no significant changes in plasma PAI-1 antigen and activity
concentrations throughout the study (Table 2). Basal coronary sinus plasma PAI-1
antigen concentrations correlated positively with plaque burden (r=0.47, p<0.03) and
negatively with release of active t-PA (r=-0.44, p=0.04).
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Multivariate regression analysis identified plaque burden and basal coronary sinus t-
PA antigen concentrations as the independent variables that were significantly
associated with release of active t-PA (p<0.02 for both).
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Table 10.3
Influence of smoking status on the tissue plasminogen activator (t-PA) release, plasminogen



































































*Area under the curve


















Arterial (open circles) and coronary sinus (closed circles) plasma tissue plasminogen activator
(t-PA) antigen (solid lines) and activity (dashed lines) concentrations during substance P (left
panel) and sodium nitroprusside (right panel) infusion.
*p<0.007 (ANOVA with repeated measures)
fp<0.01; tp<0.001 (versus baseline, paired /-test)
§p<0.05 (•versus arterial, paired /-test)
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Correlation ofthe plaque burden ofthe left anterior descending coronary artery with the AUC
for the arteriovenous concentration differences (upper panel) and the estimated net release
(lower panel) oftissue plasminogen activator (t-PA) activity.
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10.5 DISCUSSION
For the first time, we have shown a direct relationship between both the coronary
atheromatous plaque burden and smoking habit with the acute fibrinolytic capacity of
the heart. These important findings suggest that both atherosclerosis and smoking
habit influence the local fibrinolytic balance in the coronary circulation, and provide
a direct link between endothelial dysfunction, atherothrombosis and myocardial
infarction.
The clinical importance of endogenous t-PA release is exemplified by the high rate
of spontaneous reperfusion in the infarct related artery after acute myocardial
infarction; occurring in one third of patients within the first 12 hours [De Wood et al
1980; Armstrong et al 1989; Rentrop et al 1989], The present study is the first to
attempt directly to assess the acute release of t-PA in the coronary circulation of
patients with stable coronary artery disease. Although thrombin and activated
coagulation Factor X may be more physiologically relevant to acute t-PA release
than substance P, we have used the latter because its vascular actions are
endothelium-dependent [Gross et al 1994] and its administration intra-arterially is
safe and well tolerated [Crossman et al 1989; Newby et al 1997a], Using this
approach, we have been able to stimulate the fibrinolytic activity of the coronary
vascular bed and demonstrate that this response appears to be sensitive to the
presence of atheroma: a rapid decline in release of active t-PA associated with an
increasing plaque burden. This reduction in acute fibrinolytic capacity appears to
reflect both an impairment of acute t-PA release and an elevation in plasma PAI-1
concentrations. The mechanisms underlying this relationship remain to be
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established but are likely to involve chronic endothelial cell injury and an
impairment of the L-arginine:nitric oxide pathway [Newby et al 1998], In addition,
this association may reflect the chronic stimulation and up-regulation of basal t-PA
release secondary to the presence of atheroma [Steins et al 1999] and arterial
denudation. The subsequent depletion of endothelial cell t-PA stores, the associated
increases in PAI-1 concentrations and the overall reduction of the acute dynamic
fibrinolytic response, would potentially be detrimental. This hypothesis is consistent
with the epidemiological observations of a positive correlation between plasma t-PA
and PAI-1 antigen concentrations and future coronary events [Hamsten et al 1985;
Meade et al 1986; Jansson et al 1993; Meade et al 1993; Ridker et al 1993a;
Thompson et al 1995; Thogersen et al 1998] as well as our findings of inverse
correlations between the release of active t-PA, and basal coronary sinus t-PA and
PAI-1 antigen concentrations.
Questions of cause and effect cannot be resolved by the present study but our
observations are also consistent with a reduced fibrinolytic activity causing enhanced
atherogenesis. Detailed post-mortem studies have shown that plaque growth is
induced by episodic subclinical plaque disruption and thrombus formation [Mann &
Davies 1999], The prolonged presence of residual thrombus over a disrupted or
eroded plaque will provoke smooth muscle migration and the production of new
connective tissue, leading to plaque expansion [Galis et al 1997; Nomura et al 1999;
Davies 2000], This is consistent with the enhanced macrovascular fibrin deposition
and atherogenesis seen in genetic murine models of t-PA and plasminogen deficiency
[Xiao et al 1997; Christie et al 1999],
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In agreement with our previous work in the peripheral circulation [Newby et al
1999a], we have also observed an elevated basal plasma t-PA antigen concentration
and an impairment in coronary release of active t-PA in cigarette smokers. These
observations suggest that the increased risk of coronary thrombosis seen in smokers
[Burke et al 1997] relates to impaired endogenous fibrinolysis and the propagation of
thrombus that would otherwise undergo lysis and remain sub-clinical. Although
cigarette smokers have a higher overall mortality from myocardial infarction than
non-smokers [Haheim et al 1993], the in-hospital mortality is lower [Mueller et al
1992; Barbash et al 1993; Zahger et al 1995], This so-called "smokers' paradox" can
be explained by the observation that the infarct related artery is more than twice as
likely to become patent in current smokers compared to non-smokers following
thrombolytic therapy for acute myocardial infarction [Gomez et al 1993; Zahger et al
1995; De Chillou et al 1996], Indeed, it has been suggested that thrombolytic therapy
should only be given to smokers, and that alternative strategies such as primary
angioplasty used in non-smokers [Bowers et al 1996], Our findings may account for
these observations since it might be anticipated that patients with impaired
endothelial cell t-PA release would benefit most from thrombolytic therapy whilst
those with a normal endogenous fibrinolytic capacity are more likely to have
coronary thrombus resistant to fibrinolysis.
Previous studies [Zeiher et al 1991; Kuga et al 1995] have suggested that there is a
direct association between coronary atherosclerosis and endothelium-dependent
vasodilatation. These studies have assessed the vasomotor responses and the extent
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of atherosclerosis using quantitative coronary angiography (QCA). There are several
inherent limitations and inaccuracies of QCA [Newby 2000b] which permits only
crude estimates of plaque load [De Feyter et al 1991; Topol & Nissen 1995] and
underestimates the coronary artery luminal diameter and cross-sectional area [De
Scheerder et al 1994; Escaned et al 1996; Moussa et al 1999], These inaccuracies
occur because QCA can only assess the arterial lumen and the arterial wall is
extrapolated from a reference segment and does not take account of "Glagovian"
remodelling [Glagov et al 1987; Escaned et al 1996], In contrast, IVTJS provides a
more accurate assessment of intracoronary plaque volume that has been extensively
validated [Hausmann et al 1994; von Birgelen et al 1997], Using this methodology,
we have failed to detect a direct association between the atherosclerotic plaque
burden and substance P induced vasodilatation. This is, in part, likely to reflect the
independent influence of atherosclerotic risk factors on endothelium-dependent
vasomotion and is borne out by the correlation of the substance P vasodilatation and
the prevalence of these risk factors.
10.5.1 Study Limitations
The proportionate increase in coronary plasma t-PA concentrations appears to be
more modest than that obtained from the forearm circulation in healthy volunteers
[Newby et al 1997b] and is likely to reflect a number of factors including the direct
influence of atherosclerosis. Because the coronary sinus also drains regions of the
heart outwith the left anterior descending coronary artery territory, the current
methodology will also tend to underestimate the net coronary release of t-PA.
Moreover, regional and visceral differences in t-PA release do exist such that the
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upper limbs release four times the amount of the lower limbs [Keber 1988], and
unlike the systemic circulation, the liver and kidney do not acutely release t-PA when
challenged with desmopressin [Brommer etal 1988],
Since the estimated net t-PA release was defined as a product of the arteriovenous
difference and plasma flow, impaired endothelial vasodilatation may contribute to
the observed reduction in net release of active t-PA. However, this is unlikely for two
reasons. First, there was an independent correlation between the arteriovenous
difference and the atheromatous plaque burden. Theoretically, smaller increases in
blood flow would be associated with greater increases in the arteriovenous
concentration differences and obscure this latter association. Second, we failed to
detect a significant correlation between the atheromatous plaque burden and
substance P induced vasodilatation.
A clear incremental dose response to substance P infusion was not observed. The
doses of substance P were chosen on the basis of the effective end-organ
concentrations associated with t-PA release in the forearm [Newby et al 1999a],
Given that the left anterior descending coronary artery blood flow is approximately
4-5-fold forearm blood flow, we utilised substance P at doses of 10-40 pmol/min (c.f.
2-8 pmol/min in the forearm) which are at the limit of breakthrough systemic effects
[Crossman et al 1989], These intracoronary doses have previously been shown to
have a similar plateau of vasodilatation responses [Crossman et al 1989] and are
consistent with our own findings.
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In conclusion, we have demonstrated, for the first time, a direct association between
both the coronary atheromatous plaque burden and smoking habit with the acute
local fibrinolytic capacity of the coronary circulation. These important findings may
provide a direct link between endothelial dysfunction and atherothrombosis.
Interventions targeted at the enhancement of the local fibrinolytic capacity will
potentially be ofmajor importance.
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CHAPTER 11
CONCLUSIONS AND FUTURE DIRECTIONS
11.1 SUBSTANCE P MEDIATED STIMULATION OF THE
ENDOTHELIUM
11.1.1 Substance P Mediated Vasodilatation
In a series of studies, it has been demonstrated that although endogenous substance P
does not appear to contribute to the maintenance of peripheral vascular tone or
systemic blood pressure, exogenous substance P causes a dose-dependent increase in
blood flow through an endothelium- and NKi receptor-dependent mechanism. In the
human forearm, exogenous substance P administration appears to be well tolerated
and causes reproducible blood flow responses both within and between study days.
11.1.2 Substance P Mediated Tissue Plasminogen Activator Release
Substance P mediated vasodilatation is associated with a selective and reproducible
forearm release of t-PA at intra-brachial doses of 2 pmol/min or higher. This
endothelial cell stimulation is not accompanied by the co-release of other endothelial
cell peptidic products, such as PAI-1 or vWf, despite protracted cellular stimulation
of up to 2 hours. This indicates that there is a distinct dynamic intracellular storage
pool of t-PA. Our findings, therefore, suggest that significant co-localisation of t-PA
with vWf in the Weibel Palade bodies [Datta et al 1999; Rosnoblet et al 1999] is
unlikely and is consistent with separate distinct storage granules for these two
glycoproteins [Emeis etal 1997],
There appears to be a substantial capacity for t-PA release in the forearm circulation.
Assuming a forearm volume of 1000 mL, the average release of t-PA with substance
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P at 64-128 pmol/min was approximately 10 pg over 10 minutes. Moreover,
stimulation of the endothelium over a 2 hour period was associated with a sustained
release of t-PA, exceeding 30 gg in some individuals, indicating that there are large
intracellular stores which do not become readily depleted. Thus, the endothelium
appears to have a vast fibrinolytic reserve which can be rapidly mobilised in the
presence of intravascular thrombosis.
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11.2 MECHANISMS OF TISSUE PLASMINOGEN ACTIVATOR
RELEASE
11.2.1 Selective Tissue Plasminogen Activator Release
The selective endothelial cell release of t-PA is not unique to substance P. Recently,
both bradykinin [Brown et al 1999; Labinjoh et al 2000a] and desmopressin
infusions [Wall et al 1998; Newby et al 2000a] have been shown to induce selective
forearm release of t-PA in the absence of a change in PAI-1, vWf or factor VIILC
concentrations. However, it is interesting to note that not all endothelial cell
stimulants release t-PA. For example, acetylcholine administration causes no
detectable release of t-PA despite marked increases in forearm blood flow [Brown et
al 1999], Moreover, endothelin-1 administration is not associated with a significant
release of t-PA despite the stimulation of endothelial ETB receptors [Newby et al
1999d], The reason for these disparities may lie in the mechanisms of action of these
compounds and it would appear that different G-protein coupled receptors invoke
distinct endothelial cell responses.
Substance P and bradykinin are both inflammatory mediators and, when
administered into the forearm, are associated with the formation of cutaneous
oedema [Newby et al 1997b; Labinjoh et al 2000a], Moreover, desmopressin
infusion provokes a systemic inflammatory response which induces a 10-fold
increase of the cytokine, interleukin-6 [Newby et al 2000a], It may, therefore, be that
provocation of endothelial cell t-PA release requires a specific second messenger
signal which involves an inflammatory process.
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11.2.2 Cellular Mechanisms Of Tissue Plasminogen Activator Release
Unlike desmopressin [Wall et al 1998; Newby et al 2000a], substance P induced t-
PA release has a rapid onset and offset of action that reaches a maximal effect within
a few minutes. The cellular mechanisms involved in the release of t-PA from
intracellular storage granules are unclear [Rydholm et al 1995] but would appear to
involve calcium ions [Tranquille et al 1991] and, in part, relate to the action of the L-
arginine:nitric oxide system [Newby et al 1998], However, increases in blood flow
and nitric oxide release do not per se induce t-PA release since infusion of sodium
nitroprusside to increase forearm blood flow by more than 600% does not affect t-PA
release [Jern et al 1994a+b; Newby etal 1997b; Stein et al 1998 ].
The endothelium expresses a vast array of G-protein coupled receptors that, when
stimulated, can evoke the release of a range of vasoactive mediators, such as
prostanoids, nitric oxide and endothelium-derived hyperpolarising factor (EDHF). In
contrast, direct local release of t-PA appears to occur only in response to certain
agonists, whilst methods of selectively inducing vWf and PAI-1 release have yet to
be identified. Thus, the endothelium appears to have a complex and differential
response to specific receptor mediated stimuli. It is clear that these intracellular
mechanisms and pathways will be central to our understanding and interpretation of
the functional studies of the endothelium but they have yet to be precisely
characterised.
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11.3 ENDOTHELIAL DYSFUNCTION AND IMPAIRED ENDOGENOUS
FIBRINOLYSIS
To date, the majority of investigational studies assessing endothelial function have
focused upon endothelium-dependent vasomotion and have shown that it is impaired
by many of the risk factors associated with coronary artery disease, such as
hypercholesterolaemia [Chowienczyk etal 1992; Stroes etal 1995], diabetes mellitus
[Calver et al 1992], familial history of atherosclerosis [Celermajer et al 1992] and
smoking [Celermajer et al 1996; Heitzer et al 1996a+b; Newby et al 1999a],
Endothelial function is also impaired in the coronary circulation of patients with
coronary artery disease [Ludmer et al 1986] and its risk factors [Vita et al 1990]
including smoking [Zeiher et al 1995], However, endothelial regulation of
vasomotion is but one of the many aspects of endothelial function (Table 1.2) and
represents a surrogate marker for the role of the endothelium in atherothrombosis.
It is perhaps remarkable that other aspects of endothelial function, such as
haemostasis and fibrinolysis, have been relatively under investigated. Here, the
endogenous fibrinolytic capacity of subjects with risk factors for atherosclerosis,
namely cigarette smoking and hypercholesterolaemia, and patients undergoing
diagnostic coronary angiography with a range of coronary artery disease, have been
explored. Endothelial fibrinolytic dysfunction, as manifest by an impairment of
endothelial t-PA release, appears to be a feature of cigarette smoking and
atherosclerosis but not hypercholesterolaemia. This would indicate that endothelial
dysfunction can be manifest in separate distinct pathways depending upon the nature
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of the insult. Indeed, given the disparate mechanisms of inducing endothelial cell
injury, it would perhaps be surprising if the risk factors for atherosclerosis
consistently induced an identical pattern of endothelial dysfunction.
11.3.1 Impaired Endogenous Fibrinolysis And Cigarette Smoking
The components of cigarette smoke that confer this impairment of t-PA release
remain to be established. Nicotine has vasoactive effects and may play role,
especially given the suggestion that it can induce endothelial dysfunction [Sarabi &
Lind 2000], However, the composition of tobacco smoke is complex and includes a
range of potential candidates with vascular and inflammatory actions.
Increased oxidative stress is associated with cigarette smoking and is likely to play a
significant role. Antioxidant vitamins have the potential to, at least in part, reverse
the endothelial vasomotor dysfunction [Heitzer et al 1996a; Neunteufl et al 2000]
associated with cigarette smoking. The effect of antioxidant intervention, such as
vitamins C and E supplementation, on t-PA release in cigarette smokers needs to be
addressed. These issues relating to cigarette smoking are the subject of an on-going
British Heart Foundation Research Project (PG99110).
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11.4 ENDOTHELIAL DYSFUNCTION AND IMPAIRED CORONARY
ENDOGENOUS FIBRINOLYSIS
Recently, Rosenberg and Aird [Rosenberg & Aird, 1999] have postulated that
vascular-bed-specific defects in haemostasis exist, and that coronary thrombosis
critically depends on the local fibrinolytic balance. However, until now, there have
been no clinical studies which have directly assessed the acute local fibrinolytic
capacity of the coronary vascular bed in patients with coronary artery disease. For
the first time, the release of t-PA from the coronary circulation has been
characterised using substance P infusion.
The acute fibrinolytic activity of the heart has an inverse correlation with the extent
of proximal coronary artery atherosclerosis. The mechanisms underlying this
relationship remain to be established but are likely to involve chronic endothelial cell
injury and an impairment of the L-arginine:nitric oxide pathway [Newby et al 1998],
Alternatively, this association may reflect the chronic stimulation and up-regulation
of basal t-PA release secondary to the presence of atheroma [Steins et al 1999] and
arterial denudation. The subsequent depletion of endothelial cell t-PA stores, and the
desensitisation and reduction of the acute fibrinolytic response, would potentially be
detrimental. This hypothesis is consistent with the epidemiological observations of a
positive correlation between plasma t-PA antigen concentrations and future coronary
events [Hamsten et al 1985; Meade et al 1986; Jansson et al 1993; Meade et al 1993;
Ridker et al 1993a; Thompson et al 1995; Thogersen et al 1998] as well as our
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finding of an inverse correlation between basal t-PA antigen concentrations and t-PA
activity release.
Questions of cause and effect cannot be resolved by our observations and it remains
a possibility that reduced fibrinolytic activity causes enhanced atherogenesis. The
prolonged presence of residual thrombus over a disrupted or eroded plaque will
provoke smooth muscle migration and the production of new connective tissue,
leading to plaque expansion [Galis et al 1997; Nomura et al 1999; Davies 2000],
This is consistent with the enhanced macrovascular fibrin deposition and
atherogenesis seen in genetic murine models of t-PA and plasminogen deficiency
[Xiao etal 1997; Christie^al 1999],
11.4.1 Coronary And Peripheral Endogenous Fibrinolysis
A comparison of the peripheral and coronary vascular fibrinolytic responses to
endothelial cell stimulation will elucidate which factors determine both the local and
the systemic fibrinolytic capacity. Moreover, such comparisons will ascertain
whether the assessment of endothelial function and fibrinolytic capacity in the
periphery provides a valid surrogate for the coronary vascular bed. This would
potentially facilitate future studies and assist in the identification of pathogenetic
mechanisms involved in atherothrombosis. This comparison is the subject of an on¬
going British Heart Foundation Research Project (PG98150).
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11.5 FUTURE DIRECTIONS
In addition to our own work, the exploration of endothelial fibrinolytic dysfunction
has been provisionally characterised in patients with hypertension [Hrafnkelsdottir et
al 1998], but has not been determined in other conditions associated with
atherosclerosis and dysfunction of endothelium-dependent vasomotion. There are
many potential candidates that would be appropriate to investigate but three areas
have been considered here for discussion.
11.5.1 Renin-Angiotensin System And Endogenous Fibrinolysis
In patients with hypertension, an elevated plasma renin activity for a given urinary
sodium excretion is independently associated with an increased risk of acute
myocardial infarction [Alderman et al 1991], Moreover, large scale clinical trials in
patients with heart failure, ischaemic heart disease and a recent myocardial infarction
suggest a reduction in re-infarction rates with angiotensin converting enzyme (ACE)
inhibitor therapy. The mechanisms underlying the association of renin-angiotensin
system activation with coronary thrombotic events are unknown but may relate, in
part, to an effect on fibrinolytic parameters. Indeed, activation of the renin-
angiotensin system by sodium depletion causes an increase in early morning plasma
PAI-1 concentrations which can be reversed by ACE inhibition [Brown et al 1998],
Furthermore, in patients with heart failure [Goodfield et al 1999] or a recent
myocardial infarction [Wright et al 1994; Vaughan et al 1997], ACE inhibitor
therapy causes marked reductions in basal plasma t-PA and PAI-1 concentrations.
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Animal models suggest that bradykinin is an extremely potent stimulus for the
release of t-PA from the vascular endothelium in vitro [van den Eijnden-Schrauwen
et al 1995], ex vivo [Tranquille & Emeis 1990] and in vivo [Schrauwen et al 1994],
Studies in man have also indicated that local infusions are associated with elevated
levels of t-PA [Brown et al 1999; Labinjoh et al 2000a], Bradykinin is not only an
inflammatory mediator but is also released during the contact phase of coagulation
when high-molecular weight kininogen is cleaved by kallikrein to produce a
disulphide-linked light and heavy chain [Schiffman et al 1980; Reddigari et al 1987],
This liberation of bradykinin may represent an important negative feedback loop in
which bradykinin induced t-PA release inhibits thrombus formation within the
vascular lumen when localised endothelial denudation occurs. Indeed, in patients
with unstable angina, intracoronary thrombus formation is associated with activation
of the contact phase of coagulation and the kallikrein system with increased
bradykinin generation [Hoffmeister et al 1995], Furthermore, given that bradykinin
induced forearm vasodilatation is potentiated by ACE inhibition [Benjamin et al
1989], such actions may be enhanced in the presence of ACE inhibition and may, in
part, explain the anti-ischaemic action of this therapy [EIOPE Investigators 2000],
Recent preliminary data in healthy volunteers have confirmed that ACE inhibition
potentiates bradykinin induced t-PA release [Labinjoh et al 2000b], The influence of
ACE inhibition on the acute fibrinolytic capacity of the endothelium in patients with
ischaemic heart disease and heart failure has yet to be established.
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The relationship between the renin-angiotensin system and endogenous fibrinolysis
is the subject of an on-going British Heart Foundation Research Project (PG97197).
11.5.2 Hyperhomocysteinaemia And Endogenous Fibrinolysis
Elevated plasma concentrations of homocysteine are an independent risk factor for
myocardial infarction [Clarke et al 1991; Stampfer et al 1992] as well as peripheral
and cerebral vascular disease [Kang et al 1992], Severe hyperhomocysteinaemia is
rare but moderate hyperhomocysteinaemia is more common [Ueland & Refsum
1989; Kang et al 1992; McCully 1996] and present in -30% of patients with
premature coronary artery disease [Clarke et al 1991], Hyperhomocysteinaemia is
associated with thrombophilia and a more than 20-fold increased risk of coronary
artery disease [Clarke et al 1991], In contrast to serum lipid fractions, the extent of
coronary atheroma correlates only weakly with homocysteine concentrations
[Nygard et al 1997] suggesting that the association with coronary events is more
likely to represent thrombogenicity or plaque rupture rather than atherogenicity.
Hyperhomocysteinaemia is a cause of endothelial cell injury and denudation in both
animal models [Harker et al 1974; Harker et al 1976] and human clinical studies
[Celermajer et al 1993; Tawakol et al 1997; Kanani et al 1999], To date, there have
been no published studies which have directly addressed the issue of whether there is
an association between homocysteine and endogenous fibrinolysis, but it is the
subject of much debate [Kuller & Evans 1998], However, in a longitudinal study of
stroke patients, plasma t-PA concentrations were found to be an independent
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discriminator and correlated directly with plasma homocysteine concentrations
[Lindgren et al 1996], Moreover, methionine loading (a method of acutely elevating
plasma homocysteine concentrations) causes more pronounced alterations in basal
fibrinolytic parameters of patients with premature vascular disease [Freyburger et al
1997], Thus, it would appear that hyperhomocysteinaemia may be associated with
alterations in endogenous fibrinolysis although it is unknown whether this influences
the acute release of t-PA from the endothelium.
The relationship between hyperhomocysteinaemia and endogenous fibrinolysis is the
subject of an on-going British Heart Foundation Research Project (PG99025).
11.5.3 Inflammation And Endogenous Fibrinolysis
An increased risk of cardiovascular events and death appears to be associated with
systemic inflammation and is probably mediated through plaque inflammation,
erosion or frank rupture. In epidemiological studies of patients with ischaemic heart
disease [Liuzzo et al 1994; Haverkate et al 1997; Biasucci et al 1999; Ferreiros et al
1999], and in prospective studies of healthy male populations [Ridker et al 1997;
Ridker et al 2000], serum C-reactive protein and IL-6 concentrations predict the
future risk of cardiovascular events. Moreover, the use of anti-inflammatory agents
appears to be associated with a reduction in the rate of such events [Ridker et al
1997], Whilst those patients with the largest plaque mass may be expected to have
the highest C-reactive protein and IL-6 concentrations, there is evidence that
systemic inflammation can enhance the inflammatory activity of the atheromatous
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plaque [Libby et al 1997; Vallance et al 1997] and thereby increase the risk of
developing an unstable plaque and an acute coronary syndrome.
Inflammation may have significant direct effects on endothelial function. Recent in
vivo evidence indicates that inflammatory cytokines induce endothelial vasomotor
dysfunction in the dorsal hand veins ofman [Bhagate/rz/ 1996; Bhagat et al 1997], It
is plausible that such dysfunction may result in an impairment of fibrinolytic
function and thereby increase the risk of thrombotic and ischaemic events. However,
this requires further study and investigation.
The relationship between inflammation and endogenous fibrinolysis is the subject of
an on-going British Heart Foundation Junior Research Fellowship (Dr Stanley Chia).
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11.6 CLINICAL RELEVANCE
A reduction in t-PA activity or release is associated with an increased incidence of
major adverse cardiac events in healthy young men [Meade et al 1993], and in
patients with stable [Held et al 1997] or unstable angina pectoris [Munkvad et al
1990; Hoffmeister et al 1998], Moreover, a reduction in fibrinolytic activity in
patients with unstable angina is associated with the development of acute myocardial
infarction [Munkvad et al 1990],
In a recent preliminary study of patients with acute myocardial infarction [Cruden et
al 2000], we have been able to show that patients who fail to reperfuse with
thrombolytic therapy have higher concentrations of plasma t-PA antigen on
admission suggesting the presence of t-PA resistant occlusion of the infarct related
artery. In contrast, in those patients who reperfuse, lower plasma t-PA activity is
associated with a more rapid response to thrombolytic therapy suggesting that
patients with impaired endogenous fibrinolysis benefit most from thrombolytic
therapy. However, these initial findings need confirmation in a larger cohort of
patients and it now needs to be established whether patients with an impaired
endogenous fibrinolytic capacity are at greater risk of recurrent cardiac events.
Selective enhancement of local endogenous fibrinolysis could potentially lead to the
prevention of thrombotic coronary occlusion and myocardial ischaemic events.
Current systemic administration of fibrinolytic agents for myocardial infarction is
associated with significant bleeding complications including cerebral and
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gastrointestinal haemorrhage. Augmentation of local endothelial t-PA release would
be potentially more effective, while avoiding these serious systemic complications.
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Aims The current studies were designed to characterize the pharmacology,
reproducibility and tolerability of the vasodilator response to intra-arterial substance
P infusion in the forearm of healthy man.
Methods On different occasions, eight healthy male volunteers received brachial
artery infusions of substance P at doubling doses ranging from 0.5 to 128 pmol
min . Blood flow was measured in both arms using venous occlusion ple¬
thysmography.
Results Substance P induced dose-dependent vasodilatation in the human forearm
which had a log-linear relationship to dose. At doses of 1-8 pmol min-1, mean
responses were highly reproducible both within and between days. There were no
differences between responses to discontinuous doses and continuous doses of
substance P. Substance P was generally well tolerated at doses of <64 pmol min-1
with no significant alteration in arterial blood pressure or heart rate. Skin oedema in
the infused forearm and systemic vasodilatation, manifested by facial flushing and
non-infused forearm vasodilatation, occurred at doses of > 16 pmol min- '.
Conclusions Forearm vasodilatation to substance P represents a reproducible and
useful model in the assessment of peripheral endothelial cell NK} receptor function.
Keywords: Substance P, vasodilatation, forearm plethysmography, pharmacodynamics,
reproducibility, tolerability
Mduction
isnce P is a widely distributed endecapeptide which is
al principally in the neural tissue of the central,
'isral and enteric nervous systems [1—4]. The physio-
al functions of substance P include neurotransmission
Miry sensory neurones, with particular involvement in
•■ception and emesis. In addition to functioning as a
■Jtransmitter, it also acts as an inflammatory mediator
'■■] "id neurohumoral regulator [4, 8, 9], Substance P is
smber of the tachykinin family of peptides and acts
:,Sb stimulation of the neurokinin receptors, having a
®ilarly high affinity for the type 1 (NKj) receptor [10].
Hen given intra-arterially, substance P is a potent
'*tor [11-13] through an endothelium dependent
!®ism [14] which is predominantly mediated by nitric
i release [15], This response is induced via stimulation
''endothelial cell NKt receptor [10] and, increasingly,
P is being used to assess endothelial cell function
and disease in man [16—20]. Indeed, substance P
!"n mfused into the coronary artery of man at doses
J'Dpmol min 1 [16—18], However, the reproducibility
-tolerability of intra-arterial substance P in the human
'®11 has not been fully characterized and validated.
studies describing such infusions in the forearm
' e"her used less precise methodology, including
Dr D. E. Newby, Clinical Pharmacology Unit and Research Centre,
"3 of Edinburgh, Western General Hospital, Edinburgh EH4 2XU
unilateral plethysmography and inclusion of the hand
circulation [12], or have only incompletely described the
nature of the response [13].
Therefore, the aim of the present study was to characterize
the pharmacodynamics, reproducibility and tolerability of
the vasodilator responses to arterial administration of
substance P within the forearm vascular bed of healthy men.
Subjects
Eight healthy male subjects aged between 20 and 34 years
participated in a series of four studies which were undertaken
with the approval ofthe Lothian Research Ethics Committee
and the written informed consent of each subject. None of
the subjects received vasoactive or non-steroidal anti¬
inflammatory drugs in the week before each phase of the
study, and all abstained from alcohol for 24 h and from
food, caffeine-containing drinks and tobacco for at least 4 h
before each study. All studies were performed in a quiet,
temperature controlled room maintained at 23.5-24.5° C.
Synthetic pharmaceutical-grade substance P (Clinalfa AG,
Liiufelfmgen, Switzerland) of >95% purity, was administered
following dissolution in physiological saline (0.9% sodium
chloride: Baxter Healthcare Ltd, Thetford, UK).
Methods
Drugs
'"'tkwell Science Ltd 493
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bitm-arterial administration
The brachial artery of the non-dominant arm was cannulated
with a 27-standard wire gauge steel needle (Cooper's Needle
Works Ltd, Birmingham, UK) attached to a 16-gauge
epidural catheter (Portex Ltd, Hythe, UK) under 1%
lignocaine (Xylocaine; Astra Pharmaceuticals Ltd, Kings
Langley, UK) local anaesthesia. Patency was maintained by
infusion of saline via an IVAC P1000 syringe pump (IVAC
Ltd Basingstoke, UK). The total rate of intra-arterial
infusions was maintained constant throughout all studies at
lmlmin .
Measurements
Blood flow was measured in the infused and non-infused
forearms by venous occlusion plethysmography using mer-
cury-in-silastic strain gauges which were applied to the
widest part of the forearm [21]. Since forearm length
between the occlusion and collecting cuff is constant,
volumetric changes are directly proportional to circumfer¬
ential changes measured by the strain gauge [21, 22], During
measurement periods, the hands were excluded from the
circulation by rapid inflation of wrist cuffs to a pressure of
220 mmHg using E20 Rapid Cuff Inflators (D.E. Hokanson
Inc, Washington, USA). Upper arm cuffs were inflated
intermittently to 40 mmHg pressure for 10 s in every 15 s
to achieve venous occlusion and obtain plethysmography
recordings. Analogue voltage output from an EC-4 strain
gauge Plethysmograph (D.E. Hokanson) was processed by a
MacLab® analogue-to-digital converter and Chart® v3.3.8
software (AD Instruments Ltd, Castle Hill, Australia) and
recorded onto a Macintosh Classic II computer (Apple
Computers Inc, Cupertino, USA). Calibration was achieved
using the internal standard of the plethysmograph.
Blood pressure was monitored in the non-infused arm at
intervals throughout each study using a semi-automated
non-invasive oscillometry sphygmomanometer (Takeda UA
751, Takeda Medical Inc, Tokyo, Japan) [23],
Study design (Figure i)
Subjects rested recumbent throughout each study. Strain
gauges and cuffs were applied, and the brachial artery of the
a
0.5 1 2 4 8 16 32 64 128
-30 0 54 84
■
. 1 1
-30 24 54 78





Ta5f 1 P 2 I





Figure 1 Study design:
protocols a, b, c and d with
saline (111) and substance P
(pmol min~ ) (□) infusions.
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joininant arm cannulated. Saline was infused for the
Jmin to allow for equilibration. Forearm blood flow
measured for 3 min beginning at 25, 15 and 6 min
f commencing substance P infusions. Throughout all
q substance P was infused for 6 min at each dose.
1® blood flow measurements were made for the last
j, of each infusion period.
- tolerability of substance P was assessed in seven
U who were given incremental doubling doses of
,ace P from 0.5 pmol min 1 to a maximum of
mjiolmin"1 [12], followed by 30 min infusion of saline
«ol a). To determine within and between day
Suability, each subject reattended 7 to 14 days later
>received 1, 2, 4 and 8 pmol min 1 of substance P
<ied by saline for 30 min before receiving further
mental doses of 1, 2, 4 and 8 pmol min 1 ofsubstance P
-lotol b).
, order to examine whether responses to substance P
igotachyphylaxis, seven subjects were given substance P
ins at sequential doses of 1, 2, 4, 8, 4, 2 and 1 pmol
: , followed by saline for 30 min before receiving
ace P at sequential doses of 8, 4, 2, 1, 2, 4 and 8 pmol
l (protocol c). Seven to 14 days later, each subject
aided and received an infusion of substance P at doses
j, 1,2, 4 and 8 pmol min with each dose separated
illmin period of saline infusion (protocol d).
ksubject withdrew for personal reasons after complet-
ifiotocols a and b, and was replaced for protocols c and d.
urnlysis and statistics
tomographic data were extracted from the Chart data
:il forearm blood flows were calculated for individual
a occlusion cuff inflations by use of a template
dieet (Excel v4.0; Microsoft Inc, USA). Recordings
ctlie first 60 s after wrist cuff inflation were not used,
a of the instability in blood flow that this causes [24].
% the last five flows recorded in each 3 min measure-
aperiod were calculated and averaged for each arm. Basal
'How was taken to be that recorded at 6 min before
tinfusion. To reduce the variability of blood flow data,
®o of flows in the two arms was calculated for each
!PWt, in effect using the non-infused arm as a
•uporaneous control for the infused arm [21],
a were examined by two way analysis of variance
with repeated measures, regression analysis and
two tailed Student's it-test using Excel v4.0 (Microsoft). All
results are expressed as means + s.e. mean. Statistical signifi¬
cance was taken at the 5% level. Within and between day
reproducibility was assessed using the method of Bland &
Altaian [25] and coefficients of repeatability were determined
for 95% confidence intervals using the Student's t distribution.
Tolerability of intra-arterial substance P infusion
Transient and patchy flushing of the infused arm occurred
at all doses, whereas facial flushing was only observed at
doses of >32 pmol min '. Five subjects received 64 pmol
min and two subjects received 128 pmol min-1 as the
maximal dose: further infusion of substance P was discon¬
tinued because of extensive forearm skin oedema and facial
flushing. There were no significant increases in heart rate
or decreases in blood pressure up to 64 pmol min ~1
(Table 1). No subject reported discomfort or local forearm
fullness with substance P infusion, but two subjects described
transient light-headedness at doses of 16 and 64 pmol min ~ '.
In the infused forearm, patchy skin oedema developed in
some subjects at 16 pmol min-1 and consistently, in all by
32 pmol min . The oedema had an urticarial appearance,
taking the form of a raised wheal with a yellow hue.
However, there was no associated pruritis and the lesions
were non-tender. The extent of oedema varied between
subjects, beginning at the level of the elbow and extending
distally with increasing dose. The affected areas ranged from
1 to 10 cm in diameter, but all resolved completely within
1—2 h of stopping the infusion.
Dose range of vasodilator responses to substance P Substance P
increased blood flow in the infused forearm (Z5< 0.001) in
a dose-dependent manner which reached a maximum of
21 +3.1 ml 100 ml 1 min 1 (466 + 192%) by 16 pmol
min 1 (Figure 2 and Table 2). There was a significant
increase in the blood flow of the contralateral, non-infused
arm (P=0.001, ANOVA) which was apparent from 16 pmol
min-1 (P= 0.05, f-test). Relative percentage increase in
blood flow of the infused to non-infused arm was dose-
dependent and peaked at 32 pmol min 1 before declining
at 64 pmol min-1. The increases in blood flow had a linear
Bloodflow responses
Results
''Systemic haemodynamics and blood flow responses (mean+ s.e.mean) to incremental doses of substance P (*P— 0.05;
baseline).
Substance P infusion (pmol min X)
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Figure 2 Absolute and relative forearm blood flow responses to incremental doses of substance P (protocol a). (Mean+ s.e.mean).







Table 2 Absolute forearm blood flow (ml 100 ml 1 of tissue min ') in both arms during the four protocols (mean + s.e.mean).
Protocol a
0 0.5 1
Substance P infusion (pmol min
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14.4 ±2.3 17.5±2.6 5.5 ±1.2
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relationship to the logarithm of substance P dose (Figure 2:
y=174 + 242x; r=0.997, P<0.001) at doses<32pmol
min \
Reproducibility of vasodilator responses to substance P There
were no significant differences between the mean vasodilator
responses to substance P either between days or within a
496 © 1997 Blackwell Science Ltd Br J Clin Pharmacol, 43, 493—499
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i day (Figure 3a). The reproducibility of individual
ijiday and between day responses are shown in Table 3.
;.()5% confidence intervals indicated by the coefficients
Repeatability, are ~2-4 fold smaller for within day
.jnses compared to those between day. These data, for
jiple population of eight subjects at P<0.05, give 95%
,er to detect a mean shift in the dose response of > 4
y >8 fold when comparing within day and between
responses respectively.
flute was a trend for the magnitude of mean vasodilator
jinses to substance P to undergo attenuation with
ijnuous infusions, but this did not achieve statistical
jjcance (Figure 3b). Likewise, there were no significant
itences between the vasodilatation to isolated discontinu-
:Joses and incremental continuous doses of substance P
3ie3c). Absolute forearm blood flows in both arms in
iur protocols are shown in Table 2.
assion
a-arterial substance P infusion at doses up to and
.'ding 64 pmol min 1 were generally well tolerated with
ignificant changes in supine blood pressure and heart
iPrevious studies [12, 26, 27] using intravenous dosing
: induced flushing, tachycardia and decreased blood
ire at higher doses (>150 pmol min X). However,
•Gedema associated with arterial infusion has not been
nted before, despite intra-brachial infusions of up to
:»1 min 1 [12]. This disparity may reflect the
siously shorter infusion times of 4 min per dose [12]
ike relative purities of substance P administered,
fflheless, our observations are consistent with the action
distance P as an inflammatory mediator inducing protein
asation and leucocyte migration [6], These effects may
.t baseline forearm circumference but not the rate of
ai expansion with plethysmographic measurements
sthe rate of oedema formation were to approach that
Barm blood flow, or oedema formation were to raise
! extracellular fluid pressure above 40 mmHg. This
d be associated with substantial tissue swelling and
■Jexceed the observed limited oedematous response,
iitance P has been used as an endothelium dependent
fctorin the human coronary circulation [16-18]. Total
■®y blood flow is ~300mlmin 1 (60—90 ml
•1 of tissue min 1) which compares with
■nlmin 1 (3—5 ml 100 ml 1 of tissue min !) in the
Although left coronary artery blood flow is,
®e, ~3-4 times higher than that in the brachial
1i substance P does increase left coronary blood flow
and at concentrations similar to those achieved in the
forearm [18]. Therefore, given that substance P can cause
oedema in the toreann and the consequences ofunrecognised
myocardial oedema may be serious, we would caution
against the intra-coronary administration of high doses of
substance P in man.
Intra-arterial substance P caused consistent and dose-
dependent local increases in forearm blood flow without
systemic effects at doses up to and including 8 pmol min 1.
In agreement with previous studies [12, 13, 15, 19, 20, 28],
the vasodilator response was linearly related to the logarithm
of the substance P dose. However, at doses of greater than
or equal to 16 pmol min , substance P induced systemic
vasodilatation as indicated by facial flushing and an increase
in forearm blood flow of the contralateral non-infused ami,
although no significant decrease in blood pressure, or
increase in heart rate, was observed. The use of comparative
increases in forearm blood flow of the infused forearm with
respect to the non-infused arm, becomes invalid at systemic
doses and accounts for the breakdown of the log-linearity
of responses at doses of more than 32 pmol min-1.
McEwan and colleagues [13] have shown that substance P
at 1 pmol min 1 undergoes tachyphylaxis when infused
continuously for 10 min or more. However, we did not
find a statistically significant attenuation of the responses
when administering decremental doses of substance P.
Moreover, we found no greater response with incremental
discontinuous infusions than with incremental continuous
doses of substance P. Mean increases in forearm blood flow
to substance P at doses of 1 to 8 pmol min-1 were of
equivalent magnitude both within day and between days.
Eklund and colleagues [12] have reported variable measure¬
ments with substance P, but their results are confounded by
utilising cruder methodology with unilateral forearm plethys¬
mography and inclusion of the hand circulation. In contrast
to the muscular forearm, the hand is predominantly skin and
has a heterogeneous circulation which is regulated in a
complex and non-linear manner [21], We have demonstrated
good reproducibility when comparing individual within day
responses. Based on a sample size of eight, the confidence
intervals would indicate that we would have 95% power to
detect> 4-fold shift in the dose-response relationship when
comparing within day responses at each dose.
In summary, we have found using within day comparisons,
that at doses up to 8 pmol min 1, vasodilatation to
substance P is generally well tolerated and highly reproduc¬
ible. Such methodology should provide a practical and
sensitive method of assessing the in vivo efficacy of peripheral
NKj receptor antagonism in man [29].
*1 Within and between day reproducibility for individual percentage increases in forearm blood flow at 1, 2, 4 and 8 pmol min '.
Within day responses Between day responses
'"riose Mean % change Mean of the Coefficient of Mean % change Mean of the Coefficient of
) in blood flow differences repeatability in blood flow differences repeatability
131 24.4 32 158 30.7 61
189 24.7 49 217 31.3 74
281 -35.5 34 292 57.6 144
362 -22.9 30 368 34 127
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Figure 3 a) Within and between day mean increases in forearm
blood flow to 1, 2, 4 and 8 pmol min-': protocol a dose
response (O); protocol b, first dose response (EH); and protocol b,
second dose response (□). b) Development of tachyphylaxis with
protocol c: first dose response (O); second and third dose
responses (H); both were superimposable and the second response
only is shown for clarity); and fourth dose response (□).
c) Comparison of isolated discontinuous and incremental
continuous infusions: protocol c, first dose response (B); and
protocol d, first dose response (O). (mean + s.e.mean).
Dr David Newby is a British Heart Foundation Junior
Research Fellow (FS/95009).
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Substance P°8rodyced vasodilatation is mediated by the neurokinin type
| receptor but does not contribute to basal vascular tone in man
Pavid E. Hewfoy, David G. Scibeirras,1 Charles J. Ferro, Barry J. Gertz,1 David Somnnieirville,
Anup Majjumdar,1 Richard C. Lowry1 & David J. Webb
Clinical Pharmacology Unit and Research Centre, University ofEdinburgh, Western General Hospital, Crewe Road, Edinburgh, Scotland, UK and
'hlerck Research Laboratories, Clinical Pharmacology—Europe, Terlings Park, Harlow, UK, and Rahway, NJ, USA
Aims Following intravenous administration of its prodrug, L-758,298, we assessed
the pharmacodynamics of L-754,030, a novel and highly selective NK, receptor
antagonist, by examining systemic haemodynamics and the blood flow responses to
intra-arterial substance P infusion.
Methods Sixteen healthy male volunteers participated in a double-blind, randomised,
placebo controlled crossover trial of L-758 298. Forearm blood flow was measured
using venous occlusion plethysmography during intrabrachial substance P infusion
(0.125—128 pmol min ')• In Part t eight subjects received substance P infusions
before and during placebo, 0.25 nag, 1 nag or 5 mg of L-758 298. In part 2, eight
subjects received substance P infusions 24 la after placebo or 1.43 nag of L-758 298.
Results L-758 298 caused dose dependent inhibition of substance P induced
vasodilatation (P<0.001). Placebo adjusted differences (95% CI) in baseline forearm
blood flow, mean arterial pressure and heart rate showed no relevant changes with
5 mg of L-758 298 (> 1400-fold shift in substance P response): 0.00 (— 0.49 to
+ 0.49) ml 100 ml 1 min \ 1.0 (— 3.2 to +5.2) mmHg and 1.9 (— 5.9 to +9.7)
beats mm , respectively. Twenty-four hours after 1.43 mg of L-758,298, there was
~34—fold shift in response to substance P induced vasodilatation (P<0.008) at
plasma L-754 030 concentrations of 2-3 ng ml \ L-758 298 was generally well
tolerated without serious adverse events.
Conclusions Substance P induced forearm vasodilatation is mediated by the
endothelial cell NKj receptor in man but endogenous substance P does not appear
to contribute to the maintenance of peripheral vascular tone or systemic
blood pressure.
Keywords: substance P, neurokinin 1 receptor, endothelium, haemodynamics,
blood flow
Introduction
Substance P is a widely distributed endecapeptide which
»found principally in the neural tissue of the central,
peripheral and enteric nervous systems [1—4]. The
physiological functions of substance P include neuro-
tansmission in primary sensory neurones with particular
involvement in nociception and emesis. In addition to
ninctioning as a neurotransmitter, it also acts as an
inflammatory mediator [5—7] and neurohumoral regulator
[1,8].
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Substance P is a member of the tachykinin family of
peptides and acts through stimulation of the neurokinin
receptors, having a particularly high affinity for the
type 1 (NK]) receptor [9], When given intra-arterially,
substance P is a potent vasodilator [10-12] through an
endothelium dependent mechanism [13] which is partly
mediated by nitric oxide release [14, 15]. In animal
studies, this response is induced via stimulation of the
endothelial cell NK-] receptor [9] although, to date, this
has not been confirmed in vivo in man. Substance P is
found in perivascular neural tissue [16] and has been
postulated to play a role in the regulation of vascular
tone [17, 18].
Antagonism of the NK-, receptor has potentially diverse
therapeutic indications such as in the treatment of pain,
inflammation and emesis [19]. L-754 030 (2-(R)-(l-(R)
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-3,5-bis (trifluoromethyl) phenylethoxy)-3-(S)~
/ffluoro) phenyl-4-(3-(5-oxo-4H-l,2,4-triazolo)methyl
morpholine; also known as MK-869) is a long acting,
Ughly selective, competitive NKt receptor antagonist
with poor solubility in aqueous solution. L-754 030 is
more selective for the NK] than the NK3 (3000-fold) or
the NK2 and other G-protein linked receptors and ion
channels (>50 000-fold) [20], N-phosphorylation of
[.754030 produces L-758 298, a prodrug which is readily
ioluble in aqueous solutions. L-758 298 undergoes rapid
ji fitio conversion to L-754 030 and thereby provides a
prodrug which can be administered intravenously.
The primary aims of the present study were: first, to
Jeterrmne the ability of L-754 030 to inhibit substance P
induced vasodilatation during and 24 h after intravenous
jdministration of L-758 298; second, to confirm that
substance P induced vasodilatation is mediated via the
endothelial cell NK] receptor in man; and third, to
determine whether endogenous substance P regulates
peripheral vascular tone or blood pressure in man. An
additional important aim of the study was to evaluate the




Healthy nonsmoking men aged between 18 and 45 years
participated in a series of studies which were undertaken
with the approval of the Lothian Research Ethics
Committee and the written informed consent of each
subject. None of the subjects was taking regular medi¬
ations, or received vasoactive or nonsteroidal anti¬
inflammatory drugs in the week before each phase of the
study, and all abstained from alcohol for 24 h and from
food and caffeine-containing drinks for at least 9 h before
ach study. All studies were performed in a quiet,
temperature controlled room maintained at 23.5—24.5° C.
ftw(| administration
4ne brachial artery of the nondominant arm was
annulated with a 27-standard wire gauge steel needle
{Cooper's Needle Works Ltd, Birmingham, UK) under
l'/« lignocaine (Xylocaine; Astra Pharmaceuticals Ltd,
Kings Langley, UK) local anaesthesia. The cannula was
attached to a 16-gauge epidural catheter (Portex Ltd,
nythe, UK) and patency maintained by infusion of saline
|M%: Baxter Healthcare Ltd, Thetford, UK) via an
'VAC PI000 syringe pump (IVAC Ltd, Basingstoke,
®). The total rate of intra-arterial infusions was
maintained constant throughout all studies at 1 ml min
Synthetic pharmaceutical-grade substance P (Clinalfa AG,
Laufelfmgen, Switzerland) of > 95% purity, was adminis¬
tered following dissolution in saline.
Matched placebo and L-758 298 (Merck Research
Laboratories, West Point, USA) were reconstituted with
0.9% saline in glass vials containing 50 rng of mannitol
alone or 6 mg of L-758 298 and 50 mg of mannitol,
respectively. The 5 mg initial dose of L-758 298 was
chosen to exceed the ID90 of 50 gg kg ' in the guinea
pig sensorotoxin-induced systemic vascular leak model
(Merck Research Laboratories, Terlings Park, UK).
Cannulae were inserted into the veins of the antecubital
fossae of both arms. L-758 298 was administered into the
dominant arm via a 19-G cannula (Wallace Y-Can;
Wallace Ltd, Colchester, UK) and venous samples were
withdrawn from the nondominant arm via a 17-G
cannula (Venflon; BOC Ohmeda AB, Helsingborg,
Sweden).
Measurements
Blood flow was measured in the dominant and nondomi¬
nant forearms by venous occlusion plethysmography
using mercury-in-silastic strain gauges which were applied
to the widest part of the forearm [21]. Since forearm
length between the occlusion and collecting cuff is
constant, volumetric changes are directly proportional to
circumferential changes measured by the strain gauge [21,
22]. During measurement periods, the hands were
excluded from the circulation by rapid inflation of wrist
cuffs to a pressure of 220 mmHg using E20 Rapid Cuff
Inflators (D. E. Hokanson Inc, Washington, USA). Upper
arm cuffs were inflated intermittently to 40 mmKIg
pressure for 10 s in every 15 s to achieve venous occlusion
and obtain plethysmographic recordings. Analogue volt¬
age output from an EC-4 strain gauge Plethysmograph
(D. E. Hokanson) was processed by a MacLab® analogue-
to-digital converter and Chart® v3.3.8 software (AD
Instruments Ltd, Castle Hill, Australia) and recorded onto
a Macintosh Classic II computer (Apple Computers Inc,
Cupertino, USA). Calibration was achieved using the
internal standard of the plethysmograph.
Blood pressure was monitored in the dominant arm at
intervals throughout each study using a semiautomated
noninvasive oscillometry sphygmomanometer (Take da
UA 751, Takeda Medical Inc, Tokyo, Japan) [23].
Blood (10 ml) was withdrawn from the nondominant
arm before and after the incremental infusion of substance
P and admixed with 1 ml of 1% disodium EDTA. Blood
samples were placed on ice before being centrifuged
at 2000 £ for 30 min. Plasma was frozen and stored at
— 80° C prior to assay. Plasma L-754 030 concentrations
were determined using high performance liquid chroma¬
tography and mass spectrometry using an internal standard
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4-752611). The assay was validated over a concentration
range of 1-500 ng ml with a limit of detection at
lugml_1 and a coefficient of variation of <9%.
Tolerability assessments were made before, during and
following completion of the study and included: clinical
examination, repeated questioning for symptoms, clinical
chemistry screen (liver enzymes, bilirubin, electrolytes,
urea, creatinine, protein and albumin), haematology
screen (full blood and differential count), urinalysis,
[2-lead electrocardiogram.
Study design (Figure 1)
Subjects attended at 09.00 h, rested recumbent throughout
each study and intravenous cannulae were inserted into
each arm. Strain gauges and cuffs were applied, and the
brachial artery of the nondominant arm cannulated. Saline
ivas infused into the arterial cannula for the first 30 min
to allow for equilibration. Forearm blood flow was
measured for 3 min beginning at 23, 13 and 3 min before
commencing substance P infusions. Throughout all
studies, substance P was infused for 10 min at each dose.
Forearm blood flow measurements were made from 3 to
6 min of each infusion period.
Screening Before inclusion in the main study, subjects
received mtra-arterial infusions of substance P at 0.125,
0.5, 2, 8 and 32 pmol min 1 [24]. To reduce overall
variability in the responses, subjects were recruited to the
main study if 2 pmol min ' of substance P increased
forearm blood flow by > 100% and < 500%.
Part 1—Maintenance L-758 298 infusion On each
occasion, eight subjects received incremental intra-arterial
infusions ofsubstance P at 0.125, 0.5, 2 and 8 pmol min 1
followed by 60 min of saline. A second infusion of
substance P was then administered at 0.125, 0.5, 2, 8, 32
and 128 pmol min 1 [24],
At the beginning of the intervening 60 min saline
infusion, subjects received a double-blind, randomised
intravenous infusion of either L-758 298 or placebo:
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%«e 1 Schematic of protocol. Doses of substance P given in pmol min"1. Arrows indicate blood sampling time points for the
stimation of plasma L-754 030 concentrations. Part 2 infusions were commenced 24 h after 1.43 mg of intravenous L-758 298
^Ministration.
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fable 1 Schematic of drug allocation.
Subject Week 1 Week 2* Week 3f Week 4
I Placebo D, d2 D3
) D, Placebo D, d3
D, d2 Placebo d3
, D, d2 D3 Placebo
Placebo D, d2 d3
b D, Placebo d2 d3
1 d, d, Placebo d3
5 d, d2 d3 Placebo
0,=5mg of L-758 298. *If the PD100 increases by > 40-fold then
j,=l mg of L-758 298; if < 40-fold, D2 = 20 mg. flf the PD100
continues to be > 40-fold then D3 = 0.25 mg of L-758 298 or
<40-fold, D3 = 80 mg: otherwise the study is completed after 3
seeks i.e. D3 = placebo.
Jose over 20 min) was given followed by a continuous
maintenance infusion (one third of the total dose over
ihe subsequent 100 min) throughout the second challenge
ofintra-arterial substance P administration. From earlier
phase I pharmacokinetic studies in man (Merck; data on
He), this dosage regimen was predicted to produce a
stable plasma concentration of L-754 030 during the
stcond incremental infusion of intra-arterial substance P.
Plasma samples to measure L-754 030 concentrations
ivere taken 60 and 120 min after the start of the
intravenous infusion of L-758 298 or placebo. In the first
sveek, subjects received a total dose of 5 mg of L-758 298
or placebo. The next dose administered in the second
nek would be increased to 20 mg if the PD10o (defined
below) was increased by <40-fold by 5 mg of L-758 298
or reduced to 1 mg if > 40-fold (based on data from 6
subjects). The same criteria were applied to determine
whether the final dose (80 mg or 0.25 mg) of L-758 298
was to be administered, or the study completed after two
loses of L-758 298 and placebo (based on data from four
objects; see Table 1). If the third dose was not to be
wen then this would be replaced by placebo and the
Judy terminated after 3 weeks. To maintain double-blind
mdomization, all data analysis and dosage decisions were
«de at the central co-ordinating centre (Merck Research
laboratories, Terlings Park, UK) independent of the
•estigators.
IW2—24 hpost L -758 298 infusion Eight further subjects
faded on two occasions, 1 week apart, and received
® intravenous infusion of either L-758 298 or placebo
fa 30 min in a double-blind randomised manner,
objects returned 24 h later to receive infusions of
fa-arterial substance P at 0.125, 0.5, 2, 8, 32
^ 128 pmol min-1 [24], Plasma samples to measure
'■754030 concentrations were taken 24 and 25 h after
the start of the intravenous infusion of L-758 298 or
placebo. The dose of L-758 298 was derived from the
pharmacodynamic and pharmacokinetic data of part 1
and was chosen to produce an approximately 40—fold
increase in the PD100 24 h after L-758 298 administration.
L-754 030 has a plasma half-life of 15+4 h in man.
Data analysis and statistics
Plethysmographic data were extracted from the Chart
data files and forearm blood flows were calculated for
individual venous occlusion cuff inflations by use of a
template spreadsheet (Excel p5.0; Microsoft Inc, USA).
Recordings from the first 60 s after wrist cuff inflation
were not used, because of the instability in blood flow
that this causes [25]. Usually, the last five flows recorded
in each 3 min measurement period were calculated and
averaged for each arm. Basal blood flow was taken to be
that recorded immediately before drug infusion. To
reduce the variability of substance P blood flow responses,
the ratio of flows in the two arms was calculated for
each time point, in effect using the dominant arm as a
contemporaneous control for the nondominant arm
[21], Plethysmographic data were compiled by blinded
investigators.
Percentage change in forearm blood flow from baseline
was calculated using the ratios of flows in the two arms
for each of the substance P infusions. Natural logarithm
transformations of the substance P doses were used to
estimate individual PD10o values using linear regression
techniques. The PD100 was defined as the interpolated
or extrapolated dose of substance P which provokes a
100% increase in forearm blood flow. To determine
whether there was a within day difference in PD] 00
following placebo, an analysis of variance (anova) with
the terms 'subjects' and 'time' (predose and postdose)
was used to analyse the natural logarithm transformed
PD10o data from the placebo treatment group in part 1.
The influence of each dose of L-758 298 in parts 1
and 2 on the forearm blood flow response to substance P
were evaluated relative to placebo. In these analyses, the
PA oo after administration of a placebo dose was used as
the control for assessment of the fold shifts in PD100 due
to the administration of the various doses of L-758 298.
An anova with the terms 'subject' and 'treatment' was
used to analyse the natural logarithm transformed PD! 00
data from the treatments in part 1. An anova appropriate
for a two period crossover study was used to analyse the
natural logarithm transformed PD100 data from the
treatments in part 2. These anova analyses were used to
estimate the geometric means, their ratios and 95%
confidence intervals for the geometric mean ratio
for PD100.
Mean arterial pressure, heart rate and blood flow data
■^99 Blackwell Science Ltd Br J Clin Pharmacol, 4S, 336-344 339
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Figure 2 Part 1: Forearm blood flow responses to intrabrachial substance P infusion before (left panel) and during placebo or L-758 298










0 0 0 0.125 0.5 2 8 32 128
Substance P infusion (pmolmirT1)
Figure 3 Part 2: Forearm blood flow responses to intrabrachial
substance P infusion. (Mean + s.e.mean.) Placebo; 1.43 mg of
L-758,298* P<0.001; L-758 298 vs placebo, anova.
were examined, where appropriate, by multifactorial
anova with repeated measures and paired Student's
i-test. All results are expressed as mean ± s.e. mean.
Statistical significance was taken at the 5% level.
Results
Twenty-two healthy male volunteers were required to
identify 16 subjects who met the entry criteria: forearm
Hood flow increased by >500% in two subjects and
<100% in four subjects. The 16 volunteers subsequently
recruited were aged 30 + 2 years (range 20—40 years) and
weighed 76 + 3 kg (range 61—95 kg).
There were no significant baseline differences in
forearm blood flow, blood pressure or heart rate between
®y parts of the study.
hrt 1
Substance P caused dose-dependent vasodilatation in the
»ndominant arm (PcO.OOl; anova) during the first
incremental infusion of substance P which was not
significantly different between screening or the 4 separate
study days.
L-758 298 was administered in three descending doses;
5, 1 and 0.25 mg. During placebo and L-758 298 infusion,
there were no significant changes in blood pressure, heart
rate, or blood flow in the dominant forearm (Table 2).
Placebo adjusted differences (95% CI) in dominant
forearm blood flow, mean arterial pressure and heart rate
with 5 mg of L-758 298 were 0.00 (— 0.49—0.49) ml
100 ml 1 min \ 1.0 (-3.2-5.2) mmHg and 1.9
(— 5.9—9.7) beats min \ respectively. Plasma concen¬
trations of L-754 030 were not significantly different
immediately before and after the second incremental
infusion of substance P (Table 2).
In comparison with the response to the first incremental
infusion, the response to the second infusion of
substance P was significantly different following placebo
(P<0.006) and all doses ofL-758 298 in a dose dependent
manner (Table 2; Figure 2)). The geometric mean PD100
(95% CI) increased by 1.85-fold (1.27-2.86) during
placebo infusion. The influence of each dose ofL-758 298
on the forearm blood flow response to substance P was
examined relative to placebo. The geometric mean PL>iqo
(95% CI) increased by 30—fold (9-99) with 0.25 mg,
319-fold (98-1044) with 1 mg and > 1400-fold with
5 mg of L-758 298 (PcO.OOl for all).
Forearm blood flow in the dominant arm increased
at doses >32pmolmin 1 of substance P only during
placebo (P<0.02 vs baseline; paired f-test). Heart rate
and blood pressure did not change significantly (Table 2).
Part 2
Following placebo infusion, substance P again caused
dose-dependent vasodilatation in the nondominant arm
(PcO.OOl; anova: Figure 3). However, 24 h following
intravenous administration of 1.43 mg of L-758 298,
340 © 1999 Blackwell Science Ltd Br J Clin Pharmacol, 48, 336—344
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figure 4 Concentration-response relationship between the plasma concentration ofL-754 030 and the P-Dioo values for the rate of
tbstance P infusion. Individual values shown with mean+ s.e.mean. Three points with indeterminate PD100 values > 1454 are not
Sown. Placebo; O 0.25 mg, A 1 mg and H 24 h after 1.43 mg of L-758 298 r=0.62, P=0.003.
abstance P induced vasodilatation was significantly
ihibited (Table 2; Figure 3). The geometric mean PDjoo
15% CI) was increased by 34—fold (4—299; P< 0.008).
Die PD100 and plasma L-754 030 concentrations (Table 2)
sere similar to those obtained with 0.25 mg ofL-758 298
apart 1.
Forearm blood flow in the dominant arm increased at
loses >32 pmol min 1 following placebo (P<0.02 vs
aseline; paired t-test) and at 128 pmol min 1 following
'43 mg of L-758 298 (P=0.03 vs baseline; paired f-test).
hart rate and blood pressure did not change significantly
Table 2).
Mcentration-response relationship
it logarithm of the mean plasma L-754 030 con-
Wrations significantly correlated with the logarithm
'the PD100 of the rate substance P infusion (r=0.62,
-0.003; Figure 4).
'•Inability
158 298 was generally well tolerated by all the subjects,
4 no excess of adverse events (mild headaches and
12
back pain) in comparison with placebo. There were no
serious adverse events during the study and no clinically
significant abnormalities detected on safety monitoring
(urinalysis, haematology, clinical chemistry and electro¬
cardiography).
Discussion
For the first time, we have shown that substance P
induced forearm vasodilatation is inhibited by a selective
NK] receptor antagonist in vivo in man. During L-758 298
infusion, substance P induced forearm vasodilatation was
inhibited in a dose dependent manner. At the highest
dose ofL-758 298, the vasodilator response to substance P
was abolished at doses up to 8 pmol min 1, suggesting
that substance P mediated vasodilatation is entirely
dependent on the endothelial NK] receptor. Moreover,
persistent inhibition of substance P induced vasodilatation
was present 24 h after L-758 298 infusion.
Despite previous proposals [17, 18], it would appear
that substance P, acting via the NK] receptor, does mot
play a role in the regulation of peripheral vascular tone
or blood pressure. We observed no alterations in baseline
forearm blood flow or systemic haemodynamics following
© 1999 Blackwell Science Ltd Br J Clin Pharmacol, 48, 336—344
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I.J58298 infusion despite a greater than 1454-fold shift
j the PDioo f°r substance P induced forearm vasodilat¬
ion. The 95% confidence intervals indicate that if
gbstance P provides any contribution to basal peripheral
oscular tone or systemic haemodynamics then it is
other small.
We have previously shown that repeated responses to
abstance P are reproducible and well tolerated [24], In
Je current study, we have again seen good reproducibility
if both within-day and between-day responses to intra-
jterial substance P infusions. Systemic effects, such as
acreases in contralateral forearm blood flow, were also
jbserved at substance P doses of > 32 pmol min ~1
jithout significant changes in heart rate or blood pressure.
Moreover, these increases in contralateral forearm blood
iw were also inhibited by L-758 298 infusion. Finally,
7758298 infusion was generally well tolerated without
ay significant adverse events.
jiii}' limitations
lecause L-758 298 was administered systemically, there
mains the possibility that compensatory mechanisms
jay have obscured a potential haemodynamic effect,
fcct intra-arterial administration of an NK] receptor
atagonist would provide a more precise method of
aessing the role of substance P in the regulation of
acular tone. However, L-758 298 is a prodrug which
squires conversion by systemic hepatic phosphatases to
k active form L-754 030 and its intra-arterial adminis-
lation would therefore not result in local NK] receptor
utagonism.
In the present study, we did not assess the selectivity
f L-754 030 for the NK] receptor by comparing
ibstance P induced vasodilatation with an alternative
Jn-NK] receptor mediated, endothelium-dependent
wdilator, such as bradykinin or acetylcholine, and
iis requires confirmation in future studies. However,
-754 030 has been shown to be highly selective for the
1] receptor [20].
We conclude that substance P induced forearm
sodilatation is mediated by the endothelial cell NK]
■teptorin man. Endogenous substance P does not appear
'contribute to the maintenance of peripheral vascular
Me or systemic blood pressure. In this study, intravenous
•■758 298 was generally well tolerated with L-754 030
®sing long lasting and potent NK] receptor antagonism
'man.
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summary
The effects on blood flow and plasma fibrinolytic and coagulation
tiameters of intraarterial substance P, an endothelium dependent
vasodilator, and sodium nitroprusside, a control endothelium indepen-
bit vasodilator, were studied in the human forearm circulation. At
sibsystemic locally active doses, both substance P (2-8 pmol/min) and
sodium nitroprusside (2-8 pg/min) caused dose-dependent vasodilata-
ion (p <0.001 for both) without affecting plasma concentrations of
fill-l, von Willebrand factor antigen or factor VIII:C activity. Sub-
SceP caused local increases in t-PA antigen and activity (p <0.001)
rlhe infused arm while sodium nitroprusside did not. At higher doses,
stance P increased blood flow and t-PA concentrations in the
infused arm. We conclude that brief, locally active and subsystemic
isions of intraarterial substance P cause a rapid and substantial
kal release of t-PA which appear to act via a flow and nitric oxide
dependent mechanism. This model should provide a useful and
Active method of assessing the in vivo capacity of the forearm
adothelium to release t-PA acutely.
ioduction
Endothelial cells of the precapillary arterioles and postcapillary
venules (1) synthesise and constitutively secrete tissue-type plasmino-
a activator (t-PA) and its inhibitor, plasminogen activator inhibitor
Jpe 1 (PAI-1). The release of t-PA may be rapidly increased through
it translocation of a dynamic intracellular storage pool (2) in response
a stimulation by blood coagulation and humoral factors (3). Acute
:PA release plays a pivotal role in endogenous fibrinolysis and this is
amplified by a plasminogen activator deficient gene knockout mouse
add that exhibits an increased incidence of endotoxin-induced
hombosis (4). The time course of t-PA release is important, with
ambus dissolution being much more effective if t-PA is incorporated
ling, rather than after, thrombus formation (5, 6). Thus, the speed
dthwhich, and extent to which, t-PA can be released from endothelial
* may have a substantial impact on the efficacy of endogenous
linolysis.
When studying in vivo vascular responses in man, systemic drug
^ministration can cause concomitant effects on other organ systems,
lb as the liver, brain, kidney and heart, as well as influence neuro-
•oral reflexes through changes in systemic haemodynamics. There¬
ftrospondence to: Dr. D. E. Newby, Clinical Pharmacology Unit and
■Search Centre, University of Edinburgh, Western General Hospital, Crewe
H Edinburgh EH4 2XU, Scotland, UK - Tel. +44 131 332 1205;
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fore, because of these confounding influences, vascular and humoral
responses cannot be wholly attributed to a direct effect of the drug on
the blood vessels. Endogenous fibrinolysis in man has been assessed
using systemic infusion of agents such as desmopressin (7, 8) and
angiotensin II (9). These agents are vasoactive, producing changes in
blood pressure and regional blood flow, as well as having widespread
effects on many tissues. Thus, changes in systemic fibrinolytic para¬
meters might be attributable to a number of factors including changes in
hepatic release and clearance of t-PA and PAI-1, and the concomitant
release of other stimulatory, vasoactive and humoral mediators. In
contrast, the use of bilateral forearm blood flow measurements coupled
with unilateral brachial artery infusion of vasoactive drugs at subsyste¬
mic, locally active doses, provides a powerful and reproducible method
of directly assessing vascular responses in vivo (10, 11). Combined
with bilateral forearm venous sampling, this technique permits the
assessment of local release of tissue and endothelium-derived factors
(12).
Substance P is a member of the tachykinin family of peptides, acting
through stimulation of neurokinin receptors, and having a particularly
high affinity for the type 1 (NK,) receptor (13). It is widely distributed
in the body and has actions as a central, peripheral and enteric neuro¬
transmitter (14-17), inflammatory mediator (18-20) and neurohumoral
regulator (15, 21, 22). When given intra-arterially in man, substance P
enhances local fibrinolytic activity through an unknown mechanism
(23) and has actions as a potent vasodilator (24-26) through an
endothelium dependent (27) and predominantly nitric oxide mediated
mechanism (28, 29). The determination of vascular responses to the
intraarterial infusion of endothelial cell stimulants such as substance P
has been widely used to assess the integrity of endothelium dependent
vasodilatation in health and disease (30-33).
The initial aim of the present study was to assess the acute release of
coagulation and fibrinolytic factors within the forearm vascular bed in
response to intraarterial substance P using an ascending dose design to
define the dose at which systemic effects intervene. Thereafter, endo¬
thelial cell release of these factors was assessed in response to locally
active doses of substance P and a control endothelium-independent
nitric oxide donor, sodium nitroprusside (32, 33).
Sixteen healthy non-smoking men aged between 20 and 34 years partici¬
pated in two studies which were undertaken with the approval of the local
research ethics committee and in accordance with the Declaration of Helsinki.
The written informed consent of each subject was obtained before entry into the
study. None of the subjects received vasoactive or nonsteroidal antiinflamma¬
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iltohol for 24 h, and from food and caffeine-containing drinks for at least 5 h,
-efore each study. All studies were performed in a quiet, temperature control-
jdroom maintained at 23.5-24.5° C.
Blood pressure was monitored in the noninfused arm at intervals through¬
out each study using a semiautomated noninvasive oscillometry sphygmo¬
manometer (34) (Takeda UA 751, Takeda Medical Inc. Tokyo, Japan).
itmrterial Administration
The brachial artery of the nondominant arm was cannulated with a 27-
adard wire gauge steel needle (Cooper's Needle Works Ltd, Birmingham,
IS) under 1% lignocaine (Xylocaine; Astra Pharmaceuticals Ltd, Kings
lagley, UK) local anaesthesia and attached to a 16-gauge epidural catheter
iPortex Ltd, Hythe, UK). Patency was maintained by infusion of saline via an
it'AC P1000 syringe pump (IVAC Ltd, Basingstoke, UK). The total rate of
;!ia-arterial infusions was maintained constant throughout all studies at
Iml/min.
Pharmaceutical-grade substance P (Clinalfa AG, Laufelfingen, Switzerland)
ri sodium nitroprusside (Nipride; Roche, Welwyn Garden City, UK) were
iinistered following dissolution in saline (0.9%: Baxter Healthcare Ltd,
iletford, UK).
ftmrm Blood Flow and Blood Pressure
Blood flow was measured in both forearms by venous occlusion plethysmo-
japhy using mercury-in-silastic strain gauges applied to the widest part of the
(xearm (10, 11). During measurement periods the hands were excluded from
recirculation by rapid inflation of the wrist cuffs to a pressure of 220 mmHg
singE20 Rapid Cuff Inflators (D.E. Hokanson Inc, Washington, USA). Upper
in cuffs were inflated intermittently to 40 mmHg for 10 s in every 15 s to
shieve venous occlusion and obtain plethysmographic recordings. Analogue
tillage output from an EC-4 Strain Gauge Plethysmograph (D.E. Hokanson)
as processed by a MacLab® analogue-to-digital converter and Chart v3.3.8
ifeare (AD Instruments Ltd, Castle Hill, Australia) and recorded onto a
Mntosh Classic II computer (Apple Computers Inc, Cupertino, USA).
Station was achieved using the internal standard of the plethysmograph.
Venous Sampling and Assays
Venous cannulae (19G) were inserted into large subcutaneous veins of the
antecubital fossa in both arms as described previously (12). Ten ml of blood
was withdrawn simultaneously from each arm and collected into acidified
buffered citrate (Biopool® Stabilyte™, Umea, Sweden) and citrate (Monovette®,
Sarstedt, Niimbrecht, Germany) tubes, and kept on ice before being centrifuged
at 2,000 g for 30 min at 4° C. Platelet free plasma was decanted and stored at
-80° C before assay.
Plasma PAI-1 and t-PA antigen concentrations were determined using an
enzyme-linked immunosorbent assay; Coaliza® PAI-1 (35) and Coaliza® t-PA
(36) (Chromogenix AB, Molndal, Sweden) respectively. Plasma PAI-1 and
t-PA activities were determined by a photometric method, Coatest® PAI-1 (37)
and Coaset® t-PA (38) (Chromogenix AB). Intraassay coefficients of variation
were 7.0% and 5.5% for t-PA and PAI-1 antigen, and 4.0% and 2.4% for
activity, respectively. Interassay coefficients of variability were 4.0%, 7.3%,
4.0% and 7.6% respectively. The sensitivities of the assays were 2.5 ng/ml,
0.5 ng/ml, 5 AU/ml and 0.10 IU/ml respectively. Von Willebrand factor (vWf)
antigen was determined (39) using an enzyme-linked immunosorbent assay
(Dalco A/S, Glostrup, Denmark) with a sensitivity of 0.05 IU/ml. The intra¬
assay and interassay coefficients of variability were 5.2% and 7.3% respec¬
tively. Factor VIILC procoagulant activity was determined using a standard one
stage assay on an ACL-3000+ coagulometer (Instrumentation Laboratory,
Warrington, UK).
Study Design
Subjects rested recumbent throughout each study. Strain gauges and cuffs
were applied and the brachial artery of the nondominant arm cannulated.
Measurements of forearm blood flow were made between 3 and 6 min of each
infusion period unless otherwise stated. Before participating in one of the
following protocols, saline was infused for the first 30 min to allow time for
Sic J Dose ranging study: syste-
i haemodynamics, forearm blood
low, estimated net t-PA antigen and
sivity release, and vWf concentra-
ms and factor VIILC activity in the
ised and non-infused forearms
ibaseline and during substance P
ision (n = 7). * p = 0.05 (t-test);
!f <0.001 (ANOVA); § p = 0.06
fflOVA)
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equilibration, with forearm blood flow measured every 10 min and the final
measurement taken as basal blood flow.
Dose Ranging Study
[n seven men, intrabrachial substance P was administered in incremental
doubling doses from 0.5 to a maximum of 128 pmol/min for 6 min at each
Jose and was followed by 30 min saline infusion. Venous samples were taken
it baseline, following 2 pmol/min, 16 pmol/min and the maximal dose of
mbstance P, and after the final 30 min saline infusion.
Estimated net release of t-PA activity and antigen was defined as the product of
the infused forearm plasma flow (based on the hematocrit. HCt and the infused
forearm blood flow, FBF) and the concentration difference between the infused
([t-PAU and non-infused arms ([t-PA]Nonillf).
Estimated net t-PA release = FBF X {1-HCt) X {[t-PA]Inf — [t-PA]Nonint}
Data were examined, where appropriate, by two way analysis of variance
(ANOVA) with repeated measures and two tailed paired Student's f-test using
Excel v4.0 (Microsoft). All results are expressed as means ± standard errors of
the mean. Statistical significance was taken at the 5% level.
heal Forearm Study
Twelve men were given intraarterial doubling doses of substance P at
?4 and 8 pmol/min for 10 min at each dose, and sodium nitroprusside at 2, 4
aid 8 pg/min for 10 min at each dose, separated by a 30 min saline infusion.
Substance P and sodium nitroprusside were given single blind, in randomised
ider. Venous samples were obtained at the end of each period of saline infu-
iionand with each dose of substance P and sodium nitroprusside.
Results
All subjects were normotensive (Tables 1 and 2) and had a normal
fasting lipid profile with a mean total cholesterol concentration of
3.90 ±0.16 mM (150 ± 6 mg/dl), high density lipoprotein cholesterol
concentration of 1.02 ± 0.05 mM (39 ± 2 mg/dl) and triglyceride
concentration of 0.87 ± 0.08 mM (77 ± 7 mg/dl).
Illa Analysis and Statistics
Plethysmographic data were extracted from the Chart data files and forearm
blood flows were calculated for individual venous occlusion cuff inflations by
eeof a template spreadsheet (Excel v4.0; Microsoft Corporation, Cambridge,
CSA). Recordings from the first 60 s after wrist cuff inflation were not used
teause of the reflex vasoconstriction this causes (10, 11). Usually, the last
ft flow recordings in each 3 min measurement period were calculated and
averaged for each arm. To reduce the variability of blood flow data, the ratio of
lows in the two arms was calculated for each time point; in effect using the
son-infused arm as a contemporaneous control for the infused arm (10, 11).
Dose Ranging Study
There were no significant changes in arterial pressure or heart rate
throughout the study. Substance P caused an increase in blood flow
of the infused forearm (p <0.001) from a baseline of 3.7 ±
0.7 ml/lOOml/min to a maximum of 22 ± 2.4 ml/lOOml/min at
64 pmol/min in a dose-dependent manner (Fig. 1). Five subjects
received 64 pmol/min and 2 received 128 pmol/min as the maximum
dose, further infusion of substance P being discontinued because of
forearm skin oedema and facial flushing. There was a significant
el Local forearm study: systemic haemodynamics, forearm blood flow, estimated net t-PA antigen and activity release, and vWf concentrations and factor
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Absolute Forearm Non-infused Aran
Blood Flow
(ml/100 ml/min) Infused Arm
247 ± 53 370 + 73 541 ±111
4.1 ±0.5 4.1 ±0.6 3.8 ±0.6 3.8 + 0.6
4.6 ± 0.7 11.6 + 0.8 14.8 ±1.1 18.1 ±1.4
193 ±41 286 ±77 383 ±79
3.8 ±0.6 4.0 ±0.6 4.0 ±0.6 3.9 ±0.7
4.4 ± 0.6 11.1 + 1.2 13.5 ± 1.4 16.5 ± 1.7




-0.5 ±0.3 -1.6 + 0.8 -0.5 ±1.4 0.5 ±2.7












Non-infused Aral 0.66±0.08 0.60±0.07 0.64±0.10 0.68 ±0.08 0.65 ±0.10 0.59±0.08 0.61 ±0.10 0.60±0.13
Infused Arm 0.64 ±0.08 0.62 ±0.09 0.65 ±0.09 0.67 ±0.09 0.62 ±0.07 0.58 ±0.09 0.58 ±0.10 0.63 ± 0.08
factorVIII:C
(Hi/ml)
Non-infused Arm 0.61 ±0.08 0.57 ±0.08 0.59 ±0.08 0.62 ±0.08 0.57 ±0.09 0.60 ±0.08 0.59 ±0.09 0.60 ±0.09
Infused Arm 0.64±0.07 0.64±0.09 0.65±0.09 0.67±0.09 0.53±0.08 0.57 ± 0.10 0.57±0.10 0.63 ±0.09
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increase in the blood flow of the contralateral, noninfused arm
(pO.001, ANOVA) which was apparent from 16 pmol/min (p = 0.05).
Hie relative percentage increase in blood flow of the infused compared
jith the noninfused arm was dose-dependent, peaking at 32 pmol/min
feforedeclining at 64 pmol/min (Fig. 1).
Substance P caused increases in plasma t-PA antigen and activity
concentrations in the infused (p <0.001 for both) and noninfused arm
j<0.003 for both) which were dose-dependent (Fig. 2). Plasma from
ie infused arm demonstrated significantly greater increases in both
[•PA activity and antigen concentrations than the noninfused arm
I <0.001). At the maximal dose, mean t-PA activity increased by
SOft in the infused arm and 210% in the noninfused arm, whilst
icant-PA antigen increased by 240% and 62% respectively.
There were no significant or consistent changes in plasma PAI-1
utigen or activity concentrations in the infused arm. There was a
significant decrease in the plasma PAI-1 activity in the noninfused
am (p = 0.03) although PAI-1 antigen concentrations did not change
significantly (p = 0.64). There were no significant changes in plasma
fffconcentration or factor VIII:C activity in either arm (Table 1).
heal Forearm Study
There were no significant changes in blood pressure, heart rate or
Itrearm blood flow in the contralateral arm throughout the study
Table 2).
Both substance P and sodium nitroprusside caused selective in-
rases in forearm blood flow in the infused arm (p <0.001 for both) in
liose dependent manner (Table 2). Substance P caused a selective and
tadependent increase in the estimated net release (p <0.001 for both)
3d venous plasma concentrations (p <0.001 for both) of both t-PA
activity and antigen (Table 2; Fig. 3). In contrast, there were no signifi-
ant changes in plasma t-PA activity or antigen concentrations in the
■infused arm, or in PAI-1 antigen and activity, vWf or factor VIII:C
icentrations in either arm (Table 2; Fig. 3). There were no significant
ianges in t-PA, PAI-1, vWf or factor VIII:C in either arm during
inm nitroprusside infusion (Table 2; Fig. 3).
kussion
We have shown, for the first time, that intraarterial substance P
iministration causes acute, selective and substantial t-PA release in
«in man. At both systemic and locally active doses, substance P
causes t-PA release from the forearm vascular bed without significant
effects on the release of PAI-1, vWf and factor VIITC. This model
provides a selective in vivo method of assessing acute t-PA release from
the endothelium in man.
Intrabrachial substance P has been shown previously to induce
local fibrinolysis in the forearm (23) although the mechanism of this
effect had not been determined. However, taken together with our
findings, it is apparent that this enhancement of fibrinolytic activity is,
at least in part, mediated through t-PA release. Previously, bradykinin
was thought to be one of the most potent agents causing t-PA release
in animals (3, 40) and man (3, 41). However, a recent study in man
(41) using systemic intravenous bradykinin administration at doses of
up to 380 pmol/kg/min, did not show a significant release of t-PA
antigen except in the presence of angiotensin converting enzyme
inhibition and alterations in systemic haemodynamic parameters. Jern
and colleagues (42) have shown a significant net local release of t-PA
antigen and activity in response to intra-brachial methacholine.
However, a significant increase in venous concentrations of t-PA
antigen was not detected and, although measurement of arteriovenous
differences should enhance the accuracy of assessing local tissue
release, there were no significant increases in the arteriovenous
gradients of t-PA antigen or activity. Indeed, the clearest changes were
observed in the arterial t-PA activity which should have remained
constant, suggesting that there was systemic stimulation of t-PA
release in this study.
Venous plasma t-PA concentrations obtained from a given tissue
bed are composed of three components; circulating arterial t-PA, basal
or constitutive endothelial cell release of t-PA and facultative or
stimulated endothelial cell release of t-PA. The net tissue release of
t-PA is equivalent to the product of the plasma flow through the tissue
and the arteriovenous difference in plasma t-PA concentrations across
it. In the absence of endothelial cell stimulation, but with an increase in
blood flow across the tissue bed, venous plasma t-PA concentrations
would be expected to fall secondary to a dilutional effect. However, this
ignores the potential for clearance of t-PA across the vascular bed (43),
and stimulation of its release by shear stress and flow (44,45). Without
measuring the arteriovenous concentration gradient across the forearm,
net tissue release can only be derived and estimated. However, arterial
sampling requires the insertion of large bore cannulae which do not
lend themselves to multiple cannulations within the same subject.
There is also the potential to introduce artefact from the presence of a
larger thrombogenic surface given that activated factor Xa is the most
f' Dose ranging study: percen-
f change and absolute forearm
■*1 flow responses to incremental
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Substance P (pmol/min)
Fig.2 Dose ranging study: venous plasma tissue plasminogen activator
j-PA) antigen (O) and activity (□), and plasminogen activator inhibitor type 1
PAI-1) antigen (A) and activity (-v>) concentrations in the infused (closed sym-
Ms) and non-infused (open symbols) forearms in response to substance P
isions (n = 7). Maximum substance P dose was 64 pmol/min in 5 subjects
adl28 pmol/min in 2 subjects, p <0.001 for all t-PA concentrations (ANOVA)
Sodium Nitroprusside (pg/min) Substance P (pmol/min)
Fig. 3 Local forearm study: venous plasma tissue plasminogen activator
(t-PA) antigen (O) and activity (□), and plasminogen activator inhibitor type 1
(PAI-1) antigen (A) and activity (❖) concentrations in the infused (closed
symbols) and non-infused (open symbols) forearms in response to sodium
nitroprusside and substance P infusions (n = 12). * p <0.001 (ANOVA)
stent stimulant for t-PA release yet known (3). Rather than assessing
leriovenous differences, we have compared venous plasma t-PA
xentrations between infused and non-infused arms and have used
«y fine gauge arterial cannulae for drug administration only. This
Shod may potentially underestimate the net release of t-PA and fail to
ilect a modest effect due to the potential flow dependent, dilutional
Singes in venous concentrations. However, typical resting arterio¬
sus differences are only -10% of the total venous concentra-
;® (42, 46) and the basal constitutive release of t-PA antigen is
Wng/100 ml of tissue/min in the forearm (42). Thus, in the presence
'luge increases in t-PA release, the dilutional effect of increased blood
»on constitutive t-PA release will be reduced. Indeed, using this
Steral venous sampling methodology, we have been able to demon-
* a substantial, dose-dependent release of t-PA from the forearm
Sular bed in response to substance P infusion. Moreover, despite in
"o evidence that t-PA release may be influenced by shear stress
445), we have found that the endothelium independent nitric oxide
tor, sodium nitroprusside, has no significant effect on the venous
'h concentrations despite comparable increases in blood flow to
to with substance P. Sodium nitroprusside is known to have no
tot effect on the endothelial cell release of t-PA and PAI-1 in vitro
"land, therefore, it is likely that either shear stress and flow depen-
1(6
dent stimulation of endothelial cell t-PA release is counterbalanced by
the potential dilutional effects of increased flow, or that this theoretical
flow dependence of venous concentrations is negligible. This also
indicates that increases in nitric oxide and blood flow are not sufficient
in themselves to release t-PA from the endothelium. However, it
remains a possibility that the L-arginine : nitric oxide pathway plays a
role in substance P-induced t-PA release and requires further studies
using a combined infusion of substance P and a nitric oxide synthase
inhibitor such as L-A^-monomethyl arginine.
Although we have produced substantial increases in both t-PA
activity and antigen, we did not detect release of PAI-1, or the coagula¬
tion factors, vWf and factor VIII: C. This would indicate that these
agents are not stored in a rapidly translocatable pool within the endo¬
thelial cells of the forearm vascular bed or that they are not released in
response to substance P over the time course and at the doses used here.
However, protracted endothelial cell stimulation may release these
factors (7,9). In this respect, it is interesting to note the time dependent
reduction in PAI-1 concentrations seen in our studies, although these
only achieved statistical significance in the non-infused arm during
the dose ranging study. The most likely explanation for a reduction in
PAI-1 is that the released and active t-PA is complexed by circulating
PAI-1 and subsequently cleared from the circulation by the liver (48).
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litis, substantial local t-PA release will tend to reduce systemic PAI-1
jncentrations in the short term, as seen with the administration of
■iarmacological doses of t-PA (49).
As anticipated, local substance P infusion did not affect the rate of
slease of hepatically derived factor VIII: C. In contrast, it is perhaps
jiiprising that we did not observe a rise in plasma vWf concentrations
jjccompany the release of t-PA. To date, stimulation of t-PA release
sing a wide range of secretagogues such as thrombin, vasopressin,
jtdykinin, histamine and desmopressin, has invariably been accompa-
iid by concomitant vWf release (7,50,51). However, we were unable
odetect an acute local release of vWf even in the presence of high lo-
j concentrations of substance P in the dose ranging study. This novel
declivity suggests that the endothelium is able to mobilise different
jtoplasmic storage pools in response to specific (NK,) receptor
initiation. Further studies with more prolonged infusions of substance
hvould be required to determine whether the endothelial cell vWf or
81-1 release is delayed or is truly not influenced by substance P.
In summary, brief, locally active and subsystemic infusions of intra-
firial substance P produce a rapid and substantial increase in plasma
:IA activity and antigen concentrations across the forearm bed which
ipear to act via a flow and nitric oxide independent mechanism. This
«lcl provides a powerful method of assessing the in vivo capacity of
^endothelium to acutely release t-PA within the forearm vascular bed
al would be applicable to the assessment of diseases associated with
cdothelial dysfunction, such as hypercholesterolemia (52).
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Endothelin-1 does not contribute to
the release of tissue plasminogen
activator in vivo in man
D.E Newby, F.E. Strachan, N.R. Johnston, D.J. Webb
Clinical Pharmacology Unit and Research Centre, University of Edinburgh, Western General Hospital, Edinburgh, UK
Summary Objectives: Endothelin-1 is a potent endothelium-derived vasoconstrictor peptide with autocrine and
paracrine actions. Tissue plasminogen activator (t-PA) and its inhibitor, plasminogen activator inhibitor type 1 (PAI-1),
are also released from the vascular endothelium and play a pivotal role in endogenous fibrinolysis. We, therefore,
examined the effects of exogenous and endogenous endothelin-1 on t-PA and PAI-1 release in vivo in man.
Design: Open investigative study.
Setting: Clinical Research Centre, University of Edinburgh.
Subjects: Fourteen healthy male volunteers.
Interventions: Unilateral brachial artery infusions of endothelin-1 at 2.5 and 10 pmol/min, and the selective endothelin
type B (ETb) receptor antagonist, BQ-788, at 1 nmol/min.
Main outcome measures: Biood flow and plasma fibrinolytic factors were measured in both forearms using venous
occlusion plethysmography and venous blood samples withdrawn from the antecubitai fossae.
Results: Endothelin-1 caused a slow onset dose-dependent forearm vasoconstriction (P<0.001) with a maximal
reduction in blood flow of 40 ± 4% and 63 ± 3% at 2.5 and 10 pmol/min respectively. BQ-788 also caused a slow onset
reduction in forearm blood flow (P<0.001) reaching a maximum of 21 ± 3%. However, BQ-788 and endothelin-1 did not
affect plasma concentrations of t-PA or PAI-1 in the venous effluent of the infused forearm.
Conclusions: Despite sustaining significant vasoconstriction, neither endogenous nor exogenous endothelin-1
influences the release of t-PA or PAI-1 in the forearm vascular bed of man. This suggests that endothelin-1 does not
provide a major contribution to the regulation of endogenous fibrinolysis in man. © Harcourt Publishers Ltd 1999
INTRODUCTION
Endothelial cells in the precapillary arterioles and post¬
capillary venules' synthesize and release t-PA and PAI-1
both basally and in response to stimulation by various
coagulation factors and stimulants. The time course of t-
PA release is important since clot dissolution is much
more effective if t-PA is incorporated during clot forma¬
tion rather than following completion.2-' The acute
release of t-PA results from the rapid translocation of a
dynamic intracellular storage pooh and plays a pivotal
role in endogenous fibrinolysis.
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Endothelin-1 is a potent endothelium-derived vaso¬
constrictor peptide with autocrine and paracrine actions.
It is continuously released by the endothelium and con¬
tributes to the maintenance of basal vascular tone5 and
blood pressure/1 There are two main endothelin receptor
subtypes, ETA and ETn, but only the ET]t receptors are pre¬
sent on the endothelium. Endothelin-1 causes vasocon¬
striction mainly through stimulation of the smooth
muscle cell F.Tt receptor, although smooth muscle ET,
receptors may also contribute in some vessel types. This
vasoconstrictor response is modulated by autocrine
endothelial cell ET|( receptor-mediated generation of the
endothelium-derived vasodilators, nitric oxide and
prostacyclin.
Tire importance of endogenous t-PA release is exempli¬
fied.by the high rate of spontaneous reperfusion in the
infarct-related artery after acute myocardial infarction,
occurring in around 30% of patients within the first 12 Iv
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Following an acute myocardial infarction, plasma endothe¬
lial concentrations are elevated and provide an important
prognostic marker of survival at 1 year.10 Furthermore, on
the basis of in vitro studies, it has been suggested that
endothelin-1 may contribute to the regulation of endoge¬
nous fibrinolysis and t-PA release.11-13 However, the evi¬
dence is contradictory, with endothelin-1 being found to
either inhibit13 or stimulate11-12 endothelial cell t-PA release.
The role of endothelin-1 in the regulation of endogenous
fibrinolysis in man is currently unknown.
We,14-15 and others,16-17 have shown, using bilateral fore¬
arm venous occlusion plethysmography and unilateral
brachial artery infusions, that the forearm release of t-PA
and PAI-1 can be determined in vivo in man. Therefore,
the aim of the current study was, using synthetic
endothelin-1 peptide and the selective ETB receptor
antagonist, BQ-788, to determine whether endothelin-1,
of exogenous or endogenous origin, acts via the
endothelial ETB receptor to regulate the release of t-PA or
PAI-1 in vivo in man.
MATERIALS AND METHODS
Subjects
Fourteen healthy men aged between 20 and 33 years
participated in three studies which were undertaken with
the approval of the local research ethics committee and
in accordance with the Declaration of Helsinki. The writ¬
ten informed consent of each subject was obtained
before entry into the study. None of the subjects received
vasoactive or non-steroidal anti-inflammatory drugs in
the week before each phase of the study, and all
abstained from alcohol for 24 h, and from food, tobacco
and caffeine-containing drinks for at least 9 h, before
each study. All studies were performed in a quiet, tem¬
perature-controlled room maintained at 23.5-24.5°C.
Intra-arterial administration and drugs
The brachial artery of the non-dominant arm was cannu-
lated with a 27-standard wire gauge steel needle
(Cooper's Needle Works Ltd, Birmingham, UK) under 1%
lignocaine (Xylocaine; Astra Pharmaceuticals Ltd, Kings
Langlev, UK) local anaesthesia The cannula was attached
to a 16-gauge epidural catheter (Portex Ltd, Hythe, UK)
and patency maintained by infusion of saline (0.9%:
Baxter Healthcare Ltd, Thetford, UK) via an IVAC PI000
syringe pump (IVAC Ltd, Basingstoke, UK). The total rate
of intra-arterial infusions was kept constant throughout
all studies at 1 mL/min. Endothelin-1 (Clinalfa AG,
Laufelfingen, Switzerland) and BQ-788 (American Peptide
Company, Sunnyvale, USA) were administered following
dissolution in saline.
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Forearm blood flow and blood pressure
Blood flow was measured in both forearms by venous
occlusion plethysmography using mercury-in-silastic
strain gauges applied to the widest part of the fore¬
arm.18-1'-' During measurement periods the hands were
excluded from the circulation by rapid inflation of the
wrist cuffs to a pressure of 220 mmHg using E20 Rapid
Cuff Inflators (D.E. Hokanson Inc, Washington, USA).
Upper arm cuffs were inflated intermittently to 40 mmHg
for 10 s in every 15 s to achieve venous occlusion and
obtain plethysmography recordings. Analogue voltage
output from an F.C-4 Strain Gauge Plethysmograph (D.E.
Hokanson) was processed by a MacLab" analogue-to-dig-
ital converter and Chart v3.3.8 software (AD Instruments
Ltd, Castle Hill, Australia) and recorded onto a Macintosh
Classic II computer (Apple Computers Inc, Cupertino,
USA). Calibration was achieved using the internal stan¬
dard of the plethysmograph.
Blood pressure was monitored in the non-infused arm
at intervals throughout each study using a semi-auto-
mated non-invasive oscillometry sphygmomanometer
(Takeda UA 751, Takeda Medical Inc, Tokyo, Japan).20
Venous sampling and assays
Venous cannulae (17G) were inserted into large subcuta¬
neous veins of the antecubital fossa in both arms. Ten mL
of blood was withdrawn simultaneously from each arm
and collected into acidified buffered citrate (Biopool*
Stabilyte™, Umea, Sweden; for t-PA assays) and citrate
(Monovette", Sarstedt, Ntimbrecht, Germany; for PAI-1
assays) tubes, and kept on ice before being centrifuged at
2000 g for 30 min at 4°C. Platelet-free plasma was
decanted and stored at -80°C before assay.21
Plasma PAI-1 and t-PA antigen concentrations were
determined using an enzyme-linked immunosorbent
assay (ELISA); Coaliza" PAI-1 [22] and Coaliza" t-PA2!
(Chromogenix AB, Molndal, Sweden) respectively. Plasma
t-PA activities were determined by a photometric method,
Coaset" t-PA2J (Chromogenix AB). Intra-assay coefficients
of variation were 7 and 5.5% for t-PA and PAI-1 antigen,
and 4% for t-PA activity respectively. Inter-assay coeffi¬
cients of variability were 4, 73 and 4% respectively. The
sensitivities of the assays were 2.5 ng/mL, 0.5 ng/ml. and
O.lOIU/mL respectively. Haematocril was determined by
capillary tube centrifugation of blood anticoagulated by
ethylene diamine tetraacetic acid and was obtained from
the infused forearm at baseline and at 120 min.
Study design
On each study day, subjects attended fasted and rested
recumbent throughout the study. Strain gauges and cuffs
© Harcourt Publishers Ltd 1999









Eight subjects received an intra-brachial infusion of
endothelin-1 at 2.5 and lOpmol/min for 120 min, given
in random order, on two separate occasions, at least 1
week apart. Eight subjects (two had also attended for
endothelin-1 infusions) received an intra-brachial infu¬
sion of BQ-788 at 1 nmol/min for 120 min. Venous sam¬
ples were withdrawn from each arm at baseline and at 10,
20, 30, 50, 80 and 120 min after the start of endothelin-1
or BQ-788 infusion.
0 20 40 60 80 100 120
Time (min)
Fig. 1 Absolute (ml_/100 mL of tissue/min: upper panel) and
percentage (% relative to the non-infused forearm: lower panel)
change of blood flow in the infused forearm during intra-arterial
infusion of BQ-788 (1 nmol/min;0) and endothelin-1 (2.5
pmol/min:C and 10 pmol/min: •).
were applied and the brachial artery of the non-domi¬
nant arm cannulated. Throughout each of the studies,
measurements of forearm blood flow were made every 10
min. Before drug administration, saline was infused for
30 min to allow time for equilibration and the final blood
flow measurement during saline infusion was taken as
the basal forearm blood flow.
Data analysis and statistics
Plethysmographic data were extracted from the Chart
data files and forearm blood flows were calculated for
individual venous occlusion cuff inflations by use of a
template spreadsheet (Excel v5\ Microsoft Corporation,
Cambridge, USA). Recordings from the first 60s after
wrist cuff inflation were not used because of the reflex
vasoconstriction this causes.1819 Usually, the last five flow
recordings in each 3 min measurement period were cal¬
culated and averaged for each arm. To reduce the vari¬
ability of blood flow data, the ratio of flows in the two
arms was calculated for each time point: in effect using
the non-infused arm as a contemporaneous control for
the infused arm.1819 Percentage changes in the infused
forearm blood flow were calculated1819 as follows:
% Change in blood flow =
100 x {I,/NI-Ib/NIb} /
VNI„
Where Ib and NIb are the infused and non-infused fore¬
arm blood flows at baseline (time 0) respectively, and I,
and NI, are the infused and non-infused forearm blood
flows at a given time point respectively.
Estimated net release of t-PA activity and antigen was
defined previously1415 as the product of the infused fore¬
arm plasma flow (based on the mean haematocrit, ITCt,
Table 1 Systemic haemodynamics, forearm blood flow and haematocrit at baseline and after intra-arterial infusion for 120 min.
BQ-788 1 nmol/min
Basal Final
Endothelin-1 2.5 pmol/min Endothelin-1 10 pmol/min
















3.1 ±0.4 3.8 ±0.2
4.5 + 0.7 4.2 ±0.4*
1.35 + 0.15 1.14 ± 0.06t
0.41 ±0.01 0.41±0.01
136 ± 3 140 ± 4
72 ±3 71 ±3
62 + 4 58 ±4
3.4 ±0.3 3.7 ± 0 5
4.0 ±0.4 2.5 ±0.3*
1.13 = 0.03 0.42 ± 0.03f
0.42 ±0.02 0.40 ± 0.02}
133 + 4 133 ± 4
70 ± 3 73 ± 4
61 ± 5 62 ±4
3.1 ±0.3 4.1 ±0.3
3.6 ±0.4 1.6 ±0.1*
1.05 1 0.07 0.40 ± 0.03f
0.41 ±0.01 0.40 + 0.01}
"PS0.001 (two-way ANOVA; infused vs non-infused)
}P<0.001 (one-way ANOVA)
}P<0.05 (paired t-test: basal vs final)
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and the infused forearm blood flow, FBF) and the con¬
centration difference between the infused ([t-PA]mf) and
non-infused arms ([t-PA]N inf).
Estimated net t-PA release =
FBF x (1-HCt) x {[t-PA],ilf - [t-PA]Noii jnf}
Data were examined by two way analysis of variance
(ANOVA) with repeated measures and two-tailed paired
Student's t-test using Excel z/5.0 (Microsoft) where appro¬
priate. All results are expressed as mean ± SEM. Statistical
significance was taken at the 5% level. Based on previous
data,1415 the study had 90% power to detect a 20%
change in plasma t-PA concentrations between treatment
periods at the 5% level.
RESULTS
All subjects were normotensive and there were no signif¬
icant changes in blood pressure, heart rate or blood flow
in the contralateral arm throughout any of the studies
(Table 1). Haematocrit decreased slightly in each
endothelin study (Table 1). Between the 3 protocols there
were no significant differences in the baseline values of
blood pressure, heart rate, forearm blood flow, haemat¬
ocrit or plasma concentrations of t-PA and PAI-1.
Endothelin-1 infusions
Endothelin-1 decreased blood flow in the infused arm
(P<0.001) in a dose-dependent manner (Fig. 1) reaching a
minimum of 2.5 ± 0.3 mL/lOOmL/min at 2.5 pmol/min
and 1.6 ± 0.1 mL/lOOmL/min at 10 pmol/min, after 120
min. This corresponds to a relative reduction in forearm
blood flow of 40 ± 4% and 63 ± 3% respectively. The
plasma concentrations of t-PA and PAI-1 did not change
in the infused arm (Fig. 2) during endothelin-1 infusion
at either concentration (P=NS; one-way ANOVA). In com¬
parison to the non-infused arm, there was a trend
(P=0.06; two-way ANOVA) for the infused forearm
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Fig. 2 Plasma concentrations of tissue plasminogen activator (t-
PA) antigen (ng/ml_; solid lines) and activity (lU/mL; dashed lines)
in the infused (solid circles) and non-infused (open circles) forearm
during intra-arterial infusion of BQ-788 (1 nmol/min) and
endothelin-1 (2.5 and 10 pmol/min).
pmol/min of endothelin-1. However, there were no
significant differences in plasma concentrations of PAI-1
antigen (Table 2) or t-PA activity between the forearms.
Table 2 Plasma plasminogen activator inhibitor type 1 (PAI-1) concentrations (ng/mL) during endothelin-1 (ET-1) and BQ-788 infusion.
Mean ± SEM.
Time (min)
Baseline 10 20 30 50 80 120
BQ-788 (1 nmol/min)
infused arm 39 ± 15 37 + 13 43 ± 15 41 ± 13 37 ± 12 37 + 12 29 + 9
non-infused arm 38 ± 13 40 ± 14 43 ± 14 41 ± 13 37 ± 13 33 + 9 32 + 9
ET-1 (2.5 pmol/min)
infused arm 28 ±7 27 + 5 26 ± 6 26 ±5 25 ± 5 21+5 20 + 5
non-infused arm 27 ±5 29 ±6 29 ±6 27 ±5 28 + 7 25 + 5 23 + 4
ET-1 (10 pmol/min)
infused arm 25 ± 5 26 ± 4 27 + 5 26 + 5 23 ± 5 21+4 22 + 5
non-infused arm 27 ±5 27 + 5 26 ±5 25 ± 4 24 + 5 23 + 5 22 + 4
Endothclin-l 10 pmol/min
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Fig. 3 Theoretical components of venous plasma t-PA
concentration under basal conditions and during increases (upper
panel) and decreases (lower panel) in blood flow with and without
direct stimulation of t-PA release. Open bars: circulating or arterial
t-PA; grey bars: basal 'constitutive' t-PA released from the tissue
bed: black bars: stimulated 'facultative' t-PA released from the
tissue bed
BQ-788 infusion
In comparison to the non-infused arm, BQ-788 decreased
blood flow in the infused forearm after 120 min (relative
reduction of 21 ± 3%) although the absolute blood flow
was unchanged (Fig. 1 and Table 1). The plasma concen¬
trations of t-PA and PAI-1 (Fig. 2 and Table 2) did not
change in the infused forearm (_P=NS; one-way ANOVA)
or in comparison to the non-infused forearm (P=NS; two-
way ANOVA).
There was no significant net release of t-PA with infu¬
sions of either endothelin-1 or BQ-788 (Table 3).
DISCUSSION
We have demonstrated that, despite causing significant
reductions in blood flow, neither endogenous nor exoge¬
nous endothelin-1 influences the release of t-PA or PAI-1
in the forearm vascular bed of man. This suggests that
endothelin-1 does not contribute to the regulation of
endogenous fibrinolysis in man.
Endothelial cell culture techniques have limitations in
the investigation of t-PA release and may not be truly
representative of the in vivo function of these cells. The
amount of t-PA released in culture is small and necessi¬
tates prolonged incubation periods and sensitive assays.
Moreover, the phenotype of endothelial cells in culture,
and the ability to release t-PA, changes with increasing
passages. This may account for the disparity of our find¬
ings with previous endothelial cell culture studies.13
Studies in intact whole animals have suggested that
systemic endothelin-1 infusion is associated with stimu¬
lation of t-PA release,12 although plasma t-PA concentra¬
tions are not increased by low sub-pressor doses of
endothelin-1 in man.25 Systemic endothelin-1 administra¬
tion, particularly at pressor doses, will induce changes in
cardiac function and regional blood flow as well as hav¬
ing widespread effects on disparate tissues. Thus, the
consequent changes in systemic fibrinolytic parameters
will be a combination of many factors, potentially includ¬
ing hepatic production and clearance of t-PA and PAI-1.
One approach, to avoid these confounding systemic
effects, has been to use the isolated perfused rat
hindlimb model. This ex vivo model has been reported to
demonstrate that endothelin-1 infusion stimulates mod¬
est amounts of t-PA release." However, this increased
'release' may, in part, reflect the concentrating effects of a
reduction in blood flow associated with endothelin-1
infusion and the concentrations of endothelin-1 adminis¬
tered. In studies conducted to date,11-13 endothelin-1 has
been administered in nanomolar concentrations.
Table 3 Estimated net release of tissue plasminogen activator (t-PA) antigen across the forearm during endothelin-1 (ET-1) and BQ-788
infusion. Mean (95% confidence intervals)
Time (min)




Baseline 10 20 30 50 80 120
1.1 0 0.4 0.3 -0.2 0.1 0.1
(-0.1 to 2.3) (-1.6 to 1.6) (-1.0 to 1.8) (-1.5 to 2.1) (-1.8 to 1.4) (-1.3 to 1.5) (-1.7 to 1.9)
0.1 1.4 2.5 1 2 1.7 0
(-0.7 to 0.9) (-0.6 to 3.4) (0.5 to 4:5) (-0.8 to 2.6) (-1.0 to 5.0) (-1.1 to 4.5) (-0.2 to 0.2)
1.3 0.5 0.9 0.3 0.9 COoo
(-0.3 to 2.9) (-0.4 to 1.9) (0.1 to 1.7) (-0.4 to 1.7) (-0.1 to 1.9) (-0.7 to 0.9) (0.0 to1.6)
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Although local abluminal concentrations may be high,
normal human plasma endothelin-1 concentrations are
in the femtomolar range. Indeed, in the present study,
assuming a total forearm blood flow of 30-50 mL/min,
the forearm tissue concentration of endothelin-1 during
the 10 pmol/min infusion will be 200-300 fmol/mL. The
previous ex vivo animal studies,11 therefore, represent
some 4-5 orders of magnitude higher concentrations
and the release of t-PA is likely to represent a pharmaco¬
logical rather than physiological effect.
We have not detected a significant release of t-PA from
the forearm with endothelin-1 infusion despite a 63%
reduction in blood flow at the higher dose. Basal t-PA
release is of the order of -0.9 ng/100 mL of tissue/min in
the forearm16 and the apparent trend for an increase in t-
PA antigen concentrations may, in part, reflect the reduc¬
tion in blood flow associated with the marked forearm
vasoconstriction (see Fig. 3). This is borne out by the
unchanged t-PA activity, because it would be anticipated
that plasma PAI-1 and t-PA antigen concentrations would
increase proportionately with reductions in blood flow.
ETb receptor antagonism causes both inhibition of
endothelium-derived vasodilators such as nitric oxide,
and potential hyperstimulation of the unopposed ETA
receptor. However, as with endothelin-1, BQ-788 did not
affect plasma concentrations of t-PA or PAI-1 in the
infused forearm.
Forearm release of t-PA has been demonstrated using
various endothelial cell stimulants including metha-
choline,16'26 noradrenaline17 and desmopressin.27 Using
the same technique as in the present study, we have pre¬
viously demonstrated in vivo t-PA release of up to 80
ng/100 mL of tissue/min across the human forearm using
intrabrachial substance P infusion'" and this release is
sustained for at least 2h.'5 In contrast, stimulation or
antagonism of the endothelial ET., receptor, with
endothelin-1 and BQ-788 respectively, does not appear to
influence forearm t-PA release. It is, therefore, unlikely
that endothelin-1 provides a major contribution to the
regulation of t-PA release in man, although we cannot
exclude a small stimulatory effect.
Study limitations
In the forearm, typical resting arteriovenous differences
are only -10% of the total venous t-PA concentration
and the basal constitutive release of t-PA antigen is -0.9
ng/100ml of tissue/min.!h We have measured
venous-venous differences between the infused and
non-infused arms which, unlike the measurement of
arterio-venous differences of the infused arm, has the
disadvantage of not being able to correct for blood-flow-
dependent changes in venous plasma t-PA concentra¬
tions. Theoretically (see Fig. 3), in the absence of an
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alteration in t-PA release, a 60% reduction in blood flow
would be anticipated to increase total venous plasma
t-PA concentrations by only -7%, whereas a 200%
increase in flow would reduce t-PA concentrations to the
same degree (-7%). In the presence of stimulated t-PA
release, these small flow-dependent changes are propor¬
tionately reduced even further.
The measurement of arterio-venous differences neces¬
sitates arterial sampling and the insertion of large-bore
cannulae (19-20 gauge) which do not lend themselves to
multiple cannulations within the same subject.
Moreover, there is also the potential to introduce artefact
from the presence of a larger thrombogenic surface,
given that activated factor Xa is the most potent stimu¬
lant for t-PA release yet known.2S To minimize arterial
trauma and facilitate repeated studies in the same sub¬
jects, we have used 27-gauge arterial cannulae which
permit drug infusion but not arterial blood sampling.
However, we would suggest that flow-dependent
changes in venous t-PA concentrations are small, within
the variability of the t-PA assays (-5-7%) and are not of
practical importance. Interestingly, a significant fall in
the arterio-venous difference, or venous plasma concen¬
tration, of t-PA has not been detected during blood
flow increases of up to 600% with sodium nitroprusside
infusion.14'16'29
Measurement of venous-venous and arterio-venous
differences both have the potential limitation that they
can only estimate the net release of t-PA from the fore¬
arm and are unable to take account of clearance of t-PA
within the forearm. However, the majority of t-PA is
removed from the circulation by the liver10 and the con¬
tribution of forearm clearance of t-PA is, therefore, likely
to be very small.
During the present study, we did not see changes in
heart rate or blood pressure to suggest systemic effects of
endothelin-111 or BQ-788 infusion.12 However, measuring
venous concentrations bilaterally will control for any
potential systemic effects which may go unrecognized if
arterio-venous differences are measured in isolation.
Once a drug has a systemic rather than a local effect,
there is always the concern that subsequent t-PA release
may be influenced or mediated by the release of other
humoral factors, such as catecholamines. Moreover, if
the main mechanism of t-PA release is mediated by a sys-
temically released intermediate factor, then measuring
arterio-venous differences could fail to detect this since
arterial concentrations may remain unchanged and
venous concentrations will rise in both forearms.
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Abstract
Objective: Effective endogenous fibrinolysis requires rapid release of endothelial tissue plasminogen activator (t-PA). Using the nitric
oxide synthase inhibitor, i.-/Vc-monomethylarginine (l-NMMA), we examined the contribution of endogenous nitric oxide to substance
P-induced t-PA release in vivo in man. Methods: Blood flow and plasma fibrinolytic and haemostatic factors were measured in both
forearms of 8 healthy male volunteers who received unilateral brachial artery infusions of substance P (2-8 pmol/min) and l-NMMA
(1-4 pg/min). Results: Substance P caused dose-dependent increases in blood flow (P < 0.001) and plasma t-PA antigen (P = 0.04)
and activity (P< 0.001) concentrations confined to the infused forearm, but had no effect on plasminogen activator inhibitor type I
(PAI-1) or von Willebrand factor concentrations. In the presence of l-NMMA, substance P again caused significant increases in blood
flow {P < 0.001) and t-PA antigen (P = 0.003) and activity (P < 0.001) concentrations but these increases were significantly less than
with substance P alone (P < 0.001, P = 0.05 and P < 0.01, respectively). l-NMMA alone significantly reduced blood flow in the infused
arm, but had no measurable effect on t-PA or PAI-1 concentrations. Conclusions: The l-arginine/nitric oxide pathway contributes to
substance P-induced t-PA release in vivo in man. This provides an important potential mechanism whereby endothelial dysfunction
increases the risk of atherothrombosis through a reduction in the acute fibrinolytic capacity. © 1998 Elsevier Science B.V. All rights
reserved.
Keywords: Thrombolysis: Endothelial factor; Nitric oxide: Blood flow; Endothelial function
I. Introduction
The endogenous fibrinolytic system can have important
clinical effects as exemplified by the observation that in
~ 30% of patients with an acute myocardial infarction, the
infarct-related artery spontaneously reperfuses within 12 h
[1-3], The ability of the endothelium to release tissue
plasminogen activator (t-PA) rapidly is crucial if endoge¬
nous fibrinolysis within the arterial circulation is to be
effective, with thrombus dissolution being much more
effective if l-PA is incorporated during, rather than after,
thrombus formation [4,5], Epidemiological studies in a
healthy male population and patients with ischaemic heart
disease have shown a relationship between plasma fibri¬
nolytic parameters and future cardiovascular events, such
as stroke or myocardial infarction [6-9], However, the
capacity of endothelial ceils to release l-PA from intra¬
cellular storage pools, and the rapidity with which this can
be mobilised, may not be reflected in the basal circulating
plasma concentrations of t-PA antigen or activity 110],
Endothelial cell culture techniques have limitations in
the investigation of t-PA release and may not be truly
representative of the in vivo function of these cells. The
amount of t-PA released in culture is small and necessi-
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talcs prolonged incubation periods and sensitive assays.
Moreover, the phenoiype of endothelial cells in culture,
and the ability id release t-PA. changes with increasing
passages. In contrast, under in vivo physiological condi¬
tions. the endothelium is arranged within a non-planar
three-dimensional vascular bed. has a more favourable
volume to surface area ratio, and is exposed to pulsatile
blood How and pressure changes. We have recently de¬
scribed an in vivo model to assess acute t-PA release in
man [II], Using intra-brachial infusions of substance P. we
have shown a dose-dependent release of t-PA from the
human forearm without causing significant release of von
Willebrand factor (vWf) or plasminogen activator inhibitor
type 1 (PAI-1). This suggests either a selective action of
substance P or the lack of a rapidly translocatable pool of
PA1-I and vWf. However, we have previously used only
brief ( - 10 min) substance P infusions [II] and protracted
stimulation may release these factors [12-14],
Substance P causes endothelium dependent vasodilata¬
tion [15] which is mediated by the endothelial cell neu¬
rokinin type I receptor [16] and is, in part, related to the
release of nitric oxide [17-19]. However, because t-PA
release is not seen with infusions of the nitric oxide donor
and vasodilator, sodium nitroprusside [11,20], an increase
in nitric oxide and blood How together do not release t-PA
from the endothelium. Nevertheless, it remains a possibil¬
ity that the L-arginine/nitric oxide pathway contributes to
substance P-induced t-PA release.
Therefore, the aims of the current study were two-fold:
first, to ascertain whether prolonged substance P infusion
can cause vWf or PAI-1 release: and second, to determine
whether nitric oxide synthase inhibition using I.-/V '-mono-




Eight healthy men aged between 20 and 33 years
participated in three studies which were undertaken with
the approv al of the local research ethics committee and in
accordance with the Declaration ol Helsinki. I he written
informed consent of each subject was obtained belore
enlrv into the studv None ol the subjects received vasoac¬
tive or non-steroidal unit "inflammatory drugs in the week
before each phase ol the studv. and all abstained from
alcohol for 24 h. and front food, tobacco and callcine-con-
taining drinks for al least 5 h. belore each study. All
studies were performed in a quiet, temperature-controlled
room maintained at 23.5-24.5 C.
2.2. Iniru-arieritd adntinisiralioii and drut's
The brachial artery of the non-dominant arm was cannu-
lated with a 2-standard wire gauge steel needle (Cooper's
Needle Works. Birmingham. UK) under l'/< lignoeaine
(Xyloeaine: Astra Pharmaceuticals. Kings Langley. UK)
local anaesthesia. The cannula was attached to a 16-gattge
epidural catheter (Portex. Hythc. UK) and patency main¬
tained by infusion of saline (0.9<%: Baxter Healthcare.
Thetford. UK) via an IVAC PI000 syringe pump (1VAC.
Basingstoke. UK). The total rate of intra-arterial infusions
was maintained constant throughout all studies at I
ml/min. Pharmaceutical-grade substance P (Clinalfa.
Liiufclfingen. Switzerland) and l-N -monomethylarginine
(l-NMMA; Clinalfa) were administered following dissolu¬
tion in saline.
2..?. Forearm blood flow and blood pressure
Blood flow was measured in both forearms by venous
occlusion plethysmography using mercury-in-silastic strain
gauges applied to the widest part of the forearm [21].
During measurement periods, the hands were excluded
from the circulation by rapid inflation of the wrist cuffs to
a pressure of 220 mmHg using E20 Rapid Cuff Inflators
(D.E. Hokanson, Washington, USA). Upper arm cuffs
were inflated intermittently to 40 mmHg for 10 s in every
15 s to achieve venous occlusion and obtain plethysmo¬
graphy recordings. Analogue voltage output from an EC-4
Strain Gauge Plethysmograph (D.E. Hokanson) was pro¬
cessed by a MacLab analogue-to-digital converter and
Chart v3.3.8 software (AD Instruments, Castle Hill, Aus¬
tralia) and recorded onto a Macintosh Classic II computer
(Apple Computers. Cupertino, USA). Calibration was
achieved using the internal standard of the plethysmo¬
graph.
Blood pressure was monitored in the non-infused arm at
intervals throughout each study using a semi-automated
non-invasive oscillometry sphygmomanometer [22]
(Takeda UA 751. Takeda Medical. Tokyo. Japan).
2.4. Venous sampling; and assays
Venous cannulae (17-gauge) were inserted into large
subcutaneous veins of the anlecubital fossa in both arms as
described previously [23]. Ten ml of blood was withdrawn
simultaneously from each arm and collected into acidified
buffered citrate (Biopool Slabilyte. L'mca. Sweden: for
t-PA assays) and citrate (Monovette. Sarstedl. Numbreeht.
Germany: for PAI-1 assays) tubes, and kepi on ice before
being centrifuged at 2000 g for 30 min at 4'JC. Platelet-free
plasma was decanted and stored at -- 80°C before assay.
Plasma PAI-1 and t-PA antigen concentrations were
determined using an enzyme-linked immunosorbent assay
(ELISA): Coali/a PAI-1 [24] and Coaliza l-PA [25] (Chro-
mogenix AB. Mblndal. Sweden) respectively. Plasma PAI-
I and t-PA activities were determined by a photometric
method. Contest PAI-1 [26] and Coaset l-PA [27] (C'hro-
mogenix). hiira-assay coefficients of variation were 7.0
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and 5.59K lor i-PA and PAI-I antigen, and 4.0 and 2Ac/c
lor activity, respectively. Inter-assay coefficients of vari¬
ability were 4.0, 7.3, 4.0 and 7.69c, respectively. The
sensitivities of the assays were 2.5 ng/ml, 0.5 ng/ml. 5
AU/ml and 0.10 IU/ml, respectively. vWf antigen was
determined [28] using an ELISA (Dako, Glostrup, Den¬
mark) with a sensitivity of 0.05 lU/ml. The intra-assay
and inter-assay coefficients of variability were 5.2 and
7.39respectively. Factor VIITC procoagulant activity
was determined using a standard one-stage assay on an
ACL-3000 + coagulometer (Instrumentation Laboratory,
Warrington, UK). Haematocrit was determined by capil¬
lary tube centrifugation of blood anticoagulated by ethy¬
lene diamine tetraacetic acid and was obtained from the
infused forearm at baseline and at 120 min.
2.5. Study design
On 3 separate occasions, at 09.00 h, subjects attended
fasted and rested recumbent throughout each study. Strain
gauges and cuffs were applied and the brachial artery of
the non-dominant arm cannulated. Throughout all proto¬
cols, measurements of forearm blood flow were made
every 10 min. Saline was infused for the first 30 min to
allow time for equilibration and the final blood flow
measurement during saline infusion was taken as the basal
forearm blood flow. Thereafter, subjects underwent the
following protocols, in random order, each separated by at
least 1 week: protocol I, each subject received intra-arterial
substance P at 2, 4 and 8 pmol/min, for 10 min at each
dose, followed by a continuous infusion of 8 pmol/min
i for a further 90 min; protocol 2, l-NMMA was co-infused
at 4 |xmol/min for 10 min before and throughout the same
substance P infusion as protocol I; and protocol 3, subjects
received intra-arterial l-NMMA at 1,2 and 4 p.mol/min
for 10 min at each dose followed by a continuous infusion
of 4 |xmol/min for a further 90 min. Venous samples
were withdrawn from each arm at baseline and at 10, 20.
30. 50. 80 and 120 min after the start of substance P (for
protocols I and 2) or t.-NMMA infusion (protocol 3).
2.6. Data analysis and statistics
Plethysmography data were extracted from the Chart
data files and forearm blood flows were calculated for
individual venous occlusion cuff inflations by use of a
template spreadsheet (Excel v4.0: Microsoft. Cambridge,
USA). Recordings from the first 60 s after wrist-cuff
inflation were not used because of the reflex vasoconstric¬
tion this causes [21]. Usually, the last five How recordings
in each 3-min measurement period were calculated and
averaged for each arm. Estimated net release of t-PA
activity and antigen was defined previously [11] as the
product of the infused forearm plasma flow (based on the
mean haematocrit, HCt, and the infused forearm blood
flow, FBF) and the concentration difference between the
infused ([t-PA]inf) and non-infused arms ([i-PA]ni>11_inl).
Estimated net t-PA release
= FBF X { 1 - HCt} X {[t-PA]ln,
" D-PALn-in, }
Data were examined, where appropriate, by two-way
analysis of variance (ANOVA) with repeated measures
and two-tailed paired Student's t-test using Excel v4.0
(Microsoft). Tachyphylaxis was assessed by comparing the
30-min (peak) and 120-min (final) values with a two-tailed
paired Student's r-test. Area under the curve (AUC) was
calculated for the estimated net release of t-PA across the
study period. All results are expressed as mean ± s.e.m.
Statistical significance was taken at the 5% level.
3. Results
All subjects were normotensive and there were no
significant changes in blood pressure, heart rate or blood
flow in the contralateral arm throughout any of the studies
(Table I). Haematocril decreased slightly in each study
(Table I). Between the 3 protocols, there were no signifi¬
cant differences in the baseline values of blood pressure.
Table I
Haeniodwiainics and haemauicrit al baseline and completion of the 3 studs protocols
Substance P alone i.-NMMA alone Substance P - i.-NMMA
Basal Final Basal Final Basal Final
Blood pressure (mmHn)
S_\ stolic 137 ±3 136 ±3 135 ± 5 136 ± 5 133 + 6 1 *2 ... 6
Diastolic 71 ±2 71 ± 3 6X ± 3 71 ±3 69 + 4 70± 5
Heart rale (/min) 65 ± 4 61 ± 3 59 ± 2 5X + 3 60 ±3 (\! ... 3
Absolute forearm blood flow (ml / 100 ml/min)
Non-infused arm 3.1 ± 0.3 3.7 -0.5 3.4 ±0.7 3.6 ± 0.6 3.6+0.5 4.9 II.
Infused arm 3.6 ±0.4 12.1 ± 1.3" 3.9 + 0.7 2.1 ±0.2 4.2 ±0.7 9.3 • 1
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Table 2
Blood How and plasma von Willebrand's factor and factor VIII.C activity concentrations in both arms during isolated substance infusion: protocol I
Baseline Time (min)
10 20 30 50 80 120
Substance P dose (pmol/min) 0 2 4 8 8 8 8
Absolute forearm blood How (ml/100 ml/min)
Non-infused arm 3.1+0.3 3.3 + 0.3 3.4 + 0.4 3.3 + 0.3 3.5 + 0.3 3.8 + 0.4 3.7 + 0.5
Infused arm 3.6 + 0.4 11.8+ 1.8 13.8+ 1.9 15.9+1.9 14.5+1.7 12.6+ 1.2 12.1 ± I.3;|
von Willebrand's factor (IU/ml)
Non-infused arm 0.84 + 0.13 0.64 + 0.10 0.85 + 0.13 0.60 ± 0.09 0.95 + 0.18 0.80 + 0.10 1.20 + 0.16
Infused arm 0.73 + 0.09 0.72 + 0.15 0.73 + 0.11 0.86 + 0.20 0.98 + 0.16 0.99 + 0.17 1.03 + 0.17
Factor VIII:C (IU/ml)
Non-infused arm 0.50 + 0.06 0.48 ± 0.04 0.51 ± 0.05 0.51 ±0.05 0.58+0.09 0.65 + 0.10 0.72 + 0.09
Infused arm 0.50 + 0.05 0.50 + 0.05 0.51 ± 0.07 0.52 + 0.07 0.64 + 0.07 0.64 ± 0.08 0.69 + 0.10
aP <0.001.
pendent manner (Fig. 1) reaching a maximum increase of
13.7 + 1.7 ml/100 ml/min after 10 min at 8 pmol/min.
This response underwent tachyphylaxis and decreased to
9.3 ± 1.4 ml/100 ml/min after 100 min of substance P at
8 pmol/min (P <0.002 vs. 10 min). In comparison, with
the non-infused arm, substance P co-infused with l-NMMA
caused a dose-dependent increase in plasma t-PA activity
(P < 0.001) and antigen (P < 0.003) concentrations of the
infused arm which did not undergo significant tachyphy¬
laxis (Fig. 2). l-NMMA caused a significant attenuation of
substance P-induced increases in blood flow (P< 0.001)
and plasma t-PA activity concentrations (P < 0.003) in the
infused forearm, but not plasma t-PA antigen.
3.3. Estimated net t-PA production
l-NMMA infused alone had no significant effects on
t-PA release: 95% confidence intervals for t-PA antigen
and activity release are 0.31 to —0.68 ng/100 ml/min
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heart rate, forearm blood flow, haematocrit or plasma
concentrations of t-PA and PAI-I antigen and activity.
Isolated infusions of substance P aiul l-NMMA
Substance P increased blood How in the infused arm
( P < 0.001) in a dose-dependent manner (Fig. 1 and Table
2) reaching a maximum increase of 15.9+ 1.9 ml/100
ml/min after 10 min at 8 pmol/min. Following prolonged
infusion, substance P-induced vasodilatation demonstrated
tachyphylaxis and decreased to 12.1 + 1.3 ml/100 ml/min
after 100 min of substance P at 8 pmol/min (P <0.003
vs. 10 min). In comparison to the non-infused arm, sub¬
stance P caused a dose-dependent increase in venous
plasma t-PA activity (P< 0.001) and antigen (P< 0.04)
concentrations of the infused arm which did not undergo
significant tachyphylaxis (Fig. 2). Concentrations of plasma
PA1-1 activity were also reduced in the infused arm (P =
0.04; Fig. 2). In contrast, there were no significant changes
in plasma PAI-I antigen, vWf or factor VIIPC concentra¬
tions in either arm (Fig. 2 and Table 2).
i.-NMMA decreased blood How in the infused arm
( P < 0.001) in a dose-dependent manner (Fig. 1 and Table
2) reaching 2.1 +0.2 ml/100 ml/min after 100 min at 4
|xmoI/min. There were no significant changes in the
concentrations of plasma t-PA and PAI-I antigen or activ¬
ity in either arm during infusion of l-NMMA (Fig. 2).
3.2. Co-infusion of l-NMMA and substance P
In the presence of l-NMMA, substance P increased
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and l-NMMA. ® > and protocol 3 (l -NMMA alone: 0 ). P< H.OOI: /» < U.II5: t' — ().(W (ANOVA I.
)). protocol 2 (substance I'
stance P caused dose-dependent increases in the estimated
net release of t-PA antigen and activity in the presence or
absence ol i.-NMMA (P< 0.001) which did not undergo
significant tachyphylaxis. However, the magnitude of the
increase in release of both t-PA antigen (P — 0.05) and
activity (PC 0.01) was significantly reduced in the pres¬
ence of l-NMMA (Fig. i). t.-NMMA reduced the AUC for
the substance P-induced release of t-PA antigen and activ¬
ity by 40 and 46% respectively.
4. Discussion
We have shown that intra-brachial substance P infusion
increases forearm blood How and plasma t-PA concentra¬
tions for up to 2 h without a demonstrable effect on plasma
PAI-I or vWf concentrations. Although the nitric oxide
synthase inhibitor. l-NMMA, significantly reduced fore¬
arm blood How without affecting basal t-PA release, it
inhibited the increases in blood tlow. plasma t-PA concen¬
trations and t-PA release produced by substance P adminis¬
tration in the forearm. These data suggest that the l-
arginine/nitric oxide pathway contributes to substance
P-induced t-PA release in vivo in man. In contrast, we [I I]
and others [20] have shown previously that t-PA release is
not seen with the large local increases in nitric oxide
delivery and blood flow associated with infusions of the
nitric oxide donor, sodium nitroprusside. Taken together,
these findings indicate that increases in nitric oxide and
blood How are not sufficient per se to release t-PA but.
through the i.-arginine/nitric oxide pathway, are able to
enhance substance P-induced t-PA release.
The permissive role of intracellular mediators in the
mechanism of t-PA release has been described previously.
In the rat perfused hindlimb model, increasing intracellular
calcium alone is insufficient to cause t-PA release whilst it
is essential for bradykinin induced l-PA release [29], How¬
ever. the regulation of I PA release is complex and may
involve several signal transduction pathways [30]. This is
reflected by the diversity of mediators, such as thrombin,
bradykinin and desmopressin, which can release t-PA and
increase t-PA activity [12.13.31.32]. One can. therefore,
onlv speculate as to whether our findings extend to the
acute t-PA release seen with in situ thrombosis. However,
both nitric oxide mediated endothelial dyslunction [33-36]
and abnormalities of endogenous fibrinolysis [6-9] have
been described m many atherosclerotic diseases and the
associated risk factors. Thus, the coupling of acute l-PA
release to the ;.-urginine nitric oxide pathway provides an
important potential mechanism whereby endothelial dys¬
function might increase the risk ol atherothrombosis
through a reduction in the acute fibrinolytic capacity. Our
initial findings would suggest that this model could he
applied to the assessment of the acute fibrinolytic capacity
of patients with endothelial dysfunction such as those with
hy percholesterolaemia and a smoking habit [35.36], and to
the examination of the subsequent effect of i.-arginine
supplementation.
Substance P-induced vasodilatation undergoes tachy¬
phylaxis [37] which may relate to internalisation of the
neurokinin type 1 receptor from the endothelial cell stir-
lace membrane [38]. It has been suggested from ex vivo
animal studies [15.39] that the residual vasodilatation fol¬
lowing the development of tachyphylaxis is almost com¬
pletely nitric oxide-dependent. In the present study, the
degree of inhibition of substance P-induced vasodilatation
by l-NMMA was less than we [18] and others [17] have
previously described and may reflect the higher potency
and doses used in this study. Whilst we have readily
demonstrated tachyphylaxis of substance P-induced vaso¬
dilatation, the co-infusion of l-NMMA did not affect the
development of tachyphylaxis and did not abolish the
residual substance P-induced vasodilatation following its
development. Thus, in contrast to animal studies, residual
vasodilatation after the development of tachyphylaxis does
not appear to be predominantly nitric oxide mediated in
the human forearm. In addition, we were unable to detect
significant tachyphylaxis of substance P-induced increases
in plasma t-PA antigen and activity concentrations, sug¬
gesting that not all the actions of substance P undergo
tachyphylaxis.
The substance P-induced reductions in plasma PAI-1
activity of the infused arm without significant alterations
in PAI-I antigen concentrations are consistent with acute
t-PA release in the absence of PAI-I release [40], PAI-I
binds to the newly released t-PA to form an inactive
PAI-1/t-PA complex, thereby reducing the plasma PAI-1
activity. The trend for PAI-I antigen concentrations to fall
in both arms as the study progressed is consistent with
systemic (hepatic) clearance of the PAI-1/t-PA complex
[40-42], However, this trend was also seen with isolated
l-NMMA infusion in which there was no significant re¬
lease of t-PA consistent with a circadian fall of PAI-I
antigen during the morning [43],
Despite reducing forearm blood flow by half. t.-NMMA
did not significantly affect the constitutive release or plasma
concentrations of i-PA and PAI-I antigen and activity. The
95% confidence intervals indicates that if i.-NMMA has an
effect on basal l-PA or PAI-I release then it is rather
small. This suggests that the l.-arginine/nilric oxide path¬
way does not play a major role in the basal release of t-PA
or PAI-I in the peripheral vasculature of man.
4.1. Sliitly limitations
Since the derivation of t-PA release is a function of
plasma flow, it could be argued that the inhibition by
I.-NMMA of substance P-induced t-PA release reflects the
simultaneous reduction in blood How. However, the reduc¬
tion in absolute blood flow was only modest (15-20% ) in
comparison to the reduction in t-PA release (40-46% ) and
the plasma l-PA activity concentrations in the infused
forearm were also significantly reduced by co-infusion of
i.-NMMA. The findings of the present study would be
strengthened by utilising a control vasoconstrictor and
demonstrating a neutral effect on substance P-induced
t-PA release. However, standard receptor coupled vasocon¬
strictors used in forearm studies, such as noradrenaline,
vasopressin and angiotensin II, are known to stimulate
t-PA and PAI-I release [12,14,32,44] and would not help
in interpreting the influence of l-NMMA on substance
P-induced t-PA release.
We have previously been unable to detect an acute local
release of either vWf or PAI-1 during 10-min infusions of
substance P given at 8-fold higher concentrations [11], In
the present study, substance P did not cause significant
vWf or PAI-1 release, despite infusion times of up to 120
min, suggesting that the dissociation of substance P-in¬
duced t-PA release from vWf is not a temporal effect.
However, this dissociated release does not appear to be
unique to substance P since this has also been recently
described with local forearm infusions of desmopressin
[45], These findings are, however, limited to the peripheral
forearm vascular bed and the endothelium in other tissue
beds may respond differently to substance P stimulation.
The extension of this model to vascular beds associated
with atherosclerosis such as the coronary circulation, will
be of crucial relevance in determining the influence of
atheroma and endothelial dysfunction on the acute local
release of t-PA during thrombotic occlusion and plaque
rupture.
In summary, in the forearm vascular bed in vivo, we
have shown for the first time that the L-arginine/nitric
oxide pathway contributes to substance P-induced t-PA
release in man. This coupling of acute t-PA release to the
L-arginine/nitric oxide pathway provides an important
potential mechanism whereby endothelial dysfunction in¬
creases the risk of atherothrombosis through a reduction in
the acute fibrinolytic capacity.
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Endothelial Dysfunction, Impaired Endogenous Fibrinolysis,
and Cigarette Smoking
A Mechanism for Arterial Thrombosis and Myocardial Infarction
David E. Newby, BA, BSc, BM, MRCP; Robert A. Wright, MB, ChB, MRCP;
Catherine Labinjoh, BSc, MB, ChB, MRCP; Christopher A. Ludlam, PhD, FRCP, FRCPath;
Keith A.A. Fox, BSc, MB, ChB, FRCP, FESC;
Nicholas A. Boon, MD, FRCP; David J. Webb, MD, FRCP, FRCPE, FFPM
Background—Effective endogenous fibrinolysis requires rapid release of tissue plasminogen activator (tPA) from the
vascular endothelium. Smoking is a known risk factor for arterial thrombosis and myocardial infarction, and it causes
endothelial dysfunction. We therefore examined the effects of cigarette smoking on substance P-induced tPA release
in vivo in humans.
Methods and Results—Blood flow and plasma fibrinolytic factors were measured in both forearms of 12 smokers and 12
age- and sex-matched nonsmokers who received unilateral brachial artery infusions of substance P (2 to 8 pmol/min).
In both smokers and nonsmokers, substance P caused dose-dependent increases in blood flow and local release of
plasma tPA antigen and activity (P<0.001 for all) but had no effect on the local release of plasminogen activator
inhibitor type 1. Compared with nonsmokers, increases in forearm blood flow (P=0.03) and release of tPA antigen
(P=0.04) and activity (P<0.001) caused by substance P were reduced in smokers. The area under the curve for release
of tPA antigen and activity decreased by 51% and 53%, respectively.
Conclusions—Cigarette smoking causes marked inhibition of substance P-induced tPA release in vivo in humans. This
provides an important mechanism whereby endothelial dysfunction may increase the risk of atherothrombosis through
a reduction in the acute fibrinolytic capacity. (Circulation. 1999;99:1411-1415.)
Key Words: plasminogen activators ■ endothelium ■ endothelium-derived factors ■ blood flow
Clinical Investigation and Reports
cute rupture of a coronary atheromatous plaque and
subsequent coronary artery thrombosis causes the ina¬
nity of sudden cardiac deaths and myocardial infarctions.1-2
'igarette smoking not only is strongly associated with ath-
rosclerosis3 and ischemic heart disease4 but also is a major
isk factor for acute coronary thrombosis.1-5 Indeed, 75% of
iidden cardiac deaths due to acute thrombosis are in cigarette
mokers.1 Smoking causes endothelial dysfunction6 and is
ssociated with increased platelet thrombus formation.5 Small
reas of denudation and thrombus deposition are a common
nding on the surface of atheromatous plaques7-8 and are
sually subclinical. However, in the presence of an imbalance
l the coagulation or fibrinolytic systems, such microthrombi
lay propagate, ultimately leading to arterial occlusion.
The importance of endogenous tissue plasminogen activa-
ir (tPA) release is exemplified by the high rate of sponta-
;ous reperfusion in the infarct-related artery after acute
lyocardial infarction, occurring in —30% of patients within
the first 12 hours.911 It would be anticipated that high plasma
tPA concentrations should protect against subsequent coro¬
nary events. However, in epidemiological studies of patients
with ischemic heart disease12-13 and in a healthy male popu¬
lation (US Physicians Study),14 higher total plasma tPA
(antigen) concentrations positively predict future coronary
events. This is explained by the concomitant elevation of
plasminogen activator inhibitor type 1 (PAI-1), which forms
a complex with tPA and thereby causes an overall reduction
in free tPA "activity."15-16 It is this free and unbound tPA that
is physiologically active and leads to endogenous fibrinolysis.
However, the capacity of endothelial cells to release tPA from
intracellular storage pools and the rapidity with which this
can be mobilized may not necessarily be reflected in the basal
circulating plasma concentrations of tPA antigen or activity.17
Using the endothelium-dependent vasodilator substance P
to stimulate tPA release, we recently described an in vivo
model to assess the acute fibrinolytic capacity of the human
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forearm.18 Moreover, we have been able to demonstrate a
reduction in tPA release after inducing experimental "endo¬
thelial dysfunction" with nitric oxide synthase inhibition.19
We therefore hypothesized that cigarette smoking might
impair endogenous fibrinolysis by reducing the capacity of
the endothelium to release tPA acutely. The aim of the study
was to compare substance P-induced tPA release from the




Twelve healthy smokers (5 to 20 cigarettes/d) and 12 age- and
sex-matched nonsmokers between 25 and 55 years old participated in
the study, which was undertaken with the approval of the local
research ethics committee and in accordance with the Declaration of
Helsinki. The written informed consent of each subject was obtained
before entry into the study.
All subjects were normotensive without a history of diabetes
mellitus or vascular disease. Female subjects were premenopausal
and not receiving hormonal contraceptives. They were clinically well
and taking no regular medications. Control subjects were lifelong
nonsmokers and were not exposed to regular environmental tobacco
smoke. Smokers had a history of regular daily cigarette smoking of
at least 5 years' standing and maintained their normal smoking habits
in the week before attendance. None of the subjects received
vasoactive or nonsteroidal anti-inflammatory drugs in the week
before the study, and all abstained from alcohol for 24 hours before
and from food, tobacco, and caffeine-containing drinks on the day of
the study. All studies were performed in a quiet, temperature-
controlled room maintained at 23.5°C to 24.5°C.
Intra-Arterial Drug Administration
The brachial artery of the nondominant arm was cannulated with a
27-standard wire gauge steel needle (Cooper's Needle Works Ltd)
under local anesthesia. The cannula was attached to a 16-gauge
epidural catheter (Portex Ltd), and patency was maintained by
infusion of saline (0.9%: Baxter Health Care Ltd) via an IVAC
P1000 syringe pump (IVAC Ltd). The total rate of intra-arterial
infusions was maintained constant throughout all studies at 1
mL/min. Pharmaceutical-grade substance P (Clinalfa AG) was ad¬
ministered after dissolution in saline.
Measurements
Blood flow was measured in both forearms by venous occlusion
plethysmography as previously described.18-20 Blood pressure was
monitored in the noninfused arm at intervals throughout each study
with a semiautomated noninvasive oscillometric sphygmomanome¬
ter (Takeda UA 751, Takeda Medical Inc).
Venous cannulas (17-gauge) were inserted into large subcutaneous
veins of the antecubital fossae of both arms. Blood (10 mL) was
withdrawn simultaneously from each arm and collected into acidified
buffered citrate (Biopool Stabilyte, for tPA assays) and citrate
(Monovette, for PAI-1 assays) tubes and kept on ice before being
centrifuged at 2000g for 30 minutes at 4°C. Platelet-free plasma was
decanted and stored at -80°C before assay. Plasma PAI-1 and tPA
antigen and activities were determined as previously described18-19
with an ELISA (Coaliza PAI-1 and Coaliza tPA, Chromogenix AB)
and a photometric method (Coatest PAI-1 and Coaset tPA, Chro¬
mogenix AB). Hematocrit was determined by capillary tube centrif-
ugation at baseline and during infusion of 8 pmol/min of substance
P. Plasma lipid fractions were measured by an enzymatic colorimet-
ric method (Boehringer Mannheim GmbH Diagnostica). LDL cho¬
lesterol was derived according to the method of Friedewald et al.21
TABLE 1. Baseline Subject Characteristics
Nonsmokers Smokers
Age, y 35±3 34±2
Sex, male:female 10:2 10:2
Body mass index, kg/m2 23.9±0.5 24.5±1.1
Mean arterial pressure, mm Hg 92±2 91 ±2
Heart rate, bpm 59±3 66±2
Fasting plasma glucose, mmol/L 5.3±0.1 5.4±0.1
Total cholesterol, mg/dL 189+14 200±16
LDL cholesterol, mg/dL 113±13 130± 16
HDL cholesterol, mg/dL 48±3 37 ±2*
Triglycerides, mg/dL 138±16 163±27
Baseline hematocrit 0.41 ±0.01 0.43±0.01
*P=0.01 (unpaired ftest, smokers vs nonsmokers).
Study Design
At 9 am, subjects attended fasted and then rested recumbent
throughout each study. Strain gauges and cuffs were applied, and the
brachial artery of the nondominant arm was cannulated. Forearm
blood flow was measured every 10 minutes. Saline was infused for
the first 30 minutes to allow time for equilibration. The final blood
flow measurement during saline infusion was taken as the basal
forearm blood flow. Thereafter, subjects received intra-arterial sub¬
stance P at 2, 4, and 8 pmol/min for 10 minutes at each dose.
Data Analysis and Statistics
This study's population size, on the basis of power calculations
derived from previous studies, gives 90% power of detecting an 18%
difference in tPA release at a significance level of 5%. Coefficients
of repeatability22 for plasma concentrations of tPA antigen and
activity during substance P infusion at 8 pmol/min are 1.6 ng/mL and
1.4 IU/mL, respectively (data on file).
Plethysmography data were extracted from the Chart data files,
and forearm blood flows were calculated for individual venous
occlusion cuff inflations by use of a template spreadsheet (Excel
version 5.0; Microsoft Corp). Recordings from the first 60 seconds
after wrist cuff inflation were not used because of the reflex
vasoconstriction this causes.20 Usually, the last 5 flow recordings in
each 3-minute measurement period were calculated and averaged for
each arm. Estimated net release of tPA activity and antigen was
defined previously18 as the product of the infused forearm plasma
flow (based on the mean hematocrit, Hct, and the infused forearm
blood flow, FBF) and the concentration difference between the
infused ([tPA]tar) and noninfused ([tPA]Noninf) arms: Estimated net
tPA release=FBFX(l-Hct)X([tPA]Inf -[tPA]NonlnI).
Data were examined, where appropriate, by 2-way ANOVA with
repeated measures and 2-tailed Student's t test using Excel version
5.0 (Microsoft). The area under the curve was calculated for the
estimated net release of tPA across the study period. All results are
expressed as mean±SEM. Statistical significance was taken at the
5% level.
Results
There were no significant differences in baseline character¬
istics, except that smokers had a slightly lower HDL concen¬
tration (Table 1). There were no significant changes in blood
pressure, heart rate, hematocrit, or blood flow in the nonin¬
fused forearm during the study (data on file; Table 2). In the
noninfused arm, plasma tPA antigen concentrations were
higher in smokers than nonsmokers (P=0.02; Table 2). There
were no significant differences in plasma PAI-1 antigen and
activity between the groups.
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10 20 30 10 20 30
Substance P dose, pmol/min 0 2 4 8 0 2 4 8
Absolute forearm blood flow,
niL' 100 mL"1 • min"1
Noninfused arm 2.8±0.3 2.9±0.4 2.9±0.4 2.8±0.3 2.8±0.2 2.9±0.3 2.9±0.3 3.0±0.3
Infused arm 3.7±0.4 11.2+1.1 13.5± 1.3 16.2+1.5* 3.6±0.3 9.4±0.4 11.5±0.7 14.2+0.8*t
IPA antigen, ng/mL
Noninfused arm 3.3+0.5 3.4±0.5 3.4±0.5 3.7±0.5 4.0±0.5 4.3±0.5 4.4±0.5 4.4±0.6f
Infused arm 3.2±0.5 4.1+0.6 4.4±0.6 6.2±0.8* 4.1 ±0.5 4.5±0.6 5.2±0.7 5.9±0.9*
tPA activity, lU/mL
Noninfused arm 0.8±0.2 0.9+0.2 1.0±0.2 1.3±0.2 0.7+0.1 0.7±0.1 0.8±0.1 1.0±0.2
Infused arm 0.8±0.2 2.1 ±0.5 2.8±0.5 4.6±0.6* 0.7 ±0.1 1.1 ±0.2 1.7±0.4 3.0±0.5*f
PAI-1 antigen, ng/mL
Noninfused arm 29+7 29+6 28±7 28±6 29±6 26±5 25±5 26±5
Infused arm 28+6 28±7 27±6 28±5 26±5 27±6 26±6 26±5
PAI-1 activity, AU/mL
Noninfused arm 11.8±1.7 11,8± 1.7 12.1 ±1.6 11.4+1.8 12.0±2.0 11.0±1.7 9.2± 1.4 10.2± 1.3
Infused arm 10.7± 1.6 8.8±1.5 10.8± 1.7 9.3±1.5 12.5±1.9 10.6±1.5 10.5± 1.2 8.5±1.1
One-way ANOVA: *P<0.001; 2-way ANOVA (nonsmokers vs smokers): tP<0.05; f:P=0.001.
Substance P caused dose-dependent increases in forearm
blood flow in the infused arm in both smokers and nonsmok¬
ers (Table 2, Figure), but the increase in blood flow was
greater in nonsmokers (P=0.03; 2-way ANOVA, nonsmok¬
ers versus smokers). Compared with the noninfused arm
(2-way ANOVA), substance P caused dose-dependent in¬
creases in plasma concentrations of tPA antigen (P<0.001)
and activity (PC0.001) in the infused arm of both smokers
and nonsmokers (Table 2). There were no significant changes
in plasma PAI-1 antigen or activity in either group. The
increase in plasma tPA activity in the infused arm was greater
in the nonsmokers (P=0.001; 2-way ANOVA, nonsmokers
versus smokers).
Substance P increased the net release of tPA antigen
(P=0.009) and activity (P<0.001) in smokers (Figure). In
nonsmokers, substance P increased the net release of tPA
antigen (PCO.OOl) and activity (P<0.001) significantly more
than in smokers (P=0.04 and P<0.001, respectively; 2-way
ANOVA, nonsmokers versus smokers). Compared with the
nonsmokers, the area under the curve for net tPA antigen and
activity release was reduced by 51% and 53%, respectively,
in the smokers.
Subgroup analysis after exclusion of female subjects did
not alter the magnitude or the statistical significance of the
above findings. Qualitatively, the responses in female smok¬
ers and nonsmokers were similar to those observed in the
male subjects.
Discussion
We have shown here, for the first time, that despite higher
basal plasma tPA antigen concentrations, cigarette smokers
have a markedly impaired capacity of the endothelium to
release tPA acutely. This establishes an important mechanism
whereby cigarette smoking can lead to arterial thrombosis
and myocardial infarction.
The rapid mobilization of tPA from the endothelium is
crucial if endogenous fibrinolysis within the arterial circula¬
tion is to be effective, with thrombus dissolution being much
more effective if tPA is incorporated during, rather than after,
thrombus formation.23'24 The increased risk of spontaneous
thrombosis seen in smokers may therefore plausibly relate to
the propagation of thrombus, which would otherwise undergo
lysis and remain subclinical. Although cigarette smokers have
a higher overall mortality from myocardial infarction than
nonsmokers,25 the in-hospital mortality is lower.26"28 This
apparent paradox can be explained by the observation that the
infarct-related artery is more than twice as likely to become
patent in current smokers as in nonsmokers after thrombolytic
therapy for acute myocardial infarction.28"30 Indeed, it has
been suggested30 that thrombolytic therapy should only be
given to smokers and that alternative strategies such as
primary angioplasty should be used in nonsmokers. These
observations are consistent with the present findings because
it might be anticipated that patients with impaired endothelial
cell tPA release would benefit most from thrombolytic
therapy, whereas those with a normal endogenous fibrinolytic
capacity are more likely to have tPA-resistant thrombus,
which would respond less favorably.
Our findings in smokers are consistent with the previous
observational data12"14 that increased basal plasma concentra¬
tions of tPA antigen are associated with future coronary
events. The assessment of endogenous fibrinolysis has pre¬
viously relied on measurement of basal plasma tPA concen¬
trations and the acute release of tPA in response to venous






























Infused forearm blood flow and the net release of tPA antigen
and activity in smokers (•) and nonsmokers (O). P<0.001
(1 -way ANOVA) for all responses. Two-way ANOVA (nonsmok¬
ers vs smokers): *P<0.05; tP<0.001.
occlusion, systemic desmopressin infusion, or exercise.31-34
However, because of confounding systemic effects and the
nonuniformity of the stimuli applied, these responses can be
variable and give only a relatively crude measure of fibrino¬
lytic capacity. Moreover, although it has previously been
shown that systemic desmopressin infusion causes less tPA
release in smokers,31 this effect may not be directly endothe-
lium-dependent.35 In contrast, we have used locally active
doses of substance P to provide a more precise pharmacolog¬
ical stimulus to the endothelium and to cause a substantial
and dose-dependent local release of tPA.18-19 This has al¬
lowed us to demonstrate a distinct and marked inhibition of
stimulated endothelial tPA release in smokers.
Although thrombin is more physiologically relevant to
acute tPA release than substance P, we have used the latter
because its vascular actions are endothelium-dependent,36
mediated in part through nitric oxide,37 and its administration
intra-arterially is safe and well tolerated.38 Consistent with
previous workers,6-39-40 we have also found an attenuation of
the endothelium-dependent forearm blood flow responses in
smokers. This inhibition of both the blood flow and tPA
response may, in part, relate to an impairment of the
L-arginine:nitric oxide pathway in smokers.19'39 Although
differences exist,41 the forearm model may provide a useful
surrogate for the coronary vascular bed42-43 and permits a
readily accessible and reliable assessment of endothelial cell
function. However, the present findings need to be confirmed
in the coronary circulation.
We have studied the sustained effect of chronic smoking in
a selected healthy and predominantly male population at a
single time point. Although total and LDL cholesterol con¬
centrations were similar in smokers and nonsmokers, HDL
cholesterol concentrations were slightly lower in smokers.
This is not unexpected, because cigarette smoking is known
to be associated with a selective reduction in HDL cholesterol
concentrations.44'45 However, the application of this model to
other conditions associated with endothelial dysfunction,
such as dyslipidemia, is warranted. Finally, because hormonal
status influences fibrinolytic parameters,46 the assessment of
the acute fibrinolytic capacity in premenopausal and post¬
menopausal women and the modulating effect of hormonal
therapy will also be of particular interest.
In conclusion, we have demonstrated a major impairment
of tPA release from the vascular endothelium of smokers. Our
findings suggest that the fundamental mechanism whereby
cigarette smoking causes arterial thrombosis and myocardial
infarction relates, at least in part, to impairment of the acute
endogenous fibrinolytic capacity.
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